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ABSTRACT

Myocardial infarction is the most serious manifestation of coronary artery disease
and the cause of significant levels of mortality and morbidity worldwide.
Galectin-1 (GAL-1) and Galectin-3 (GAL-3) are beta galactoside binding lectins
with diverse functions. Hypoxia inducible factor-1 alpha (HIF-1α) is a
transcription factor mediating early and late responses to myocardial ischemia.
We aim to study the direct effects of ischemia on GAL-1, GAL-3 and HIF-1α in
the heart. Male C57B6/J and GAL-3 knockout mice were used for our two disease
models. In the Myocardial infarction (MI) model, the left anterior descending
artery of the heart is permanently ligated to create ischemia in the anterior
myocardium. In the Ischemia reperfusion model (IR), the artery is temporarily
ligated for a specific period of time and then reperfusion is established. Heart
samples were processed for immunohistochemical and immunofluorescent
labeling, western blotting, Enzyme linked immunosorbent assay and quantitative
real time PCR. Inflammatory, Apoptotic and Oxidative stress markers were also
studied. We show for the first time that GAL-1, GAL-3 and HIF-1α levels in the
left ventricle are raised in early ischemic period in conjunction with a
predominant antiapoptotic activity in the heart. Our identification of the pattern
of expression of GAL-1, GAL-3 and HIF-1α in the heart during the first 24 hours
following acute MI has helped in understanding early molecular changes in this
event and may provide methods to overcome serious complications. Our work
further showed that GAL-3 acted as a regulator of proinflammatory and
antiapoptotic mechanisms in the myocardium after myocardial infarction that will
shape the future course of the disease. GAL-3 was also shown to interfere with
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redox pathways controlling cell survival and death and plays a protective role in
the pathogenesis of ischemia reperfusion injury in the heart.

Our work has

contributed in understanding the local microenvironment in which GAL-3 works
in the heart after ischemia/infarction or ischemia-reperfusion and has opened a
new window in understanding the exact role of GAL-3 in the heart.

Key words: Myocardial infarction, Ischemia reperfusion injury, Galectin-1,
Galectin-3, HIF-1 α.
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)ABSTRACT (ARABICملخص األطروحة
يعتبر احتشاء العضلة القلبيه من اخطر مظاهر أمراض الشريان اإلكليلي وسبب رئيسي للوفيات والمراضه
في جميع انحاء العالم .جالكتين  1و جالكتين  3هي بروتينات لها خاصية االتحاد مع بيتا جالكتوسايد وتتمتع
بوظائف متنوعة .اما العامل المحرض لنقص االكسجة ١-نوع أ فهو عامل نسخ يساهم في االستجابات
المبكرة والمتأخرة الناجمة عن ضعف تروية العضلة القلبيه .في هذا العمل ،نهدف الى دراسة االثار
المباشرة لنقص تروية العضله القلبيه على بروتينات جالكتين  1و جالكتين  3و العامل المحرض لنقص
االكسجة  1-نوع أ في القلب .تم استخدام فئران نوع  C57B6وفئران منزوعه لجين الجالكتين  3في
نموذجي التجارب المستخدمه في هذه الدراسه .ففي نموذج احتشاء العضله القلبيه قمنا بعمل عقده دائمية
للشريان القلبي االمامي االيسر النازل لخلق نقص في تروية عضلة القلب األمامية .بينما في نموذج نقص
الترويه واعادة الضخ قمنا بعمل عقده مؤقته للشريان القلبي االمامي االيسر النازل بعدها يتم اعادة الضخ .تم
تجهيز عينات القلب الجراء الصبغات النسيجية المناعيه و الصبغات المستشعه المناعيه و فحص التنشيف
الغربي وفحص االنزيم المرتبط المناعي وفحص الوقت الحقيقي الكمي لتفاعل سلسة البلمرة .وكذلك تم
دراسة معلمات االلتهابات والموت المبرمج للخاليا و والشد التأكسدي .أظهرنا للمره االولى ارتفاع تركيز
بروتينات جالكتين  1و جالكتين  3و العامل المحرض لنقص االكسجة  1-نوع أ في البطين االيسر في فتره
مبكره بعد نقص الترويه بالتزامن مع نشاط مضاد لموت الخاليا المبرمج .و تعتبر نتائجنا عن زيادة تركيز
بروتينات جالكتين  1و جالكتين  3و العامل المحرض لنقص االكسجة  1-نوع أ في البطين االيسرخالل
االربع والعشرين ساعة االولى بعد نقص الترويه مهمة جداً لفهم التغيرات الجزيئيه المصاحبه لنقص التروية
ويمكن أن توفر وسائل للتغلب على مضاعفات خطيرة .وكذلك اظهرت نتائجنا بأن بروتين جالكتين 3يعمل
كمنظم آلليات األلتهابات وموت الخاليا المبرمج في عضلة القلب بعد احتشاء عضلة القلب والتي ستشكل
المسار المستقبلي للمرض .وقد تبين أيضًا بأن بروتين جالكتين 3يتدخل في مسارات األكسده المسيطره على
بقاء وموت الخليه ويلعب دوراً وقائيا ضد األذى الناتج عن نقص التروية وأعادة الضخ في القلب .وقد ساهم
عملنا في فهم البيئه المجهريه المحليه التي يعمل بها بروتين جالكتين 3في القلب بعد نقص التروية أو نقص
الترويه واعادة الضخ  ،وفتحت نافذة جديدة في فهم الدور المحدد من بروتين جالكتين 3في القلب.

الكلمات الرئيسية :احتشاء عضلة القلب ،نقص التروية واعادة الضخ  ،جالكتين  ، 1جالكتين  ، 3العامل
المحرض لنقص االكسجة  1-نوع أ
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Chapter 1: Introduction
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1.1 Overview
Cardiovascular diseases (CVDs) are the number one cause of death in the
world today. According to the World Health Organization (WHO), more people
die annually from CVDs than from any other cause (1). An estimated 17.3
million people died from CVDs in 2008 and out of these deaths, 7.3 million were
due to coronary heart disease (1). The number of people who will die from CVDs
is projected to increase to 23.3 million by 2030 (1, 2). These figures show that the
epidemic of CVD is a global phenomenon (3) and the magnitude of this problem
will increase.

CVDs are also the major cause of death in the United Arab

Emirates (UAE). Health Authority Abu Dhabi (HAAD) statistics from 2012 put
cardiovascular diseases as the leading cause of death in Abu Dhabi comprising
39% of all causes of deaths (4).

Coronary artery disease (CAD) is the leading cause of heart failure (HF).
The Framingham Heart Study suggests that the most common cause of HF is no
longer hypertension or valvular heart disease, as in previous decades, but rather
CAD (5). This shift may be related to improved survival of patients after acute
myocardial infarction (MI) (6).
manifestation of CAD.

MI is the most dreaded but most likely

Early diagnosis and timely intervention remains the

cornerstone of therapy for acute MI. The standard care for the treatment of acute
MI is primary reperfusion therapies, including primary percutaneous coronary
intervention (PCI) and thrombolysis.

Prompt restoration of blood flow to

ischemic myocardium on the one hand limits infarct size and reduces mortality (7)
but on the other hand can lead to further damage to the heart, referred to as
reperfusion injury (8).
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Understanding the very early changes that occur in the myocardium after
myocardial infarction is essential in understanding the pathophysiology of the
disease. It is the key to devising ways that will ultimately enable diagnosing a
cardiac ischemic event before it has caused significant damage to the heart. In
addition, looking at the players that take part in myocardial ischemia/infarction
(MI) and myocardial ischemia reperfusion (IR) injuries is also fundamental to our
understanding of the critical differences between these two types of injuries.
In this thesis we have attempted to look at these processes in association with
our proteins of interest Galectn-1 (GAL-1), Galectin-3 (GAL-3) and Hypoxiainducible factor-1 alpha (HIF-1 α). In the results and discussion chapter of the
thesis in Sections 1, 2 and 3, we have shown that GAL-1, GAL-3 and HIF α -1 are
expressed in the myocardium at various time points post MI. Section 4 deals with
how GAL-1 and GAL-3 correlate with HIF-1 α within 24 hours post MI time. In
Section 5, we have shown that at 24-hour post MI time GAL-3 is a proinflammatory and anti-apoptotic mediator using GAL-3 knockout animals.
Section 6 emphasizes GAL-3’s role in oxidative stress after IR injuries in the
myocardium. Finally Section 7 explains the differences we observed in the two
models of disease studied i.e., MI and IR and discusses GAL-3’s contribution to
these two mechanisms of injury.
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1.2 Review of Literature
1.2.1 The Heart
“The

heart

has

its

reasons

which

reason

knows

not.”

Blaise Pascal
The heart beats more than 2.5 billion times in an average life time. Its
muscular walls contract to pump blood to all parts of the body. Effective function
of the heart requires an efficient oxygen delivery system. The heart maintains a
high level of oxygen extraction of 70% to 80% compared with 30% to 40% in
skeletal muscle (9) which is supported by capillary density of 3000 to 4000
compared with 500 to 2000 per 1 mm2 in skeletal muscle and a tight regulation of
the coronary blood flow (10). The human heart contains an estimated 2 to 3 billion
cardiac muscle cells which make up less than a third of the total number of cells in
the heart. The other cell types are smooth muscle and endothelial cells of the
coronary vasculature and the endocardium, fibroblasts and other connective tissue
cells, mast cells, and immune system–related cells (11). The normal anatomy of
the heart is comprised of 4 chambers, 2 atria and 2 ventricles and 4 valves, the
mitral, tricuspid, aortic and pulmonary. The heart has its own vascular system
called the coronary arterial system. It comprises two major coronary arteries, the
right and the left. The two coronary ostia arise from the sinuses of Valsalva just
above the aortic valve. The left coronary artery divides into the left anterior
descending artery (LAD) and circumflex artery (LCX). It supplies the lateral and
anterior walls of the left ventricle, and the anterior two thirds of the
interventricular septum. The right coronary artery supplies the right ventricle, the
posterior wall of the left ventricle and posterior third of the septum.
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Balance between metabolic demand and supply in the myocardium is crucial
for the survival and proper functioning of the heart. Myocardial ischemia can
result if there is an imbalance due either to decreased coronary blood flow or
increased requirement, giving rise to the clinical conditions of acute coronary
syndrome or stable coronary artery disease. Hypoxia is an integral component in
ischemic cardiomyocytes which triggers multiple signaling pathways that cause
these cells to adapt and subsequently survive ischemic insult (12).
1.2.2 The Galectins family
Galectins are a family of β-galactoside-binding lectins (13).

Fifteen

members have been identified and are found to be widely distributed from lower
invertebrates to mammals (14, 15). Barondes et al.

proposed the name of

galectins and suggested that all the galectins need to have affinity for βgalactosides and sequence similarity in the carbohydrate binding site (13, 14).
Galectins are classified on the basis of their biochemical structure into three
groups (16): (a) Prototype galectins (galectins-1, -2, -5, -7, -10, -11, -13, -14 and 15). These contain one carbohydrate recognition domain (CRD) and a short Nterminal sequence and can exist as monomers or non-covalent homodimers; (b)
Tandem Repeat group (galectin-4, -6, -8, -9, and -12). These consist of two CRDs
linked via a short peptide sequence, and (c) Chimera-type galectins (galectin-3).
These exist as monomers with a long N-terminal tail containing a proline-,
glycine-, tyrosine-rich domain fused onto the CRD that allows the formation of
oligomers (17, 18) (Fig. 1.1).
Galectins are highly conserved evolutionary (19). They are present in
intracellular as well as extracellular compartments. They lack the signal sequence
required for secretion through the classic secretory pathway suggesting that they
5

are secreted through the non-classical pathway (20, 21).

Their extracellular

functions are through the interactions with cell surface and extracellular matrix.
The intracellular functions are via interaction with cytoplasmic and nuclear
proteins (22-25). Galectins show great diversity in functions. From regulation of
cell growth, apoptosis, inflammation and cell adhesion to embryonic
development, they play variable roles at different times and under different
conditions (15, 22, 24-29). GAL-1 and GAL-3 are the most studied galectins of
all and we will focus our attention on these two members with emphasis on their
role in the heart under ischemic/hypoxic conditions.
1.2.3 Galectin-1
Galectin-1 (GAL-1) is a pleiotropic dimeric protein of 14 kD participating in
a variety of normal and pathological processes (13). In humans it is encoded by
the LGALS1 gene and is highly conserved across species. GAL-1 belongs to the
galectin family of lectins and is characterized by one carbohydrate recognition
domain (CRD) that can occur as a monomer or as a non-covalent homodimer
consisting of subunits of one CRD (13, 26).
GAL-1 is ubiquitously expressed. It can act both inside cells, via sugarindependent interactions, and outside cells displaying lectin activity (26). GAL-1
is secreted and found on the cell surface, as well as in the extracellular matrix.
GAL-1’s

export from mammalian cells have been shown to occur in a

nonclassical manner independent of the function of the endoplasmic reticulum
(ER) and the Golgi (20). It lacks recognizable secretion signal sequences and is
secreted via inside-out transportation involving direct translocation across the
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Figure 1.1: Types of Galectin.
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plasma membrane

requiring unidentified integral membrane proteins and

cytosolic factors (30).
In the extra cellular compartment, GAL-1 forms lattice-like complexes with
receptors that participate in recognition of cell matrix (31-34). It binds to various
cell matrix components in a dose-dependent and β-galactoside-dependent manner
in the following order: laminin > cellular fibronectin > thrombospondin > plasma
fibronectin > vitronectin > osteopontin (35). In the Intracellular compartment
GAL-1 has been shown to be present in cells nuclei and cytosols (26). Due to its
pervasive presence both inside and outside the cells and its production by various
cells of vascular, interstitial, epithelial, and immune origin (36-39), GAL-1 is
involved in a variety of biological functions, including cell-cell and cell-matrix
interactions, cell adhesion, migration, invasion, metastasis, apoptosis, regulation
of cell cycle, RNA splicing and transcription (34, 40-44).
GAL-1 has both positive and negative effects on cell growth depending on
cell type, activation status or intracellular versus extracellular forms (26). For
example, GAL-1 is mitogenic for hepatic stellate cells (45) and mammalian
vascular cells (46, 47) but inhibits growth in bone marrow cells (48).

The

antiproliferative effects of GAL-1 result from the inhibition of the Ras-MEK-ERK
pathway. Gal-1 induces p21 transcription and selectively increases p27 protein
stability. This GAL-1 -mediated accumulation of p27 and p21 inhibits cyclindependent kinase 2 activity which ultimately results in G1 cell cycle arrest and
growth inhibition (49).
GAL-1 is also involved in apoptosis.

The events that lead to GAL-1

mediated apoptosis involve the modulation of Bcl-2 protein production,
cytochrome c release, activation of caspases and the participation of the ceramide
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pathway among other pathways (50, 51). GAL-1 is also implicated in cytochrome
c and caspase

independent cell death which

involves the rapid nuclear

translocation of EndoG from mitochondria (52).
GAL-1 is

known to be

involved in the initiation, amplification, and

resolution of inflammatory responses (36). GAL-1 also suppresses the secretion
of the proinflammatory cytokine IL-2 and favors the secretion of the antiinflammatory cytokine IL-10 (53, 54).

GAL-1 has been shown to reduce

transmigration of both neutrophils and mast cells into the tissue (55) and to be
responsible for inhibiting mast cell degranulation, and eosinophil migration (5658). These studies suggest that GAL-1 inhibits the migration of inflammatory
cells. GAL-1 plays a role in neutrophil priming by inducing an oxidative burst in
neutrophils that have extravasated into tissue (59). GAL-1 is important in chronic
inflammation.

It attenuates disease processes in experimental models of

autoimmune encephalomyelitis (60), arthritis (61), colitis (62) and hepatitis (63).
As a whole, GAL-1 functions as a homeostatic agent by modulating innate and
adaptive immune responses (26).
Although GAL-1 is involved in very important functions in vitro and in vivo,
GAL-1 null mice are viable indicating that its presence is not critical for
mammalian development or survival (33).
1.2.3.1 Galectin-1: a hypoxia induced protein
Studies have identified GAL-1 as hypoxia-induced protein. The hypoxic
regulation of GAL-1 at mRNA and protein levels has been demonstrated in tumor
biology and has the potential to be used as a prognostic marker of malignancy
(64). Under hypoxic or ischemic conditions in the brain either in vitro or in vivo,
GAL-1 was found to inhibit the proliferation of astrocytes and attenuate
9

astrogliosis. GAL-1 treatment reduces apoptosis of neurons, decreased brain
infarction volume and improved neurological function induced by the ischemia,
making GAL-1 a potential therapeutic target for attenuating neuronal damage and
promoting recovery of brain ischemia (65). Studies have shown that in lung
tissue, the expression of GAL-1 is diffusely distributed throughout the interstitium
and near to the basement membrane of vessels and airways in both normal and
hypoxia-exposed mice. The difference is that the intensity of GAL-1staining was
increased in hypoxia-exposed mice, which suggests that GAL-1 may be important
in adaptive responses of murine lung to chronic hypoxia (66). The abovementioned studies have shown that GAL-1 is regulated by hypoxia but its exact
mechanism remains elusive.
Recently, Zhao et al (67) have demonstrated that hypoxia inducible factor1α (HIF- 1α) significantly increases GAL-1 expression in messenger RNA and
protein levels in four colorectal cancer cell lines and it has been proposed that
GAL-1 gene is a direct target of transcriptional factor HIF-1 α (66, 67).
1.2.3.2 Galectin-1 in heart
GAL-1 plays a role in the development and regenerative ability of the
muscles. It induces non-committed myogenic cells to express myogenic markers
and in this way increases terminal differentiation of committed myogenic cells
(68-70).

GAL-1 is a major component of the contractile machinery in

cardiomyocytes (71) which suggests that it must be playing an important role in
regulating cardiac functions. Very recently it was seen in a study by Seropian et
al that GAL-1 expression is increased in patients with end stage chronic heart
failure (72). In murine models of MI it was increased at one week after MI
suggesting a role of this lectin in post infarction remodeling (72).
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GAL-1

knockout animals showed enhanced cardiac inflammation and the animals treated
with recombinant GAL-1 attenuated cardiac damage which points towards a
positive role of GAL-1 in cardiac homeostatsis and post infarction remodeling via
preventing cardiac inflammation.
GAL-1’s role in the pathophysiology of the heart is an area of ongoing
research. Till today very little is known about the exact function of GAL-1 in the
myocardium and in this thesis we will investigate whether there is any change in
the endogenous production of GAL-1 in early ischemia and its pattern of
expression in the ischemic and non-ischemic cardiomyocytes.
1.2.4 Galectin-3
Galectin-3 (GAL-3) plays a central regulatory role in several diverse
biological processes and disease states. GAL-3 is a member of the Galectin
family of lectins that specifically bind to N-acetyl-lactosamine-containing
glycoproteins (13). GAL-3 is the sole member of this family that contains one
CRD linked to a proline, glycine, and tyrosine-rich repeat N-terminal domain
(ND) (19). The CRD is composed of approximately 130 amino acids and is
responsible for the lectin activity of GAL-3. The ND is composed of 110-130
amino acids, lacks the carbohydrate binding activity but is essential for full
biological activity of GAL-3(73).

GAL-3 exists in both phosphorylated and

unphosphorylated forms. Phosphorylated form is found in cytoplasm and nucleus
whereas unphosphorylated form is only found in the cytoplasm (74).
GAL-3 is ubiquitously expressed. It is expressed in a variety of cells, e.g.,
endothelial and epithelial cells, activated macrophages (75-77), activated
microglial cells (78, 79), inflammatory cells including macophages, basophils,
mast cells, eosinophils, and neutrophils (41, 80, 81) (20, 82) and subsets of
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neurons (83). Galectin-3 is considered a “macrophage activation marker” due to
the fact that its expression is up-regulated in phagocytic macrophages (84).
In tissues, galectin-3 is expressed in lung, spleen, stomach, colon, adrenal
gland, uterus, ovary, prostate, kidney, heart, cerebrum, pancreas, and the liver
(85).
GAL-3 is distributed in the extracellular as well as intracellular
compartments. Extracellular GAL-3 plays a role in cell-cell adhesion, cell-matrix
interaction and signaling (86-89). There have been reports of extracellular GAL-3
acting as a factor that induces apoptosis (90). Intracellular GAL-3 on the other
hand is involved in cell proliferation, mitosis and acts as an anti-apoptotic
mediator (91-94). It affects K-Ras (95, 96) and Akt proteins (97, 98) and so also
regulates differentiation, survival, and death (99, 100). Intra-nuclear localization
of GAL-3 is well documented even in the absence of a nuclear localization signal.
It is involved in spliceosome assembly (101) and pre-mRNA splicing (101-103).
Also it is implicated in regulation of gene transcription (92) and Wnt/β-catenin
signaling pathway.
Cellular localization of GAL-3 determines its biological functions. Some
cell types show intense cytoplasmic localization but do not express GAL-3 in the
nucleus (104, 105) even if GAL-3 is overexpressed (106), suggesting

the

importance of variable GAL-3 functions in specific cell types. Its localization
depends on factors such as proliferation state of cells (107-111), cultivation
conditions (112), neoplastic progression (113-117) and transformation (118) (73).
Its distribution in many types of cells and tissues, combined with variable
subcellular localization signifies that GAL-3 is central to many physiological and
pathological conditions (119, 120).
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GAL-3 is secreted outside the cell through non-classical pathway (121).
Despite its lack of appropriate signal peptides GAL-3 can cross the plasma
membrane through its interaction with extracellular matrix proteins. Secretion of
GAL-3 is critically regulated at the plasma membrane (122). Regulation of GAL3 expression is a very complex mechanism that involves many transcription
factors and signaling pathways.
1.2.4.1 GAL-3 in inflammation
GAL-3 is involved in many processes during the acute inflammatory
response. In addition to being highly expressed and secreted by macrophages
(123), it causes neutrophil activation and adhesion (124), chemoattraction of
monocytes or macrophages (77) and activation of mast cells (125). Intracellular
GAL-3 is also shown to promote the survival of inflammatory cells resulting in
persistence of inflammation (76). Secreted GAL-3 can also stimulate oxidative
burst in neutrophils (126). In a study involving GAL-3 knockout mice, it was
shown that these mice developed severe pneumonia and that GAL-3 induced lung
damage by acting as a neutrophil activating agent. Exogenous galectin-3 also
augmented neutrophil phagocytosis of bacteria and delayed neutrophil apoptosis
(127). Neutrophils expression can be activated by extracellular GAL-3. It was
found that neutrophil survival is enhanced after incubation with exogenous
galectin-3 (127). The same observation regarding GAL-3 was also reported in a
study of airway inflammation and bronchial hyper-responsiveness in a murine
model of ovalbumin-induced asthma (27). Peribronchial inflammatory cells and
bronchoalveolar lavage fluid expressed large amounts of galectin-3 in
experimental animals compared to experimental controls (128).
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In addition to its role in acute inflammatory responses, GAL-3 also acts as a
very important factor in chronic inflammation and its resulting fibrosis. In a
mouse model of renal unilateral ureteric obstruction leading to renal fibrogenesis
it was found that GAL-3 was raised in the kidney and played a role in renal
myofibroblast accumulation and fibrogenesis (129). In some instances GAL-3
can also act as a protective factor in disease processes. It was observed in diabetic
mice that GAL-3 null mice developed increased proteinuria, albuminuria,
glomerular sclerosis and more marked accumulation of glomerular advanced
glycation endproduct (AGE) suggesting a favorable role of GAL-3 in the kidney
(130, 131). Therefore GAL-3 can be viewed as a regulatory molecule acting at
various stages along the continuum from acute inflammation to chronic
inflammation and tissue fibrogenesis (132).
1.2.4.2 GAL-3 in Apoptosis
GAL-3 can act as both proapoptotic and antiapoptotic protein. Intercellular
GAL-3 acts as an antiapoptotic factor and extracellular GAL-3 as a proapoptotic
factor in various states (73). There is evidence that GAL-3 contains the anti-death
Asp-Trp-Gly-Arg (NWGR) motif (7, 13) which is critical for its antiapoptotic
function.

The anti-apoptotic activity of GAL-3 was also demonstrated in

peritoneal macrophages when those from galectin-3-deficient mice were more
sensitive to apoptotic stimuli than those from control mice (75). GAL-3 protects
cells against apoptosis by working through different mechanisms which suggests
that GAL-3 regulates the common apoptosis commitment step. Regarding the
proapoptotic activity of GAL-3, Lee et al. have shown that GAL-3 overexpression
potentiated TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)
induced cytotoxicity (97).
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GAL-3 translocates to the perinuclear membrane following apoptotic stimuli
(133) (134).

It is enriched in the mitochondria and prevents mitochondrial

damage and cytochrome c release. GAL-3’s antiapoptotic effect is proposed to be
due to its activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway,
which blocks loss of the mitochondrial membrane potential, resulting in inhibition
of caspase-9 and caspase-3 activation and suppression of apoptosis (98).
The most interesting feature regarding GAL-3 is its expression in different
cell types under different physiological and pathophysiological conditions.
Although considerable work has been conducted to elucidate the pathways
regulating its expression precise mechanism nevertheless still remains uncertain.
1.2.4.3 GAL-3 in the heart
Recently published data has established a very strong role of GAL-3 in heart
failure (135). Sharma et al. (136) showed that a 4-week continuous infusion of
low dose GAL-3 into the pericardial sac of healthy Sprague–Dawley rats led to
left ventricular dysfunction, with a threefold differential increase of collagen I
over collagen III.

In heart failure prone hearts in mice, it was also shown that

GAL-3 was a robustly over-expressed gene in failing versus functionally
compensated hearts (136). Thandavarayan et al. (137) recently showed that
upregulation of GAL-3 in the left ventricle is a general phenomenon of LV
dysfunction and not confined to models with increased angiotensin II (AngII)
signaling. Increased Gal-3 secretion stimulates release of various mediators, such
as transforming growth factor β and promotes enhanced macrophage and mast cell
infiltration, cardiac fibroblast proliferation, with development of interstitial and
perivascular fibrosis, collagen deposition, and ventricular dysfunction (136, 138).
GAL-3 was localized at the very sites of fibrosis, colocalizing with fibroblasts and
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macrophages and its binding sites were localized predominantly to fibrotic areas
(136).
In humans, ventricular biopsies from patients with aortic stenosis with
preserved or depressed ejection fraction were studied. The results showed that
GAL-3 was upregulated in the biopsies from patients with depressed ejection
fraction (136) lending support to the notion that GAL-3 is associated with
decompensated heart failure.

Higher levels of GAL-3 were associated with

recurrent heart failure and increased risk of death in a number of studies (139142). This has led to the use of GAL-3 levels as a prognostic marker in patients
with heart failure. GAL-3 also predicted all-cause death (143) and demonstrated a
relationship between GAL-3 and future heart failure and re-hospitalizations in the
general population (144).
Despite its established role in heart failure, GAL-3 has not been studied
directly in relation to cardiac ischemia. In other organs, e.g., Galectin-3 mRNA
increased after ischemic injury in acute renal failure in rats (145). There was also
up-regulated expression of GAL-3 in the ischemic brain following transient
middle cerebral artery occlusion in rats and in neonatal hypoxic ischemic brain
injury (79, 146). In this thesis, we aim to study the direct effects of ischemia on
GAL-3 levels in the heart very early in the course of events following myocardial
infarction.
1.2.5 HIF-1 alpha

Hypoxia-inducible factor-alpha (HIF-1α) is the master regulator of cell
response to hypoxia (147). It activates transcription of many genes, the protein
products of which increase oxygen delivery or facilitate metabolic adaptation to
hypoxia, and thus plays an essential role in the pathophysiology of ischemic
16

diseases. HIF-1 α is a heterodimeric DNA-binding complex composed of two
basic helix-loop-helix proteins, the constitutive expressed HIF-β or aryl
hydrocarbon receptor nuclear translocator

(ARNT) and the oxygen sensitive

hypoxia-inducible HIF-α (148). HIFα exists in three isoforms HIF1α, HIF2α and
HIF3α (149). which heterodimerize with ARNT (HIF-1β), ARNT2, or ARNT3
subunit through their HLH (helix-loop-helix) and PAS (Per – period circadian
protein, Arnt – aryl hydrocarbon receptor nuclear translocator protein, Sim –
single-minded protein) domains. HIF heterodimers recognize and bind to hypoxia
response elements (HREs) in the genes that have the consensus sequence
G/ACGTG (150) . HIF-1α and ARNT (HIF-1β) mRNA are expressed in most of
the mammalian tissues; though, HIF-2α, HIF-3α, ARNT2, and ARNT3 show a
more restricted pattern of expression (151).
1.2.5.1 Regulation of HIF-1 α
Normoxic conditions lead to hydroxylation of two prolyl residues by prolyl
hydroxylases (PHDs) in the oxygen dependent degradation domain (ODDD) of
the α-subunit of HIF-1 α. This causes the von Hippel–Lindau tumor suppressor
protein (pVHL) to interact with the α-subunit, targeting it for proteolysis by the
ubiquitin–proteasome pathway (152, 153). Therefore, in normoxia HIF-α subunit
has a very short half-life (154) and cells continuously synthesize and degrade
HIF-α protein. Hypoxia causes inhibition of the prolyl hydroxylation, HIF-α
protein escapes proteasomal degradation, translocates to the nucleus and
dimerizes with HIF-1β. This complex then binds to the HRE in promoter or
enhancer sequences of target genes (155) and results in their transcription. HIF α
subunits are also degraded by oxygen sensitive Factor Inhibiting HIF-1α (FIH1),
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an asparaginyl hydroxylase that stops the interaction between HIF-1α and coactivators p300/CBP and impairs transcription (156, 157).
1.2.5.2 HIF-1 α in the heart
HIF-1α is involved in the pathophysiological responses of a variety of
diseases, including cancer, inflammation and tissue ischemia (158). Expression
microarray analysis of genes induced by hypoxia showed that 45 genes were upregulated by hypoxia and 40 (89%) of these were regulated by HIF-1 α (159).
There is a great body of evidence supporting the protective role of HIF-1α in
cardiovascular pathophysiology, however, newer studies hint at a maladaptive and
deleterious role of this transcription factor that merits further investigation.
1.2.5.3 HIF-1 α is cardio-protective
An increase in the level of HIF-1α is one of the first adaptations of human
myocardium to ischemia (160) (Fig.1.2)

HIF1α can directly reprogram the

metabolic state in cells (158) and set it in a prosurvival mode. HIF-1 α on the one
hand increases transcription of glucose transporters and glycolytic enzymes to
improve glucose utilization (161-163) and on the other hand inhibits
mitochondrial respiration (164-166) to decrease oxygen usage.

It establishes

balance between glycolytic and oxidative metabolism that maximizes ATP
production without increasing ROS (reactive oxygen species) levels (167).
HIF-1 α targets that have cardioprotective effects in the setting of ischemic
and or ischemia/reperfusion injury include a variety of genes, including
erythropoietin (EPO), vascular endothelial growth factor (VEGF), inducible
nitrics oxide synthase (iNOS), hemeoxygenase-1 (HMOX-1) and cardiotrophin.
EPO is well known for its effect on the red cell mass to increase oxygen delivery
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Figure 1.2: Protective and deleterious effects of HIF-1α. BNIP3 indicates
BCL2/adenovirus E1B 19 kDa protein-interacting protein3; CT-1, cardiotropin-1;
EPO, erythropoietin; GLEN, glycolytic enzymes; GLUT, glucose transporters;
GPER, G-protein estrogen receptor; HIGD-1, hypoxia-induced gene domain
family-1α; HMOX-1, hemeoxygenase-1; iNOS, inducible nitric oxide synthase;
MEN, mitochondrial enzymes; p53, tumor suppressor protein 53; ROS, reactive
oxygen species; SERCA, sarco/endoplasmic reticulum Ca2+-ATPase; sFlt-1,
soluble fms-like tyrosine kinase-1; VEGF, vascular endothelial growth factor.
(Hashmi S, Al-Salam S. Hypoxia-inducible factor-1 alpha in the heart: a double
agent? Cardiol Rev. 2012 Nov-Dec; 20(6):268-73)
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to the tissues in response to hypoxia (168). This effect is protective in the long
term but EPO is also shown to have cardioprotective effects in vivo and in vitro in
directly improving left ventricular function and deceasing activity of the proapoptotic caspase-3 by activating PI3K-Akt cell survival pathways (169, 170).
VEGF imposes cardioprotection through increased cardiac vascularization (171,
172) while iNOS achieves this (173-175) through cGMP and subsequent opening
of mitochondrial potassium-ATP channels, hence preventing ATP depletion,
which is advantageous in the heart. HIF-1 α target HMOX-1 is cardioprotective
(176, 177)

via multiple pathways that involve direct cytoprotective and

antiapoptotic

effects

of

carbon

monoxide

and

antioxidant

effects

of

biliverdin/bilirubin and ferritin (178). HIF-1 α is directly involved in the upregulation of Cardiotrophin-1 (CT-1) which protects cardiomyocytes from
hypoxia-induced apoptosis (179, 180).
Cardioprotection mediated by HIF-1 α results in decreased infarct size and
improved cardiac function. These beneficial effects were seen in murine hearts
exposed to constitutive overexpression of HIF-1α (172).

HIF-1α contributes to

the limitation of infarct size mainly by promoting angiogenesis (181). Cultured
neonatal cardiomyocytes were protected against ischemia-reperfusion injury by
adenovirus-mediated expression of constitutively stable hybrid forms of HIF-1 α
through induction of multiple protective genes (182). HIF-1α is also involved in
cardioprotection by ischemic pre-conditioning and post-conditioning.

Pre-

conditioning is a phenomenon where one or more short ischemic episodes confer
protection against cell death following the actual prolonged ischemic insult (183).
HIF-1α is postulated to play a role by regulating mitochondrial respiration (184).
Post-conditioning is induced by repetitive short episodes of reperfusion and
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ischemic re-occlusion before permanent reperfusion and HIF-1α attenuates
myocardial injury through this phenomenon (185).
Some authors suggest a positive association of HIF-1α with ischemiainduced coronary collateralization (186, 187) which by increasing blood supply to
hypoperfused regions of the heart confers protection to the myocardium against
ischemic injury.
PHDs inhibition is another mechanism to achieve HIF-1α mediated effects.
Mammalian cells have 3 types of PHDs: PHD1, PHD2 and PHD3. PHD2 and
PHD3 are highly expressed in the heart (188).

Inhibition of PHD2 by

Dimethyloxalylglycine (DMOG) and GSK360A (189, 190), short hairpin RNA
interference (shRNA) (191)

and use of transgenic mice with cardiomyocyte

specific PHD2 knockout (192) showed cardioprotective effects.

Up-to-date

studies have identified HIF-1α to be a very credible candidate for gene therapy
and this has led to encouraging results. HIF-1α gene delivery in skeletal muscle
preceding induction of myocardial infarction has led to reduction in infarct size
and left ventricular remodeling as well as preservation of hemodynamic function
in vivo (193). Initial data from a clinical trial with HIF-1α delivered to ischemic
cardiac muscle via a type 2 adenoviral (Ad2HIF) vector is also promising (194).
Results at one year follow up show improved ventricular function and increased
perfusion of the myocardium which was initially viable but hypoperfused. Newer
studies are constantly reporting on the advantageous effects of HIF-1α. Up
regulation of HIF-1α protected cardiac myocytes against nitrate tolerance (195)
and improved the responsiveness of ageing myocytes to inotropic stimulation
(196).
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There are considerable sex related differences in the HIF-1α response which
merit careful consideration. HIF protein increased significantly in both male and
female murine hearts subjected to myocardial infarction by ligation of left anterior
descending artery (LAD), relative to sham-operated animals, but this increase was
60% greater in females than in males (197).

mRNA expression of HIF was

significantly increased in 24 hour post myocardial infarction in female mice hearts
versus male and sham-operated animals. Expression of downstream HIF target
genes was increased in proportion to the levels of HIF expression (197). Many
studies have shown that in the cardiovascular system, estrogens play a protective
role against ischemia (198, 199). The ability of 17- beta estradiol (E2) to counter
the oxygen radicals has been considered as a principal factor of overall
cardioprotection (200). G-protein estrogen receptor (GPER), has been found
recently to mediate the estrogen effects (201). GPER is an HIF target gene,
providing evidence for a new mechanism by which estrogens exert biological
effects under hypoxic conditions. Hypoxia-induced expression of GPER may be
included among the mechanisms involved in anti-apoptotic effects elicited by
estrogens, particularly in a low oxygen microenvironment (202).
There are also significant sex differences in adaptation to chronic hypoxia
that may reflect the different sensitivity of males and females to oxygen
deprivation and other stresses (203). Sex dependence in development of cardiac
hypertrophy and the reduced risk for cardiovascular diseases in females have also
been reported in both epidemiological and experimental studies (204, 205). In
light of the above observations, the diagnostic and therapeutic procedures related
to HIF-1 α have to be optimized based on sex (203).
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1.2.5.4 HIF-1 α is cardio-deleterious
The first evidence for a cardio-deleterious role of HIF-1α came from a study
by Lei et al. where knocking-out the von Hippel- Lindau gene led to stabilization
of HIF-1α and resulted in dilated cardiomyopathy with a variety of marked
histological findings including lipid accumulation, myocyte loss, fibrosis, and
even malignant transformation (206). HIF- 1α was implicated in this development
due to the observation that concomitant deletion of von Hippel- Lindau gene and
HIF-1α in the heart prevented this phenotype and restored normal longevity.
Bekeredjian et al (207) generated a transgene containing the human HIF1α cDNA with alanine substitutions at Pro402, Pro564, and Asn803 (denoted
HIF-1a-PPN) to study the effects of enhancing HIF-1 α activity in the adult
animals in a normoxic environment (207).

These animals showed enhanced

angiogenesis which was expected, but also showed ventricular dysfunction. A
possible explanation for this observation was substantial down-regulation of the
mRNA for sarco/endoplasmic reticulum Ca2+-ATPase gene (SERCA) (Fig.1.2)
leading to reduced ionotropy, and ventricular dysfunction (207). Interestingly,
these effects were reversible on cessation of transgene expression indicating that
the dysfunction was not related to cardiomyocyte death (207). Another study
showed that although infarct size and perioperative mortality were significantly
lower in the mice which lacked cardiac PHD2 compared with the PHD2-proficient
mice, cardiac function deteriorated more rapidly in mice which lacked cardiac
PHD2 (208). Combined loss of PHD2 and PHD3 in the heart shows significant
left ventricular dysfunction and premature mortality associated with myocardial
thinning and LV dilatation, hallmarks of severe cardiomyopathy (208).
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HIF1α also plays an important role in adaptive cardiopulmonary responses.
Some studies have shown that HIF-1 plays a protective role in cardiac
hypertrophy through maintenance of the cGMP signaling pathway (209),
however, others have concluded that pressure-overloaded cardiac hypertrophy in
the rat leads to abnormal regulation of HIF-1α, VEGF and BNP (210). Increased
hemodynamic load is also known to unmask deleterious consequences of cardiacspecific PHD2 inactivation (208).
An interesting observation made by Bohuslavová et al. is that the hypoxic
responses by HIF-1α target genes are differently regulated in left and right
ventricles as a means of adaptation to sustained chronic hypoxia (203) and that the
regulation of gene expression is significantly affected by HIF-1α deficiency.
1.2.5.5 The heart of the matter lies in balance
How HIF-1α will ultimately influence the heart depends on the balance
between its various actions.

Taking into account the results of the studies

reviewed, these actions at times appear to act in conflict. HIF-1α transcribes a
number of genes that play proapoptotic or antiapoptotic roles according to tissue
specificity and conditions (211). HIF -1α interacts with and activates tumor
suppressor p53, which increases mitochondrial apoptosis by inducing Bax
production, cytochrome C release and activation of caspases 3 and 9 (212). HIF1α also activates genes for the pro-apoptotic proteins NIP3 (213), BNIP3 (214),
and Noxa (215). Regarding specific effects on the heart, HIF-1a pathway is
potentially cardioprotective in reducing cytochrome c levels (166) and inducing
Higd-1 (hypoxia induced gene domain family-1a), a mitochondrial membrane
protein possessing anti-apoptotic effect through inhibition of cytochrome C
release and reduction of caspase activities (216, 217). The direct evidence of the
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role of HIF-1α- mediated apoptosis in the cardiomyocytes came from a study
which showed acute hypoxia for 24 hours enhanced primary neonatal rat
ventricular myocyte apoptosis through the activation of HIF-1α. In addition,
hypoxia increased the expression levels of HIF-1α and proapoptotic protein Bnip3
and when HIF-1α was inhibited by YC-1 (3-(5'-hydroxymethyl-2'-furyl)-1benzylindazole), there was a corresponding decrease in the level of expression of
Bnip3 protein and the degree of apoptosis (218, 219).
Biological activity of VEGF is increased by the hypoxic upregulation of
VEGF receptor-1 (VEGFR-1/Flt-1) (220).

VEGF mRNA stability is also

increased under hypoxic conditions (221). VEGF directly induced by HIF-1 α
(222) is generally considered to be cardioprotective. Both intramyocardial gene
delivery of HIF-1α and cardiac-specific over expression of HIF-1α has led to
increased cardiac vascularization with increased VEGF (171, 172). VEGF derived
increased capillary vascularity in addition to being advantageous in restoring the
delivery of blood to the heart can also contribute to cardiac dysfunction through
changes in tissue architecture, interstitial edema, or perhaps paracrine signaling
between endothelial cells and cardiomyocytes (208). VEGF exerts its effects
through its receptor vascular endothelial growth factor receptor (VEGFR).
VEGFR-1 (or Flt-1) exists under soluble fms-like tyrosine kinase (sFlt-1) or
membrane-bound

fms-like

tyrosine

kinase

(mFlt-1)

antiangiogenic, and mFlt-1 is proangiogenic (223).

form.

sFlt-1

is

sFlt1 traps circulating

VEGFA, VEGFB preventing their further binding to membrane associated
VEGFRs (224).
Long term hibernation of cardiomyocytes was induced by conditional
overexpression of sFlt1 which was accompanied by cardiomyocyte dysfunction
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and reduced ventricular contraction (225). sFlt1 levels are increased in coronary
artery disease (226) post MI (227) and in patients developing severe acute heart
failure (228). They are also shown to predict mortality in patients with symptoms
of acute MI (229). HIF-1 α upregulates sFlt1 expression (230) and so this factor
needs to be considered in the sustained HIF-1 α activity in the setting of chronic
ischemia.
1.2.5.6 Is there a cutoff point?
There is a general agreement that HIF-mediated responses appear to differ
under conditions of acute and chronic oxygen deprivation. The intensity and
sustainability of HIF-1α activation are major determinants of whether the
responses are pathological or beneficial. HIF activation is seen to be beneficial in
the setting of acute myocardial ischemia and deleterious in chronic conditions
(208). Sustained angiogenesis over a long term (208), uninhibited mitochondrial
apoptosis (212) and HIF-1 α controlled metabolic changes in the cell which may
be adaptive over a short period of time but maladaptive if sustained over
prolonged periods, are some possible mechanistic basis for these differences
between acute and chronic activation of HIF.
1.2.5.7 HIF-1 α: more questions?
The role of HIF-1α is extremely complex. The heterogenousity of its effects
on the heart is a challenge for scientists because on the one hand the therapeutic
strategies aiming at increasing HIF-1α in the heart are very actively being pursued
but, on the other hand, the long term effects of these modalities are yet to be made
clear.

It is not merely a matter of acute and chronic hypoxia exposure, but the

challenge now for scientists is to determine the cutoff or the threshold where HIF1α stops being beneficial and starts its detrimental effects.
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A very recently

published study shows that in the heart, exposure to acute or chronic hypoxia does
not involve HIF-1α stabilization (231). In this study, the measured HIF-1α in
cardiac nuclear extracts at both protein and transcriptional levels by
immunoblotting and by qRT-PCR, showed no changes in HIF-1α protein and
mRNA amounts (231).

The authors claimed that inhibition of complex I and

complex III of the electron transport chain in the mitochondria destabilizes HIF1α (232-235) and so in acute hypoxia AMPK (AMP-activated protein kinase)
activation governs the metabolic adaptation with Bnip3 upregulation and PGC-1
(peroxisome proliferator-activated receptor γ coactivator-1) downregulation,
whereas in chronic hypoxic conditions up-regulation of enzymes involved in
antioxidant defense and misfolded protein degradation and down-regulation of
enzymes controlling anaerobic metabolism are important.
To add to the complexity of HIF -1α influence in our cellular functions, we
know that HIF-1α is not only induced in hypoxia but other factors such as
insulin-like growth factor, epidermal growth factor, interleukin-1 and Ras and Src
oncogenes are also known to regulate it (236-240). There is a possibility therefore
that an interplay of these and other factors-in addition to the hypoxia-creates a
local environment that will cause HIF-1 α levels to fluctuate and exert its
prosurvival or disadvantageous effects.
The effects of HIF-1 α in the heart should not be taken only in the context of
its effects in response to decreased oxygen levels or the duration of its activity in
ischemia but in relation to other players that are increased or decreased in
myocardial ischemia and which can independently regulate HIF-1 α. Further
work needs to be done to understand these interactions so that a clearer picture
emerges regarding the role of HIF-1 α in the heart.
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1.2.6 Myocardial infarction and Myocardial Ischemia reperfusion Injuries
Myocardial infarction denotes the death of cardiac myocytes due to extended
ischemia, which may be caused by an increase in perfusion demand or a decrease
in blood flow. Persistent elevation of the ST-segment on ECG indicates total
occlusion of a coronary artery that causes necrosis of the myocardial tissue. The
term "acute" denotes infarction less than 3-5 days old, when the inflammatory
infiltrate is primarily neutrophilic (241). If coronary occlusion is removed within
approximately 20 minutes after onset, tissue viability is preserved (242) and the
myocardial damage is transient resulting in temporary contractile failure of the
myocardium, but it is not associated with development of necrosis. Prolonging the
period of acute myocardial ischemia for more than 20 minutes causes a ‘wave
front’ of cardiomyocyte death that begins in the subendocardium and extends
transmurally toward the epicardium (242). This is the reason that when a patient
is presented with an acute myocardial infarction, the most effective therapeutic
intervention is timely myocardial reperfusion using thrombolytic therapy or
primary percutaneous coronary intervention to salvage the ischemic myocardium.
Myocardial reperfusion is the restoration of coronary blood flow, which either
occurs spontaneously or is therapeutically induced, after a period of coronary
occlusion. Reperfusion has the potential to salvage ischemic myocardium but
paradoxically it can cause a wide spectrum of deleterious effects results from
reperfusion itself when it is superimposed on already ischemic-altered
myocardium.

The net effect depends upon the severity and duration of the

ischemic insult before reperfusion (243).
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1.2.6.1 Mechanism of Injury in MI
In severe myocardial ischemia, there is lack of oxygen which switches the
cell metabolism to anaerobic respiration. This leads to the production of lactate
which decreases the intracellular pH. Glycogenolysis and anaerobic glycolysis
with production of ATP continue for a while (244) but is ultimately inhibited by
lactate accumulation and acidosis. In myocardial tissue, metabolic markers of
ischemia are initially decreasing levels of creatine phosphate and ATP, followed
by increasing lactate (245).

The change in pH causes Na+-H+ exchanger to

extrude H+ which leads to an intracellular Na+ overload, which activates the 2Na+Ca2+ exchanger to function in reverse to extrude Na+ and leads to intracellular
Ca2+ overload. Due to lack of ATP the Na+-K+ ATPase ceases to function,
exacerbating intracellular Na+ overload (246). The acidic conditions during
ischemia prevent the opening of the mitochondrial permeability transition pore
(MPTP) at this time.
With severe ischemia, cardiomyocyte cell death begins within 20 to 60 minutes
after the onset and continues to nearly all cells in the ischemic area within 6 hours
(247). The major determinants of myocardial infarct size are duration and severity
of ischemia, size of the myocardial area at risk, and magnitude of collateral blood
flow.
Alterations in the adrenergic nervous system and local alterations in the
adrenergic receptor-adenylate cyclase system also influence the progression of
myocardial ischamic injury. During myocardial ischemia, concentrations of
catecholamines may rise in the ischemic tissue (248) which may impose a risk of
further damage to the myocardium. In addition to the above mechanisms,
myocardial ischemia and infarction may induce serious ventricular arrhythmias
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early within the first hour of ischemia (249) which may add to the direct ischemic
damage.
1.2.6.2 Pathology of Acute Myocardial infarction
Myocardial infarction shows features of typical ischemic coagulative
necrosis (241). Grossly, the earliest change that can be seen is pallor of the
myocardium, which is visible 12 hours or later after the onset of irreversible
ischemia. The infarcted area is well defined at 2-3 days, with a central area of
yellow discoloration surrounded by the appearance of dark mottling. At 5-7 days,
the central yellow area is surrounded by hyperemic borders; At 1-2 weeks, the
borders assume a red‐grey color, from 2–8 weeks the scar starts to develop from
the periphery to the centre and healing may be complete as early as 4-6 weeks for
small infarcts or may take as long as 2-3 months for large ones (241, 250).
Microscopic appearance before 12 hours is difficult to interpret but there are
hypereosinophilic changes of the myocyte sarcoplasms with loss of cross
striations before neutrophilic infiltrates flood the area of infarct. “Waviness” may
be seen at the border of the ischemic myocardium. Coagulative necrosis starts at
12 hours post myocardial infarction.

There is nuclear pyknosis, early

karyorrhexis, and karyolysis. Neutrophil infiltration is prominent at 24 hours post
infarction which becomes extensive by 48 hours. By 5-7 days, macrophages and
fibroblasts begin to appear in the border areas. Macrophages remove the necrotic
myocytes.

After the first week, the number of neutrophils decline and

granulation tissue is established. Fibroblasts actively produce collagen, and
angiogenesis occurs in the area of healing. The granulation tissue promotes the
deposition of dense collagen by the second week and complete scar formation is
completed by the second month (241).
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1.2.6.3 Mechanism of injury in IR
It was thought initially that reperfusion only has a beneficial effect on the
ischemic myocardium and there was no cell death related to myocardial
reperfusion (243, 251, 252). When cell death was observed after reperfusion a
new idea emerged that reperfusion only accelerates the death of already
irreversibly damaged cardiomyocytes during ischemia, but does not induce death
of the cells which are still viable (253). The concept of “reperfusion injury” states
that reperfusion by itself may be able to induce death to cells that have survived
through ischemia (254). There are four recognizable forms of reperfusion injury
(255).
1) Reperfusion-induced arrhythmias: Reperfusion can lead to cardiac
arrhythmias which can terminate by themselves or are treated (256).
2) Myocardial stunning: Reperfusion can also lead to a transient and reversible
myocardial contractile dysfunction (257).
3) Microvascular obstruction: Microvascular obstruction or

"no-reflow"

phenomenon is the “inability to reperfuse a previously ischemic region” (258).
The main causes of this phenomenon include capillary damage , external capillary
compression by endothelial cell and cardiomyocyte swelling, micro-embolization
of friable material released from the atherosclerotic plaque, platelet microthrombi, the release of soluble vasomotor and thrombogenic substances, and
neutrophil plugging (259-262). No effective therapy currently exists for reducing
this phenomenon in patients who have undergone PCI.

4) Lethal myocardial reperfusion injury

Reperfusion can cause death of

cardiomyocytes that were viable at the end of the index ischemic event (8). This
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is called lethal myocardial reperfusion injury. We will discuss the mechanism of
this injury in detail below. The major contributory factors in lethal myocardial
reperfusion injury include oxidative stress, calcium overload, mitochondrial
permeability transition pore (MPTP) opening, and hypercontracture (263).

A hallmark of myocardial reperfusion is the increased generation of reactive
oxygen species (264). Mitochondria are the most important source of ROS in the
myocardium. There are many reasons for this. Cardiomyocytes have very high
energy demands thus contain a large amount of mitochondria (265). Mitochondria
have all the biomolecules that are exposed to free radical reactions, e.g., they
contain high levels of unsaturated fatty acids that are susceptible to peroxidation
reactions (266). Mitochondria are an important source of superoxide, hydrogen
peroxide and nitrous oxide generation during ischemia and reperfusion (267-270)
and so regulate ROS mediated cell death (271). During reperfusion, the electron
transport chain is reactivated, generating ROS. Other sources of ROS include
xanthine oxidase from endothelial cells and NADPH oxidase from neutrophils
(255). ROS mediate myocardial reperfusion injury by inducing the opening of the
MPTP, acting as a neutrophil chemoattractant, and mediating dysfunction of the
sarcoplasmic reticulum (SR) (255).

At the time of myocardial reperfusion, there is an abrupt increase in
intracellular Ca2+. This phenomenon is termed the calcium paradox. This is
caused by damage to the sarcolemmal membrane and sarcoplasmic reticulum
which are then unable to regulate Ca2+ in the cardiomyocyte. This Ca2+ overload
can cause injury by opening the MPTP and thereby causing hypercontracture in
the cardiomyocytes (8).
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Reperfusion causes rapid restoration blood flow to the ischemic area which
results in washout of lactic acid and recovery of physiologic pH.

This

phenomenon is termed the pH paradox. It causes activation of the Na+-H+
exchanger which contributes to lethal reperfusion injury by releasing the
inhibitory effect on MPTP opening and cardiomyocyte contracture (272).

Mitochondrial PTP is a critical determinant of lethal reperfusion injury. It
is a nonselective channel on the inner mitochondrial membrane. Opening of this
channel causes loss of

mitochondrial membrane potential and uncouples

oxidative phosphorylation, resulting in ATP depletion and cell death (273).
Mitochondrial PTP opens in reperfusion in response to mitochondrial Ca2+
overload, oxidative stress, restoration of a physiologic pH, and ATP depletion
(274, 275).

Neutrophils also accumulate in the infarcted myocardial tissue several hours
after the onset of myocardial reperfusion in response to the release of the
chemoattractants ROS, cytokines, and activated complement (255).

All the above described factors involved in the lethal myocardial reperfusion
injury attenuate the full benefits of myocardial reperfusion. The importance of
myocardial reperfusion injury is evident from the fact that it may account for up to
50% of the final MI infarct size (255, 263).

1.2.6.4 Pathology of IR
The macroscopic appearance of reperfused MI is typically haemorrhagic. In
the reperfused myocardium the infarcted region appears red because of trapping of
the red cells and hemorrhage from ruptured necrotic capillaries.
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Ischemic

myocytes following reperfusion develop ultrastructural changes which is
indicative of cell death, but from a histological point of view they may seem
normal (276). There is a possibility that most of the myocytes are already
irreversibly injured by the time reperfusion occurs, and reperfusion is simply
accelerating the phenomenon (277).
Morphologic features which are typical of reperfusion are contraction band
necrosis, the no‐reflow phenomenon, and intramyocardial haemorrhage. These
changes are in addition to the coaglative necrosis that occurs in ischemic
myocardial damage (276). Contraction band necrosis occurs due to a rapid
re‐energisation of myocytes with calcium overload (278). Contraction bands are
seen in irreversibly injured myocytes and morphologicaly they are characterised
by intensely eosinophilic transverse bands comprising of
hypercontracted sarcomeres (250).

closely packed

No‐reflow phenomenon concerns small

vessels which are either damaged or showing small thrombo‐ or athero‐emboli.
This leads to endothelial cell swelling which occludes the small capillaries and
prevents local reperfusion of ischemic myocardium (279, 280).

Reperfused

myocardial infarcts frequently appear reddish because of intramyocardial
haemorrhage (281). They are caused by vascular cell damage with leakage of
blood from the injured vessels (282).
1.2.6.5 Antioxidants in IR
Most cells contain enzymatic antioxidant defense mechanisms that quickly
tackle the ROS generated during biological processes. Antioxidants can act
through many mechanisms such as scavenging the ROS, inhibiting the formation
of ROS, attenuating the catalysis of ROS generation via binding to metals ions

34

and enhancing endogenous antioxidant generation (283).
endogenous antioxidants produced within the body.

There are many

Superoxide dismutase

(SOD), catalase and glutathione (GSH) are among the most important.
SOD is present in the cytoplasm as well as on the endothelial cell surface
with either copper or zinc (CuSOD, ZnSOD) and in the mitochondria with
manganese (MnSOD)(284). SOD can be either reduced or oxidized to convert
superoxide to oxygen and hydrogen peroxide (21, 285). Hydrogen peroxide is
subsequently converted to water by either catalase (286) or by the glutathione
peroxidase system (287). Guarnieri et al. (288) have demonstrated that ischemia
and reperfusion impaired superoxide dismutase activity and decreased the cellular
glutathione-to-glutathione disulfide ratio.

Experiments using isolated heart

models in the presence or absence of superoxide dismutase also showed ROS as
likely mediators of reperfusion injury (289, 290).
The effectiveness of GSH as an antioxidant is a result of its ability to remove
hydrogen peroxide, a reaction catalyzed by GSH peroxidase.

The oxidized

glutathione (GSSG) is reduced back to GSH by GSH reductase. Glutathione is an
important antioxidant enzyme in myocardial ischemia-reperfusion injuries (291).
Intracellular GSH status appears to be a sensitive indicator of the overall health of
a cell, and of its ability to resist toxic challenge. Myocardial glutathione plays an
important role in protecting the ischemic myocardium against reperfusion injury
(292).
Catalase is a membrane bound enzyme which is present in peroxisomes and
in the mitochondrial matrix (293). Catalase activity and its mRNA expression
was found to be higher in rabbit hearts subjected to IR injury (294) (295, 296).
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Catalase and SOD together are important in protecting the myocardium against
ischemia reperfusion (297, 298). This has been shown in genetically engineered
animal models as well as isolated heart models (299).
The effectiveness of antioxidants in protecting the heart against ischemia
reperfusion injuries depends on the severity of oxidative stress and the interaction
of antioxidants with ROS.
1.2.6.6 The dilemma of Myocardial reperfusion
The model of reperfused infarction (300, 301) affects mostly a larger portion
of left ventricle than the infarction itself (302), but reperfusion still leads to a
faster resolution of inflammation and scar formation emphasizing the importance
of reperfusion in restoring the viability of the myocardium. With new advances in
medicine, the process of myocardial reperfusion continues to improve with more
timely and effective reperfusion strategies.

PCI technology, antiplatelet and

antithrombotic agents are very effective in maintaining the patency of the infarctrelated coronary artery, but there is still no effective therapy for preventing
myocardial reperfusion injury. Myocardial reperfusion injury reduces the full
benefits of myocardial reperfusion and thus represents an important target for
cardioprotection in patients.
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1.3 Aims and Objectives
The main aim of our project was to establish a murine model of myocardial
infarction and ischemia reperfusion injury in our lab and to use these two models
to investigate the role of GAL-1, GAL-3 and HIF-1α in myocardial infarction and
Ischemia reperfusion injury. Specific objectives of our work are listed as follows:
1. Identifying the role of GAL-1, GAL-3 and HIF-1 α in early cardiac
ischemia.
2. Determining the expression of GAL- 1, GAL-3 and HIF-1α within cardiac
myocytes, macrophages and endothelial cells and interstitial cells during
ischemia.
3. Determining the potential of using Galectins as markers for early detection
of cardiac ischemia/infarction.
4. Comparing the two types of myocardial injury, MI and IR in terms of their
mechanism of injury.
5. Investigating specific role of GAL-3 in MI and IR by using GAL-3
knockout mice.

37

Chapter 2: Materials and methods
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2.1 Ethical Approval
The Animal Research Ethics Committee of the College of Medicine and
Health Sciences, UAE University, has approved all experimental procedures
(Protocol No.A12/10 Murine Model of Myocardial Infarction). All experiments
were performed with the guidelines from the ‘Principles of Laboratory Animal
Care’ and the ‘Guide for the care and use of laboratory animals’ published by NIH
(NIH Publication No. 85-23, revised 1996), and specific national laws have been
observed.
2.2 Animal strains and experimental groups
C57B6/J mice and Galectin-3 knockout (KO) mice with C57B6 background
were used in this study. All the animals were male, aged 10-14 weeks and
weighed 20-25g.
Wild type C57B6/J mice were divided into 5 groups with the following time
points: Group I: 20 minute post MI (n=8), Group II: 30 minute post MI (n=8),
Group III: 60 minute post MI (n = 8), Group IV: 4- hour post MI (n = 8) and
Group V: 24- hour post MI (n =8). Samples from sham operated animals, which
are our controls, (20 minute sham, n=7, 30 minute sham, n=7, 60 minute sham,
n=7, 4- hour sham, n=7 and 24- hour sham, n=7) for each mentioned time points
were also studied. Samples from non-operated normal animals (Naïve, n=7) were
also studied.
Wild type C57B6/J (WT) mice and GAL-3 KO mice were also used for our
Myocardial infarction and Ischemia reperfusion comparison experiments. WT
24hour MI group (n=8), WT 24 hour sham group (n=8), WT IR group (n=8),
GAL-3KO 24hr MI group (n=8), GAL-3 KO sham group (n=6) and GAL-3 KO
IR group (n=8).
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Separate experiments for each group (n=6) were performed for sample collection
for RNA extraction and quantitative real time PCR.

Also, another set of

independent experiments were conducted for respective time points for formalin
fixed

paraffin

embedded

tissue

preparation

for

H&E

staining,

immunohistochemistry and immunofluorescent techniques.
2.3

Murine model of myocardial infarction and Ischemia Reperfusion

Injury
C57B6/J mice and GAL-3 KO for the experimental groups mice were
anesthetized by an intraperitoneal injection of a combination of Ketamine (100
mg/kg) and Xylazine (10 mg/kg). The animal is checked by toe-pinch reflex to
determine adequate anesthesia. The mice were then intubated by transesophageal
illumination using a modified 22-gauge plastic cannula and fixed on the operating
pad in the supine position by taping all four extremities. The mice were connected
to a mouse ventilator (Harvard apparatus Minivent Hugo Sachs Electronik) which
supplied room air supplemented with 100% oxygen (tidal volume 0.2 ml/min.,
rate 120 strokes/min). Rectal temperature was continuously monitored and
maintained within 36–37o C using a heat pad. The lead II ECG (ADInstrument
multi-channel recorder interfaced with a computer running Power lab 4/30 data
acquisition

software)

was

recorded

from

needle

electrodes

inserted

subcutaneously.
Myocardial infarction was induced in the mice by permanently occluding the
left anterior descending coronary (LAD) artery as described earlier (303, 304).
The chest was opened with a lateral incision at the 4th intercostal space on the left
side of the sternum. Next the chest wall was retracted for better visualization of
the heart. With minimal manipulation, the pericardial sac was removed and the
40

left anterior descending artery (LAD) was visualized with a stereomicroscope
(Zeiss STEMI SV8). An 8-0 silk suture was passed under the LAD and ligated 1
mm distal to left atrial appendage. The distance of 1mm was measured by a scale
and strictly followed in all the animals to maintain constant area of infarction.
This position induces ischemia in about 40–50% of the LV area (305). Occlusion
was confirmed by observing immediate blanching of the left ventricle (LV) post
ligation. An accompanying ECG recording showed characteristic ST-elevation,
which further confirmed ischemia. The chest wall was closed by approximating
the third and fourth ribs with one or two interrupted sutures. The muscles returned
back to their original position and the skin closed with 4-0 prolene suture. The
animal was gently disconnected from the ventilator and spontaneous breathing
was seen immediately. Postoperative analgesic (Butorphanol 2 mg/kg, s/c, 6
hourly) was given at the end of the procedure. The animal was gently placed in a
warm cage and temperature maintained for 2-3 hours until the animal was fully
conscious and moving. The body temperature of the animal was strictly controlled
at 36-38 degree Celsius throughout the procedure.
For our IR model, after the 8-0 silk suture was passed under the LAD, a
small 1 mm polyethylene tubing (PE) was placed on top of the LAD and the
suture was ligated on the top of the PE tubing without damaging the artery.
Ischemia was confirmed by the discoloration of the left ventricle.

An

accompanying ECG also showed corresponding ST- elevation. After 30 minutes
of ischemia the ligature is removed by cutting the knot on top of this PE tube.
Reperfusion was confirmed visually and by ECG changes. Sham operated mice
groups are our controls for MI and IR experimental groups and they exactly
follow the same time points of corresponding MI and IR groups. Sham operated
41

mice underwent exactly the same procedure described above, except that the
suture passed under the LAD is left open and untied.
2.4 Methods
2.4.1 Sample Collection
According to the experimental protocol, mice were sacrificed at a designated
time after induction of MI or IR. The method of euthanasia started with
intraperitoneal injection of anesthetic drugs, which included a combination of
Ketamine (100 mg/kg) and Xylazine (10 mg/kg). When the mouse was
completely anesthetized, skin and chest wall were reopened. Blood was collected
in EDTA vacutainers and the heart was resected, washed in ice cold phosphate
buffered saline (PBS), the right ventricle and both atria were dissected away and
LV was immediately frozen in liquid nitrogen and stored in a freezer at -80oC for
later protein extraction. Collected blood was centrifuged at 3000 RPM for 15
minutes. The plasma was collected, alliquoted and stored at -80oC until further
analysis. Heart samples from the same time point following LAD ligation were
also fixed in 10% buffered formal-saline for 24 hours. Heart samples from the
respective time points were also stored in RNA later for RNA extraction and
subsequent Real time PCR.
2.4.2 Protein and RNA Extraction
2.4.2.1 Protein extraction
Total protein was extracted from heart samples by homogenizing with lysis
buffer and collecting the supernatant after centrifugation. For total cell lysate, the
left ventricular heart along with the septum samples were thawed, weighed and
put in cold lysis buffer containing 50 mM Tris, 300 mM NaCl, 1 mM MgCl2, 3
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mM EDTA, 20 mM b-glycerophosphate, 25 mM NaF, 1% Triton X-100, 10%w/v
Glycerol and protease inhibitor tablet (Roche Complete protease inhibitor cocktail
tablets). The hearts were homogenized on ice by a homogenizer (IKA T25 Ultra
Turrax). The samples were then centrifuged at 14000 RPM for 15 minutes at 4o C,
supernatant collected, alliquoted and stored at -80oC until further analysis.
Nuclear and cytoplasmic protein extraction was done following the protocol
described elsewhere (306). Briefly, the heart LV were thawed on ice, weighed and
homogenized on ice with buffer containing Tris HCl 10 mmol/l, CaCl2 3 mmol/l,
MgCl2 2 mmol/l, EDTA 0.1 mmol/l, Phenylmethanesulfonyl fluoride (PMSF) 0.5
mmol/l, Sucrose 0.32 mmol/l, Dithiothreitol (DTT) 1 mmol/l, Nonidet P-40 (NP40) 0.5% and Protease inhibitor cocktail 1%. The homogenates were centrifuged
at 800 g for 10 minutes. The supernatant was removed and kept as cytoplasmic
fraction. The pellet was washed twice with homogenization buffer without NP-40
and resuspended with a low salt buffer containing HEPES 20 mmol/l, MgCl2 1.5
mmol/l, KCl 20 mmol/l, EDTA 0.2 mmol/l. Glycerol 25%, PMSF 0.5 mmol/l and
DTT 0.5 mmol/l. After incubation on ice for 5 minutes, an equal volume of high
salt buffer containing HEPES 20 mmol/l, MgCl2 1.5 mmol/l, KCl 800 mmol/l,
EDTA 0.2 mmol/l. Glycerol 25%, PMSF 0.5 mmol/l, DTT 0.5 mmol/l, NP-40 1%
and protease inhibitor cocktail 1%, was added, the mixture incubated on ice for 30
minutes, centrifuged at 14000 g for 15 minutes at 4oC and supernatants saved as
the nuclear fraction. Total protein concentration was determined by BCA protein
assay method (Thermo Scientific Pierce BCA Protein Assay Kit).
2.4.2.2 RNA Extraction
The mouse LV heart samples were divided into infarcted and non-Infarcted
tissue by using stereomicroscope. The tissues were homogenized in TRI Reagent
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(Ambion) and RNA was isolated by phenol-chloroform method (307). Briefly, 1
ml of TRI Reagent and tissue samples were put in a 2 ml DNase/RNase-Free tube
and homogenized on ice using a mechanical homogenizer (IKA T25 Ultra
Turrax). Homogenized samples are incubated at room temperature for 10 minutes
with occasional vortexing. Phase separation is achieved by adding 200ul of
chloroform, shaking vigorously, incubating for 2-3 minutes at room temperature
and then centrifuging at 12000 g for 15 minutes at 4oC. Aqueous phase is
transferred carefully to a fresh DNase/RNase-Free tube and isopropanol is added
to it, mixed by pipetting up and down and incubated at room temperature for 10
minutes. The mixture is then centrifuged for 12000 g for 15 minutes at 4oC, the
supernatant obtained is discarded and 75% cold ethanol is added to it and
centrifuged at 7500 g for 5 minutes at 4oC. The supernatant is discarded and the
pellet is washed again with 75% cold ethanol. After the second wash the RNA
pellet is air dried for 5-10 minutes and resuspended in nuclease-free water and
stored at -80oC. RNA was quantified using a NanoDrop spectrophotometer.
2.4.3 Sample Processing for Histology
Hearts were excised, washed with ice-cold PBS and weighed. Each heart was
sectioned into 4 equal transverse (coronal) sections, cassetted and fixed directly in
10% buffered formalin. Sections were dehydrated in increasing concentrations of
ethanol, cleared with xylene and embedded in paraffin. Three-um sections were
prepared from paraffin blocks and stained with haematoxylin and eosin (H&E).
H&E stain was performed as follows. Sections were dewaxed with xylene,
rehydrated with graded alcohol and washed in running tap water for 5 minutes.
Tissue sections were incubated in haematoxylin for 5 minutes followed by
washing in tap water. The slides were checked for bluing of the nuclei. If the
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intensity of blue color is high, the slides were given a quick dip in1% acid alcohol
solution. Sections were rinsed in running tap water until a satisfactory blue colors
of nuclei were achieved. The slides were then stained with Eosin for 1 minute,
washed in running tap water, dehydrated, cleared and mounted with DPX.
2.4.4 Immunohistochemistry
5-um

sections

were

prepared

and

mounted

on

aminopropyltriethoxysilane-coated slides. After dewaxing with xylene and
rehydrating with graded alcohol, slides were placed in a 0.01 M citrate buffer
solution (pH=6.0) and pre-treatment procedures to unmask the antigens was
performed in a microwave oven for 10 minutes. Sections were treated with
peroxidase and protein block for 60 minutes each and then incubated overnight at
4oC with anti- GAL-1 (rabbit anti-mouse polyclonal antibody 1:2500, Davids
Biotechnologie GmbH, Germany), anti- HIF 1 a (rabbit anti-mouse polyclonal
antibody 1:300, Davids Biotechnologie GmbH, Germany), anti- GAL-3 (rabbit
anti-mouse polyclonal antibody 1:2500, Davids Biotechnologie GmbH,
Germany), anti-cleaved caspase- 3(Rabbit polyclonal, ASP 175, Cell Signaling
Technology, USA), anti-Bcl2 (Mouse monoclonal , SP66, Cell Marque, USA ),
anti-ki67 (Rabbit monoclonal, SP6, 1:100, Cell Marque, USA), antiMyeloperoxidase (MPO) (Rabbit Polyclonal, 1:2000, Santa Cruz biotechnology,
USA), anti-cyclin D1 (Rabbit monoclonal , SP4, 1:25, Thermo Scientific, USA,
USA ), anti- Cytochrome c (Rabbit Polyclonal, 1:400, Santa Cruz biotechnology,
USA) and anti-Catalase (Rabbit Polyclonal, 1:400, Sigma) antibodies. Sections
were then washed with PBS for 15 minutes in three changes and incubated with
biotin-labeled secondary antibody (Thermo Scientific, USA) for 20 minutes at
room temperature. Finally, sections were incubated with streptavidin–peroxidase
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complex for 20 minutes at room temperature (Thermo Scientific, USA),
Diaminobenzidine (DAB) chromogen (Thermo Scientific, USA) added and
counter staining done with haematoxylin. Appropriate positive controls were
used. For negative control, the primary antibody was not added to sections and the
whole procedure carried out in the same manner as mentioned above. Positive
and negative controls were used in every batch of slides that were stained.
2.4.5 Immunofluorescent labeling
5-um sections were deparaffinized with xylene and rehydrated with graded
alcohol. Sections were placed in EnVisionTM FLEX Target Retrieval Solution
with a high PH (PH 9) (DAKO Cytomation, Denmark) in a water bath at 80 oC for
one hour. Sections were washed with distilled water for 5 minutes followed by
PBS for 5 minutes. Later they were incubated with anti-HIF-1 α (rabbit antimouse polyclonal antibody, 1:50,Davids Biotechnologie GmbH, Germany), antiGAL-1 (rabbit anti-mouse polyclonal antibody, 1:50, Davids Biotechnologie
GmbH,

Germany),

anti-GAL

3(rabbit

anti-mouse

polyclonal

antibody,

1:50,Davids Biotechnologie GmbH, Germany), anti-caspase-3 (Rabbit polyclonal,
(CPP32) Ab-4, 1:50, Thermo Scientific TM Lab Vision, USA), anti-Ki67 (Rabbit
monoclonal, SP6, 1:50, Cell Marque, USA) and anti-MPO (Rabbit Polyclonal,
1:50, Santa Cruz biotechnology, USA), anti-desmin (Rabbit polyclonal antibody,
1:50, Santa Cruz biotechnology, USA), anti-CD31 (Rabbit polyclonal antibody,
1:50, Santa Cruz biotechnology, USA), anti-CD68 (Rabbit polyclonal antibody,
1:50, Santa Cruz biotechnology, USA), anti-Factor-8 related antigen (Rabbit
polyclonal antibody, Ab-1,1:50, Thermo Scientific TM Lab Vision, USA ), and
anti-Lysozyme

(Rabbit

polyclonal

antibody,

EC

3.2.1.17,1:50,

DAKO

Cytomation, Denmark), overnight at room temperature. Sections were
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subsequently incubated with Donkey anti-rabbit Ig conjugated- Rhodamine (Santa
Cruz Biotechnology, USA, 1:100), or with donkey anti-rabbit Alexa Fluor 488,
(Invitrogen, USA, 1:100) antibodies. Finally, sections were mounted in watersoluble mounting media and viewed with Olympus Fluorescent microscope.
Immunofluorescent double labeling was done following the same procedure as
above. The first primary antibody was labeled with fluorescein-labeled secondary
antibody; the second primary antibody was added afterwards followed by
fluorescein-labeled secondary antibody with different excitation colour.
Appropriate positive control sections were used. For negative control, the primary
antibody was not added to sections and the whole procedure carried out in the
same manner as mentioned above. Positive and negative controls were used in
every batch of slides that were stained.
2.4.6 Morphometric analysis
Morphometric analysis of expression of our proteins of interest in
cardiomyocytes, endothelial cells and neutrophil polymorphs was done at
different time points following ligation of LAD using ImageJ software
(http://rsbweb.nih.gov/ij/).
GAL-1 labeling was determined by counting the number of cardiomyocytes,
endothelial cells and neutrophil polymorphs in 10 randomly-selected fields in the
left ventricle. For GAL-1 labeling, cells were considered positive when there was
a cytoplasmic and/or nuclear staining pattern. The labeling index for
cardiomyocytes, endothelial cells and neutrophils were expressed as the
percentage of labeled cells against the total number of cells enumerated.
For HIF-1α labeling, cells were considered positive when there was a nuclear
staining pattern. The labeling index for cardiomyocytes, endothelial cells and
47

neutrophils were expressed in the same way as done for GAL-1. Neutrophil
polymorphs were counted only in 24h post MI time point.
Cyclin D1 labeling was determined by counting the number of cells
expressing cyclin D1 in 10 randomly selected fields in the left ventricle. For
Cyclin D1 labeling, cells were considered positive when there was a nuclear
staining pattern. The labeling index was expressed as the percentage of labeled
cells against the total number of cells enumerated.
2.4.7 Enzyme Linked Immunosorbent Assay
Left ventricular myocardial concentration and plasma levels of our proteins
of interest was determined using DuoSet enzyme linked immunosorbent assay
(ELISA) Development kit (R&D Systems, Minneapolis, MN, USA) for sandwich
ELISA, using standard procedure according to the manufacturer’s instructions
(Mouse galectin-1 (DY1245), Mouse galectin-3 (DY1197), Mouse Total HIF-1 α
(DYC1935-5),

Mouse IL-6 (DY406), Mouse IL-1β/IL-1F2 (DY401), Mouse

cleaved caspase-3 (Asp175) (DYC835-5), Mouse Total Akt-1( DYC1775-5). 96well plates (Nunc-Immuno Plate MaxiSorp Surface (NUNC Brand Products, A/S,
Roskilde, Denmark), were coated with antibody specific to our proteins.
Biotinylated detection antibody and streptavidin conjugated horseradish
peroxidase were used for detection of captured antigens. The plates between steps
were aspirated and washed 3 times using ELISA plate washer (BioTek ELx50).
Captured antigens were visualized using tetramethylbenzidine (TMB)/hydrogen
peroxide. Absorbance readings were made at 450 nm, using a 96-well plate
spectrophotometer (BioTek ELx800). Protein levels in samples were determined
by interpolation from a standard curve. Standards and samples were assayed in
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duplicate. For any particular protein of interest, each assay was at least repeated
twice. The levels were normalized to total protein concentrations.
2.4.8 Quantitative Real Time Polymerase Chain (qRT-PCR)
2.4.8.1 Reverse transcription
Reverse transcription of RNA into cDNA was done using High-Capacity
cDNA Reverse Transcription kit (Part #4368814, PN 4374967, Applied
Biosystems) according to the recommended protocol. A total volume of 20ul
reaction was prepared with 10 μl of sample mixture containing 2 μg of template
RNA and 10 μl of master mix. The master mix for 1 reaction was prepared as
below.
10x RT Buffer

2.0μl

25x dNTP Mix

0.8μl

10xRTRandomPrimers

2.0μl

MultiScribeReversetran criptase

1.0μl

RNase Inhibitor

1.0μl

Nuclease-free H2O

3.2μl

Total volume

10 μl

The RT reaction was carried out in a programmable thermal controller (GeneAmp
PCR system 9700, Applied Biosystems Inc CA, USA) with the following
conditions.
Step 1

Step 2

Step 3

Step 4

Temp oC

25 oC

37oC

85oC

4oC

Time

10 minutes

120 minutes

5 minutes

The cDNA was diluted 1:10 and stored at -80oC.
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2.4.8.2 Real Time Polymerase Chain Reaction
The expression levels of mRNA were analyzed using target specific TaqMan
gene expression assays using the 7500 Real-Time PCR system (Applied
Biosystems Inc CA, USA). The reaction mix of 20 ul contained 5 µL of sample,
10 uL of TaqMan® Gene Expression Master Mix (Part # 4369016), 1ul of Primer
probe mix and 4 ul of nuclease free water. Each well was run in duplicate for gene
of interest and reference primer 18S rRNA (Applied Biosystems). The following
primers and probes, purchased from Applied Biosystems, were used for TaqMan
real-time RT-PCR reactions:
HIF-1α: Mm00468869_m1
GAL-1: Mm00839408_g1
GAL-3: Mm00802901_m1
Rn 18S: Mm03928990_g1
The PCR reaction was carried out as follows: 95°C for 3 minutes, followed
by 95°C for 15 seconds, 55°C for 15 seconds, 72°C for 1 minute X 40 cycles, then
followed by 95°C for 15 seconds, then 60°C for 15 seconds and finally 95°C for
15 seconds. Data acquisition was done by using 7500 software v2.0.6 (Applied
Biosystems, US). Analysis was carried out using the comparative Ct method. The
level of GAL-1, GAL-3 and HIF-1α expression was normalized to 18S rRNA and
fold changes calculated relative to expression in sham operated LV heart tissue
using the formula 2-ΔΔCt. Many aspects of MIQE guidelines were taken into
consideration for methods and analysis (308).
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2.4.9

Sodium dodececyl-sulphate polyacrylamide gel electrophoresis (SDS-

PAGE) and Western Blotting
Total protein extracts (30 ug) from each sample were resolved by SDS
PAGE on 12% polyacrylamide gels using a vertical electrophoresis tank Biorad
Mini ProteanTetra Cell system. Samples were electrophoresed at 200 volts using
electrophoresis buffer for 35-40 minutes, adjacent to pre-stained molecular weight
markers (PageRuler Prestained Protein Ladder,Thermo scientific). The protein on
gels was transferred onto nitrocellulose membranes (Whatman, GE Healthcare )
using the semi dry blotting system (Pierce Fast Semi-Dry Blotter, Thermo
scientific). Non-specific binding sites were blocked by incubation with 5% non-fat
dry milk solution in Phosphate Buffered Saline (PBS)-Tween 20 (0.1%) (PBST)
for one hour at room temperature. The membranes were subsequently incubated
overnight with Primary antibody anti-GAL-3 (rabbit anti-mouse polyclonal
antibody 1:1000, Davids Biotechnologie GmbH, Germany) and anti-GAL-1
(rabbit anti-mouse polyclonal antibody 1:5000, Davids Biotechnologie GmbH,
Germany), diluted in blocking buffer at 4o C. Membranes were also incubated
overnight 4oC for Beta-actin antibody (1:5000, Abcam, USA) diluted in PBST to
control for equal loading. Blots were then incubated with horseradish peroxidaseconjugated secondary antibodies (rabbit anti-mouse Thermo-Pierce) and
developed using ECL plus substrate (Thermo Pierce). Protein bands were
visualized by a laser scanner (Typhoon FLA 9500). Appropriate positive control
samples were used with each run.
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2.4.10 Troponin-I Assay
Mouse cardiac troponin I levels in plasma were measured by using a high
sensitivity mouse cardiac troponin-I Elisa kit (2010-1-HSP, Life Diagnostics, Inc.)
according to the manufacturer’s instructions.
2.4.11 Glutathione Assay
Total glutathione level in the heart protein extract was measured by a
Glutathione Assay kit (CS0260 Sigma-Aldrich).

The sample was first

deproteinized with 5% 5-sulphosalicylic acid, centrifuged to remove precipitated
protein and then assayed for glutathione.
2GSH +DTNB ---› GSSG +2 TNB
Glutathione reductase

GSSG +NADPH + H+ -------------------------------------› 2 GSH +NADP+
The combined reaction:
Glutathione reductase
+

DTNB + H + NADPH-------------------------------------› 2 TNB +NADP+
GSSG/GSH

Glutathione (GSH) cause a continuous reduction of 5, 5’-dithiobis (2-nitrobenzoic
acid) (DTNB) to TNB and the GSSG forms was recycled by glutathione reductase
and NADPH.

The yellow product, 5-thio-2-nitrobenzoic acid (TNB) was

measured spectrophotometrically at 412nm by a kinetic read at 1 minute interval
for 5 minutes.

Glutathione standard solutions were used to generate a standard

curve and GSH levels calculated using Megallan6 software.
2.4.12 Superoxide dismutase (SOD) activity assay
Superoxide dismutase (SOD) activity was measured using the SOD determination
kit (19160 Sigma-Aldrich).
WST-1

Dojindo’s highly water-soluble tetrazolium salt,

(2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H52

tetrazolium, monosodium salt) produces a water-soluble formazan dye upon
reduction with a superoxide anion. The rate of the reduction with O2 is linearly
related to the xanthine oxidase (XO) activity, and is inhibited by SOD, therefore,
the IC50 (50% inhibition activity of SOD) is determined by a colorimetric
method. The samples were added to the 96-well plate. Appropriate blanks were
also set up according to the manufacturer’s instructions. WST working solution
and enzyme working solution were added to the samples, incubated at 37 o C for
20 minutes and absorbance was read at 450 nm. SOD activity (inhibition rate %)
was calculated by an equation:
SOD activity (inhibition rate %) = {[(Ablank 1 - Ablank 3) - Asample - Ablank
2)]/ (Ablank 1 - Ablank 3)} x 100.
2.5 Bioinformatic Analysis
We used the bioinformatic analysis program Clustalw2 available on the
Internet (http://www.ebi.ac.uk/Tools/msa/clustalw2/) to find out the core HIF-1α
binding motif ‘RCGTG’, the Hypoxia response element (HRE) (150) in the
promoter region of the mouse and human GAL-1 gene.
2.6 Statistical Analysis
Statistical analysis was conducted using IBM SPSS Statistics version 20.
Data are presented in mean ± Standard Error. Statistically significant differences
(p<0.05) were calculated between experimental group and corresponding shamoperated group for each time point by Student t test. One-way ANOVA was used
to test for differences among the various time points within the MI groups. Chi
square test was used to assess differences in the expression of GAL-1 and HIF-1α
in cardiomyocytes & endothelial cells at different time points following MI for
morphometric analysis.
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Chapter 3: Results and Discussion
Section 1: Galectin-1 in Early Myocardial
infarction
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3.1.1 Background
Galectin-1 (GAL-1) is a prototypical member of the galectin family of
lectins. It is a divalent 14.5-kDa protein characterized by one carbohydrate
recognition domain (CRD) that can occur as a monomer or as a non-covalent
homodimer (13, 26).
GAL-1 is produced by a variety of vascular, interstitial, epithelial, and
immune cells (36-39). GAL-1 is present both inside and outside cells, and has
both intracellular and extracellular functions. The extracellular functions require
the carbohydrate-binding properties while the intracellular functions are
associated with protein-protein interactions (26).

GAL-1 lacks recognizable

secretion signal sequences and does not pass along the standard endoplasmic
reticulum/Golgi pathway (20). GAL-1 is secreted through the non-classical
pathway via inside-out transportation involving direct translocation across the
plasma membrane (30). In the extracellular compartment GAL-1 regulates cellcell and cell-matrix interactions, the immune response, apoptosis, and neoplastic
transformation. In the intracellular compartment it regulates cell cycle, RNA
splicing and transcription (34, 40-44). Intracellular GAL-1 has been shown to be
present in cells nuclei and cytosols (26). Although GAL-1 is involved in very
important functions in vitro and in vivo, GAL-1 null mice are viable indicating
that its presence is not critical for mammalian development or survival (33).
GAL-1 is a hypoxia-induced protein. Studies have shown that GAL-1 is an
important mediator in the adaptive responses of murine lung to chronic hypoxia
(66). The expression of GAL-1 was increased throughout the interstitium and near
to the basement membrane of vessels and airways in the lung of hypoxia-exposed
mice as compared to the control mice. In the brain, under hypoxic or ischemic
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conditions, both in vitro and in vivo, GAL-1 was found to attenuate the
proliferation of astrocytes.

It reduced apoptosis of neurons, decreased brain

infarction volume, improved neurological function and promoted recovery of
brain ischemia (65). GAL-1 is also regulated by hypoxia at the gene and protein
levels in some tumors (64). The above-mentioned studies have shown that GAL-1
is regulated by hypoxia but its exact mechanism remains elusive.
GAL-1 is a major component of the contractile machinery in cardiomyocytes
(71) which suggests that it must be playing an important role in regulating cardiac
functions but its exact pathophysiological role in the heart is unknown. In the
present study we investigated if there is any change in the endogenous production
of GAL-1 in early ischemia and its pattern of expression in the ischemic and nonischemic cardiomyocytes. For this purpose we have employed Murine model of
Permanent ligation of Left anterior descending artery (LAD). Details can be seen
in the Material and Methods section (p.40) of this dissertation.
3.1.2 Results
3.1.2.1 Electrocardiographic Study
The ECG records for mice groups, 20 minute, 30 minute, 60 minute, 4 hour
and 24 hour following permanent ligation of LAD show persistent ST elevations.
The ECG for 20 min, 30 min and 60 min post LAD ligation groups were
monitored for the whole duration of time whereas for 4 hours and 24 hours post
MI groups it was monitored for the first 15 minutes (Fig 3.1). We have used
persistent elevation of ST- segment in the ECG as a control for selection of
animals to be included in our study.
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3.1.2.2 GAL-1 in the heart tissue
GAL-1 concentration in Left ventricular (LV) heart tissue of naïve group is
66.32±4.69 ng/mg. GAL-1 concentration in LV tissue is significantly increased at
20 minutes (148.91±6.65 vs. 117.20±4.45 ng/mg P = 0. 001*) and 30 minutes
(117.45±3.49 vs 101.79±2.63 ng/mg, P = 0.004*) post MI groups compared to
corresponding sham operated control groups (Table 3.1) (Fig 3.2 A). GAL-1
values at 60 minutes and 4 hours post MI groups show a higher tendency than
their corresponding sham operated control groups but do not reach statistical
significance (100.43±3.05 vs 94.99±2.76 ng/mg, P = 0.208 and 97.01±3.31 vs
91.07±3.26 ng/mg, P = 0.224). At 24-hour post MI group, GAL-1 concentration
in sham-operated control group is slightly higher than its corresponding MI group
(85.24±2.42 ng/mg vs 75.71±3.87) but shows no statistical significance. GAL-1
values in LV in all MI groups are higher than the baseline naïve control group.
This is also shown in the corresponding blots where the difference between MI
and Sham blots is seen in the first hour post MI time points (Fig. 3.3).
There was a statistically significant difference between the different time points
within the MI groups as determined by one-way ANOVA (F (4,35) = 40.693, p =
.000). A Tukey post-hoc test revealed that the 20 minutes post MI GAL-1 level
(M = 148.9, 95% CI [133.18, 164.6]) is significantly higher than the 30 minutes
(M = 117.4, 95% CI [109.2, 125.72], p = 0.00), 60 minutes(M = 100.43.9, 95% CI
[93.22, 107.65], p = 0.00), 4 hour (M = 97.01, 95% CI [89.18, 104.84], p = 0.00)
and 24 hour post MI group (M = 75.71, 95% CI [66.57, 84.86], p = 0.00 ). 30
minutes post MI.
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Figure 3.1: Electrocardiography of the heart at 20 minute, 30 minute, 60 minute,
4-hour and 24-hour post MI groups showing ST elevation compared to normal
ECG in sham operated groups.
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A.

B.

Figure 3.2 (A) The graph represents left ventricular GAL-1 concentrations at 20
min, 30 min, 60 min, 4 hour and 24 hour post myocardial infarction with
corresponding sham operated groups in C57BL6 mouse heart. Control represents
non-operated normal animal heart. (B) GAL-1 mRNA expression in the ILV
(Infarcted left ventricle) and NILV (Non-infarcted left ventricle) expressed as fold
changes relative to sham at respective time points post MI (* shows p<0.05).
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Table 3.1: GAL-1 levels in ng/mg of total protein at different time points post
myocardial infarction.
Groups

n

Mean (ng/mg)

Std Dev

Std Error

Naïve

7

66.32

12.39

4.69

20 min MI

8

148.91

18.81

6.65

20 min sham

8

117.20

12.57

4.45

30 min MI

8

117.45

9.88

3.49

30 min sham

7

101.79

6.97

2.63

60 min MI

8

100.43

8.63

3.05

60 min sham

7

94.99

7.29

2.75

4 hour MI

8

97.01

9.36

3.31

4 hour sham

7

91.07

8.63

3.26

24 hour MI

8

75.71

10.94

3.87

p value

0.001*

0.004*

0.208

0.224

0.079
24 hour sham

6

85.24

5.92

2.42

* shows p<0.05.

Table 3.2: Fold changes in GAL-1 mRNA expression in the ILV (Infarcted left
ventricle) and NILV (Non-infarcted left ventricle) relative to sham at respective
time points post MI.

Sham

NILV

ILV

P
value†

20 min Post MI

1.0139

1.0299

1.0504

0.746

30 min Post MI

1.0508

1.1841

1.6064

0.026*

60 min Post MI

1.0176

1.0354

1.5278

0.129

4 hr Post MI

1.0119

1.0632

1.3229

0.007*

24 hr Post MI

1.0082

1.4205

2.9667

0.00*

† shows p values comparing ILV and sham groups for respective time points.
* shows p<0.05
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Sham
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Figure 3.3 Western blot for detection of GAL-1 and beta actin in respective time
points post MI with corresponding sham.
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GAL-1 value is also higher than the 4 hour (p = 0.015), and 24 hour time point (p
= 0.00). 30 minute post MI GAL-1 value is also higher than 60 minute post MI
group but does not reach statistical significance (p = 0.058). 60 minute post MI
group value is significantly higher than the 24 hour MI group (p = 0.002) and 4
hour MI level is significantly higher than 24 hour post MI time point (p = 0.01).
In normal hearts, GAL-1 is mainly seen to be expressed by cardiomyocytes
and endothelial cells (Fig. 3.4). The expression is more pronounced in the right
ventricle as compared to the left ventricle (Fig. 3.4, D, E, F). In the left ventricle,
GAL-1 is mainly expressed by endothelial cells and few cardiomyocytes (Fig. 3.4,
E). A very characteristic staining pattern is seen in immunofluorescent labeling of
GAL-1, which gives a mesh-like staining pattern of myocardium (Fig. 3.4 G, H,
I). There is an increase in the expression of GAL-1 in the LV as compared with
sham operated heart sections.
In MI groups, the expression of GAL-1 is well demarcated in the area
supplied by LAD artery at 24- hour, 20, 30, 60 minute and 4- hour following MI
(Fig. 3.5, 3.6, 3.7, 3.8, 3.9 respectively). Both cardiac myocytes and endothelial
cells show high expression of GAL-1 (Fig. 3.5 E, 3.6 F, 3.7 F, 3.8 F). In addition,
there are foci of low or no expression of GAL-1 surrounded by areas of high
expression (Fig. 3.5, 3.6, 3.7, 3.8, 3.9 ). The number of cardiac myocytes that
express GAL-1 is decreased as the time following ligation is increased. This
phenomenon is also seen to a lesser extent in endothelial cells. Hence, areas of
low or no expression of GAL-1 increase in size and become more demarcated as
we reach 4 hours and then 24 hours following MI (Fig. 3.9 E, F, G & 3.8 D, E, F,
G, H). In 24 hour post MI, the GAL-1 expression is seen in areas surrounding the
infarction (Fig. 3.8 E, F, G, H& I). There is no expression of GAL-1 in the dead
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cardiomyocytes hence, these areas are very sharply demarcated (Fig. 3.9 E, F, G,
H& I). Neutrophil polymorphs, which are abundant at 24 hour post MI group, also
show high expression of GAL-1 (Fig. 3.9 G& H). GAL-1 shows many patterns of
staining in the heart at different time points following MI which include diffuse
cytoplasmic staining (Fig. 3.6 G& I), Z bands staining (Fig. 3.5 H), cell
membrane staining (Fig. 3.4 G, H, I) and nuclear staining (Fig. 3.5 E&F).
3.1.2.3 GAL-1 mRNA expression in post MI heart tissue
GAL-1 gene expression is first seen to be significantly increased at 30 min
post MI time points in the infarcted part of left ventricle compared to the sham.
GAL-1 mRNA at 4 hour and 24 hour post MI group is also significantly high in
the Infarcted LV as compared to Sham. 60 min post MI GAL mRNA is higher
than the Sham but does not reach statistical significance (p=0.129). (Refer to
Table 3.2 and Fig. 3.2 B for fold differences in the GAL-1 mRNA expression in
the infarcted and non infarcted left ventricular tissue compared to the sham
operated LV tissue).
3.1.2.4 GAL-1 Levels in Plasma
Plasma GAL-1 concentration in naïve group is 8.71±0.83 ng/ml. Plasma
GAL-1 concentration is significantly raised at 4 hour (15.05±1.09 vs 9.91±1.35
ng/ml, P = 0.012*) and 24 hour (22.59±0.42 vs 17.86±0.93 ng/ml, P = 0.001*)
post MI groups compared to corresponding sham operated control.
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Figure 3.4: GAL-1 expression in naïve heart.
A. Low power view of the heart showing the left ventricle (arrow head),
interventricular septum (thick arrow) and right ventricle wall (thin arrow), H&E
stain. B&C are representative sections of the left and right ventricles respectively,
H&E stain. D. showing low and focal expression of galectin-1 in the wall of the
right ventricle (thin arrow) and the interventricular septum (thick arrow). E. A
representative section of left ventricle showing mild expression of galectin-1 by
endothelial cells (arrow head). F. A representative section of right ventricle
showing low cytoplasmic expression of galectin-1 by cardiac myocyte (arrow
head) and endothelial cells (thin arrow). G, H&I, immunofluorescent labeling of
sections of the heart showing a net-like pattern of galectin-1 staining of cardiac
myocytes (thin arrow) and cytoplasmic staining of endothelial cells (arrow head).
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Figure 3.5: GAL-1 expression 20 minutes following ligation of LAD.
A. Low power view of the heart showing a high expression of galectin-1 in the
anterior wall of left ventricle in the area supplied by LAD (thin arrow) and the
interventricular septum (thick arrow). There is also increase in the expression of
galectin-1 in the right ventricle (arrow head). B. Sham operated heart showing
lower expression of galectin-1 in the left ventricle and right ventricle (thin arrow).
C. Negative control section of the heart showing absence of galectin-1 staining. D,
E&F. Representative sections of the left ventricle from area supplied by LAD
showing high cytoplasmic expression of galectin-1 by cardiac myocytes (thin
arrow D). High power views show a well demarcated area of high cytoplasmic
expression of galectin-1 by cardiac myocytes (thin arrow) and endothelial cells
(arrow head, E&F), There is also nuclear expression of galectin 1 by cardiac
myocytes (thick arrow E&F), streptavidin- biotin immunoperoxidase method. G,
H&I. Representative section from left ventricle shows a well demarcated area of
high cytoplasmic expression of galectin-1 by cardiac myocytes (thin arrow).There
is also high expression of galectin- 1 in the Z bands (arrow head), Alexa Fluor 488
immunofluorescent technique.
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Figure 3.6: GAL-1 expression 30 minutes following ligation of LAD.
A. A low power view of the heart showing a high expression of galectin-1 in the
anterior wall of left ventricle in the area supplied by LAD (thin arrow) and the
interventricular septum (thick arrow). There is also increase in the expression of
galectin-1 in the right ventricle (arrow head), streptavidin- biotin
immunoperoxidase method. B. Sham operated heart showing lower expression of
galectin-1 in the left ventricle and right ventricle (thin arrow), streptavidin- biotin
immunoperoxidase method. C. Negative control section of the heart showing
absence of staining of galectin-1. D. A galectin-1 positive control section from
prostate gland showing cytoplasmic expression of galectin- 1 by prostatic acini. E,
F & G. Representative sections of the left ventricle from areas supplied by LAD
showing high cytoplasmic expression of galectin-1 by cardiac myocytes (thin
arrow), streptavidin- biotin immunoperoxidase method. H, I&J. Representative
sections from left ventricle showing a well demarcated area of high cytoplasmic
expression of galectin-1 by cardiac myocytes (thin arrow), Alexa Fluor 488
immunofluorescent technique.
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Figure 3.7: GAL-1 expression 60 minutes following ligation of LAD.
A& B, A low power view of the heart showing a high expression of galectin-1 in
the anterior wall of left ventricle in the area supplied by LAD (thin arrow) and the
interventricular septum (thick arrow). There is also increase in the expression of
galectin-1 in the right ventricle (arrow head), streptavidin- biotin
immunoperoxidase method. C. Sham operated heart showing low expression of
galectin-1 in the left ventricle and right ventricle (thin arrow), streptavidin- biotin
immunoperoxidase method. D. Negative control section of the heart showing
absence of staining of galectin-1. E, F & G, Representative sections of the left
ventricle from areas supplied by LAD showing high cytoplasmic expression of
galectin-1 by cardiac myocytes (thin arrow) surrounding areas of low or absence
of expression (star shape), streptavidin- biotin immunoperoxidase method. H, I&
J, Representative section from left ventricle showing a well demarcated area of
high cytoplasmic expression of galectin-1 by cardiac myocytes (thin arrow),
Alexa Fluor 488 immunofluorescent technique.
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Figure 3.8: GAL-1 expression 4 hours following ligation of LAD.
A.A low power view of the heart showing a high expression of galectin-1 in the
anterior wall of left ventricle in the area supplied by LAD (thin arrow) and the
interventricular septum (thick arrow). There is also increase in the expression of
galectin-1 in the right ventricle (arrow head), streptavidin- biotin
immunoperoxidase method. B. Sham operated heart showing low expression of
galectin-1 in the left ventricle (thin arrow) and right ventricle (arrow head),
streptavidin- biotin immunoperoxidase method. C. Negative control section of the
heart showing absence of staining of galectin-1. D. Representative section of the
left ventricle from area supplied by LAD showing high cytoplasmic expression of
galectin-1 by cardiac myocytes (thin arrow) surrounding areas of low or no
expression (star shape), streptavidin- biotin immunoperoxidase method. E&F,
Representative section of the left ventricle from area supplied by LAD showing a
well demarcated area of high cytoplasmic expression of galectin-1 by cardiac
myocytes (thin arrow), streptavidin- biotin immunoperoxidase method. G, H&I.
Representative section from left ventricle showing a well demarcated area of high
cytoplasmic expression of galectin-1 by cardiac myocytes (thin arrow)
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Figure 3.9: GAL-1 24 hours following ligation of LAD.
A. A high power view of left ventricle in an area supplied by LAD showing
coagulative necrosis (thin arrows) accompanied by heavy neutrophil polymorphs
infiltration (arrow heads), H&E. B. A low power view ofthe heart showing areas
of high expression of galectin-1 (thick arrows) surrounding areas of no expression
(star shape) in the left ventricle and interventricular septum in the area supplied by
LAD, streptavidin- biotin immunoperoxidase method. C. Sham operated heart
showing lower expression of galectin-1 in the left ventricle and right ventricle
(thick arrows), streptavidin- biotin immunoperoxidase method. D. Negative
control section of the heart showing absence of staining of galectin-1. E, F&G.
Representative section of the left ventricle from area supplied by LAD showing
high cytoplasmic expression of galectin-1 by cardiac myocytes (thick arrow),
surrounding areas of no expression (thin arrow). Many neutrophil polymorphs are
also showing cytoplasmic expression of Galectin-1(arrow head), Streptavidinbiotin immunoperoxidase method. H, I&J. Representative section from left
ventricle showing a well demarcated area of high cytoplasmic expression of
galectin-1 by cardiac myocytes (thick arrow) surrounding areas of no expression
(thin arrow), many neutrophil polymorphs (arrow head) show cytoplasmic
expression of Galectin-1, Alexa Fluor 488 immunofluorescent technique.
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groups (Fig. 3.10). Plasma GAL-1 values at 30 minute and 60 minute post MI
groups are not significantly different from their corresponding sham-operated
control groups (15.49±1.29 vs 14.06±0.78 ng/ml and 14.27±0.72 vs
13.33±1.49 ng/ml).

3.1.2.5 Morphometric analysis
The frequency of cardiomyocytes expressing GAL-1 in 20 and 30 minute
post MI groups is higher than other MI groups and show statistically significance
when compared with 24-hour post MI group (Chi squared = 6.779 with 1 degree
of freedom, P = 0.009* and Chi squared = 9.968 with 1 degree of freedom, P =
0.001*, respectively). The frequency of endothelial cells expressing GAL-1 in 20
minute post MI group is higher than other MI groups and shows statistical
significance when compared with 60 minute, 4-hour and 24-hour post MI groups
(Chi squared = 4.282 with 1 degree of freedom, P = 0.03*, Chi squared = 6.627
with 1 degree of freedom, P = 0.01*, Chi squared = 9.29 with 1 degree of
freedom, P = 0.002*, respectively). The frequency of endothelial cells expressing
GAL-1 in 30 minutes post MI group is significantly higher than 24-hour post MI
groups (Chi squared = 3.931 with 1 degree of freedom, P = 0.047*).

The

frequency of endothelial cells expressing GAL-1 is significantly higher than
cardiomyocytes at 20 minute, 30 minute, 60 minute, 4-hour and 24-hour post MI
groups (Chi squared = 42.4 with 1 degree of freedom, P = 0.0001*, Chi squared =
25.9 with 1 degree of freedom, P = 0.0001*, Chi squared = 31.1 with 1 degree of
freedom, P = 0.0001*, Chi squared = 34.3 with 1 degree of freedom, P = 0.0001*,
Chi squared = 38.8 with 1 degree of freedom, P = 0.0001*, respectively).
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The frequency of neutrophil polymorphs expressing GAL-1 is significantly higher
than cardiomyocytes and endothelial cells at 24-hour post MI groups (Chi squared
= 69.8 with 1 degree of freedom, P = 0.0001* and Chi squared = 5.72 with 1
degree of freedom, P = 0.016*, respectively). A decrease in the number of
cardiomyocytes and endothelial cells that express GAL- 1 is associated with the
increase in post MI time. Neutrophil polymorphs were counted at 24-hour
following MI as they are not seen before 4 hour post MI time (Table 3.3).
3.1.3 Discussion
Galectins are highly conserved, from fungi to mammals with their existence
dating back more than 800 million years. This suggests that these endogenous
proteins must be serving an important purpose (309-311).

Although GAL-1

knockout mice fail to show any abnormalities (33), but knocking down GAL-1like protein in the zebrafish shows defects in muscle development and
disorganized muscle fibers (312). There is also evidence that GAL-1 has a
significant role in the regeneration of muscles (68, 313, 314).
Galectin-1 is endogenous to the heart. The level of expression in cardiomyocytes
is among the highest compared to other organs of the body (71). In accordance
with a previous report (71) , our immunohistochemistry and immunoflorescence
staining of heart sections show that it is expressed in cardiac muscles as diffuse
cytoplasmic staining, as an organized Z bands staining, as a membranous staining
and as nuclear staining.
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Figure 3.10:
Plasma GAL-1: The graph represents ratio of GAL-1
concentration in myocardial infarction to sham operated C57BL6 mice. 4 hour
and 24 hour post myocardial infarction show significant difference from sham
operated mice (* p<0.05).

Table 3.3 : Morphometric analysis of expression of GAL-1 in cardiomyocytes,
endothelial cells and neutrophil polymorphs at different time points following
ligation of LAD.
Galectin-1 Morphometric analysis
Post MI Time
points

Cardiomyocytes

Endothelial cells

Neutrophils

%

%

%

20 MINUTES

49

92

0

30 MINUTES

53

87

0

60 MINUTES

41

81

0

4 HOURS

36

78

0

24 HOURS

30

75

89
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Acute MI in our mice model shows an increase in the level of GAL-1 in the
heart at a very early stage in the course of events. We show a significant increase
in tissue GAL-1 levels at 20 minutes and 30 minutes following MI as compared to
related sham operated control groups. The values at 60 minutes and 4 hours are
also higher than their corresponding sham operated control groups but do not
reach statistical significance (Fig. 3.2). These results demonstrate that there is a
transient rise in the GAL-1 level in the LV within one hour of permanent ligation
of LAD. This is supported by one-way ANOVA and Tukey post-hoc test analysis
of MI groups which show GAL-1 values at 20 and 30 minutes MI group are
significantly higher than other MI groups.
The immunohistochemical and immunofluorescent staining patterns for
GAL-1 in cardiac muscles are also very characteristic and supportive of this
finding. The increased expression of GAL-1 in the left ventricle is very well
demarcated in the MI group in all tested time points. We also noticed that as the
time of ischemia increases from 20 minutes to 4 hours and then 24 hours we are
able to recognize areas of low or no expression of GAL-1 being surrounded by
areas of high expression of GAL-1. The well demarcated areas of no or low
expression of GAL-1 are increased as the time of ischemia increases which means
that as time proceeds dying cells will stop expression of GAL-1 in the area
supplied by LAD, while survived cells in the ischemic zone, which are seen at the
periphery of infarction zone, are showing high expression of GAL-1, which might
explain the absence of statistical significance at 60 minute, 4-hour and 24-hour
post MI time points when compared to corresponding sham operated control
groups. This is supported by our morphometric analysis which shows a significant
decrease in the frequency of cardiomyocytes and endothelial cells that express
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GAL-1 with the increase of post MI time. This phenomenon is clearly seen in 24
hour post MI sections (Figure 3.9 E, F, G, H, &I) where GAL-1 is observed to be
high in the surviving cardiomyocytes and invading neutrophil polymorphs in the
immunohistochemical and immunofluorescent- stained sections, while dead cells
in the infarction zone do not show any expression which explains the absence of
statistical significance in our ELISA results at this time point.
GAL-1mRNA in the infarcted tissue is detected to be higher at 30 minute
post MI time compared to Sham. GAL-1 mRNA is also significantly increased at
4 hour and 24 hour post MI time points. This result indicates that the increase in
GAL-1 at the protein level in early post MI time is due to transcriptional pressure
from transcription factors like HIF-1α that have come into play due to
Ischemic/hypoxic injury to the myocardium.
Another significant finding of our study is that GAL-1 plasma level is
significantly high around 4 hour and 24 hour post MI compared to sham operated
control mice (Fig. 3.10).

There can be two possible explanations for this

phenomenon. We know that GAL-1 is present in the heart tissue in significant
amounts, acute myocardial infarction and subsequent cell membrane damage and
necrosis promotes its leakage outside the cells into the blood. This phenomenon
is similar to the raised Troponin-I protein (315)

that escapes the injured

cardiomyocytes and can be detected in the blood. The other explanation for raised
plasma levels is that GAL-1 in heart tissue is increased in early ischemic period
due to increased transcriptional pressure from transcriptional factors that come
into action in response to hypoxia and is secreted from the heart through the nonclassical pathway. We suspect that plasma GAL-1 levels in the first hour post
infarction signify an increase in transcription of the protein and leakage from the
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cells, whereas, at 4 hour and 24 hour post MI, the high GAL-1 plasma levels are
mainly due to leakage of this protein from cardiomyocytes.
We have observed in our study that the levels of GAL- 1 in sham operated
animals were higher than the non- operated naïve animals. This increase in sham
operated animals can be due to factors related to surgical stress. There have been
reports in germane literature that there is stress-induced increase of GAL-1 in
serum which is regulated by the sympathetic nervous system (316). As there is
some degree of mechanical/surgical stress applied to the sham operated mice we
suggest that GAL-1 levels seen in sham groups may be the result of these factors.
For these reasons we made sham operated groups as our controls for all time
points, and all our statistics were done in comparison between MI groups and
sham-operated groups to take out the effect of mechanical/surgical stress from the
real ischemic effect due to ligation of LAD. In all early MI groups the values of
GAL-1 are higher than corresponding sham groups and show statistical
significance at certain time points. So the significant rise of GAL-1 levels at
certain time points in MI groups when compared to sham-operated groups is
purely due to ischemia and not surgical stress.
3.1.4 Conclusions
We show for the first time that GAL-1 level in the LV is increased in early
ischemic period.

We also report for the first time that in mouse model of

myocardial infarction plasma GAL-1 level is significantly raised as early as 4
hours of the event. This is significant because it can help in understanding the
very early changes that occur in the myocardium after acute infarction and help
devise ways to an early diagnosis and save viable tissue before permanent damage
sets in. Raised plasma GAL-1 levels in this early phase of infarction in the mice is
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significant in terms of its potential use as a biomarker for MI, but further studies
are still needed to elaborate on its role.
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Section 2: Galectin-3 is expressed in the
myocardium very early post myocardial
infarction
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3.2.1 Background
Galectin-3 (GAL-3) is ~35 kDa protein. It is a unique chimera-like galectin
that has one C-terminal carbohydrate recognition domain (CRD) connected to a
long N-terminal domain (ND) (19). It is found on the cell surface and within the
extracellular matrix, as well as in the cytoplasm and the nucleus of cells. Its
localization depends on factors such as cell type and proliferation status (107111), cultivation conditions (112), neoplastic progression (113-117) and
transformation (73, 118). The distribution in many types of cells, together with
varied subcellular localization, indicates galectin-3 has many different roles in
normal and pathophysiological conditions (119, 120).
Intracellular GAL-3 is involved in regulating cell differentiation, survival,
and death (99, 100), through its effect on mitosis, proliferation of cells and antiapoptotic mechanisms (91-94). Extracellular GAL-3 mediates cell-cell adhesion,
cell-matrix interaction and signaling (86-89) and pro-apoptotic mechanisms (90).
GAL-3 is expressed in a variety of cells, e.g., endothelial and epithelial cells,
activated macrophages (75-77), activated microglial cells (78, 79), inflammatory
cells including macrophages, basophils, mast cells, eosinophils, and neutrophils
(20, 41, 80-82). In tissues, GAL-3 is expressed in the lungs, spleen, stomach,
colon, adrenal gland, uterus, and ovary and at a lower level in kidney, heart,
cerebrum, pancreas, and the liver (85).
GAL-3 plays a very well documented role in heart failure (135). Higher
levels were associated with recurrent heart failure and increased risk of death in a
number of studies (139-142). This has led to its use as a prognostic marker in
patients with heart failure.

GAL-3 also predicted all-cause death (143) and

demonstrated a relationship with future heart failure and rehospitalizations in the

78

general population (144). Despite its established role in heart failure, GAL-3 has
not been studied directly in relation to cardiac ischemia. In other organs, e.g., in
kidneys GAL-3 mRNA increased after ischemic injury in acute renal failure in
rats (145). There was also up-regulated expression of GAL-3 in the ischemic brain
following transient middle cerebral artery occlusion in rats and in neonatal
hypoxic ischemic brain injury (79, 146). We aim to study the direct effects of
ischemia on GAL-3 levels in the heart very early in the course of events following
myocardial infarction (MI).
3.2.2 Results
3.2.2.1 Left ventricular GAL-3 level is increased within one hour post MI
GAL-3 level in the naïve heart was measured to be 1754.86 ± 103.51 pg/mg.
We observed an increase in GAL-3 protein level in the left ventricular heart tissue
as early as 30 min post MI as compared to sham operated animals (2623.69 ±
61.90 vs 2373.59 ± 72.72 pg/mg, p=0.021*) (Fig. 3.11 and Fig. 3.12). GAL-3
levels are continuously high in the heart till 24 hour post MI time point (Table
3.4). This is also shown in the corresponding blots where the difference between
MI and Sham blots till 24 hour post MI time points is shown (Fig. 3.12)
Immunohistochemistry results show that in the normal naïve heart, GAL-3 is
mainly seen to be expressed by endothelial cells and only a few cardiomyocytes.
The expression is more prominent in the right ventricle as compared to the left
ventricle and GAL-3 is mostly seen as a cytoplasmic staining (Fig. 3.13). In MI
groups, the expression of GAL-3 is well demarcated in the area supplied by LAD
artery in all the time points tested (Fig. 3.14, 3.15, 3.16, 3.17, and 3.18). Both
cardiac myocytes and endothelial cells show high expression of GAL-3. GAL-3
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is seen as diffuse cytoplasmic staining, Z bands staining, cell membrane staining
and nuclear staining at the different post MI time points. At 30 min, 60 min and
4-hour post MI groups (Fig. 3.15, 3.16, 3.17 respectively) we see that the intensity
and pattern of staining is the same although higher than the 20 min post MI group
(Fig. 3.14). GAL-3 shows both nuclear and cytoplasmic staining. The 24 hour
post MI group has a very characteristic pattern. There is very high expression in
the area of LAD supply surrounding an area of very low or no expression
(Fig.3.18). We observed that the area showing no expression is the area of the
infarct consisting of dead cardiomyocytes and the surviving cardiomyocytes and
endothelial cells surrounding the infarct are showing very high GAL-3 staining
(Fig. 3.18). Neutrophil polymorphs, which are abundant in the area of the infarct
at 24 hour post MI are the only cells in the infarct region that show high
expression of GAL-3 (Fig. 3.18). The sharp demarcation between completely dead
cardiomyocytes and those which survived is very characteristic at this time point.
3.2.2.2 GAL-3 mRNA expression in post MI groups
GAL-3 gene expression is first seen to be significantly increased at 60 min
post MI time points in the infarcted part of left ventricle compared to the sham
(p=0.032*).

GAL-3 mRNA at 4 hour and 24 hour post MI group is also

significantly high in the Infarcted LV as compared to Sham (p=0.012*, p=0.00*).
30 min post MI GAL mRNA is higher than the Sham and almost reaching
statistical significance (p=0.056) (Table. 3.5, Fig. 3.19).
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A.

B.

Figure 3.11 (A) GAL-3 levels measured by ELISA in the LV of post MI heart
compared to sham operated hearts at respective time points. (B)Time course of
GAL-3 protein levels in the LV for the first 24 hours post MI. * shows p<0.0
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Table 3.4: GAL-3 levels in pg/mg of total protein at respective points post
myocardial infarction
Groups

N

Mean

Std Dev

Std Error

Control

7

1754.86

273.86

103.51

20 min MI

8

2257.52

259.05

91.59

20 min sham

8

2422.93

140.17

49.56

30 min MI

8

2623.69

175.09

61.90

30 min sham

7

2373.59

192.39

72.72

60 min MI

8

2470.46

178.59

63.14

60 min sham

7

2153.66

311.86

117.87

4 hours MI

8

2648.68

236.28

83.54

4 hours sham

7

2302.82

239.76

90.62

8

14543.3

4799.95

1697.04

8

4784.59

773.57

273.49

60 min
MI

60 min
Sham

24 hour
MI

24 hour
Sham

p
value

0.135

Heart

0.021*

Galectin3 pg/mg

0.029*

0.015*
24 hour MI
24 hour Sham

30 min
MI

30 min
Sham

0.01*

GAL-3
Beta actin

4 hour
MI

4 hour
Sham

GAL-3
Beta actin

Figure 3.12: Western blot for detection of GAL-3 and beta actin in respective
time points post MI with corresponding sham.
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Figure 3.13: GAL-3 expression in naïve heart.
Naïve heart: A, Low power view of the cross section of the murine heart showing
low cytoplasmic GAL-3 in the left ventricle, interventricular septum and right
ventricle wall (arrow heads). B, showing expression of GAL-3 in the wall of the
right ventricle (black arrow head) and interventricular septum (white arrow head),
Streptavidin- biotin immunoperoxidase method. C, Immunofluorescent labeling of
sections of the naïve heart showing pattern of GAL-3 staining. D, Cardiac
myocytes (arrow head) show a characteristic sub-sarcolemmal distribution while
and nuclear staining (arrow), Alexa Fluor 488 immunofluorescent technique. E,
GAL-3 positive control section from prostate gland showing cytoplasmic
expression in prostatic acini, Streptavidin- biotin immunoperoxidase method. F,
Negative control section of the heart showing absence of GAL-3 staining,
Streptavidin- biotin immunoperoxidase method.

83

Figure 3.14: GAL-3 expression at 20 min post MI
A, Low power view of the cross sectional area of the heart showing a patchy
expression of GAL-3 in the anterior wall of left ventricle in the area supplied by
LAD, interventricular septum and the right ventricular wall (arrow heads). B,
Sham operated heart showing lower expression of GAL-3 in the left ventricle and
right ventricle (arrow heads). C. Representative sections of the left ventricle from
area supplied by LAD showing high cytoplasmic expression of GAL-3 by cardiac
myocytes (arrow head). D, High power views show a well demarcated area of
high cytoplasmic expression of GAL-3 by cardiac myocytes bordering with area
of no expression of GAL-3. Streptavidin- biotin immunoperoxidase method.
E&F, immunoflorescence pattern of GAL-3 in the area of LV supplied by LAD
showing fields of cardiomyocytes with higher cytoplasmic expression of GAL-3
(E) (arrow heads). High power view (F) shows GAL-3 expression in
cardiomyocytes (arrow head) with prominent staining of cross striations and
endothelial cell (thin arrow). Alexa Fluor 488 immunofluorescent technique.
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Figure 3.15: GAL-3 expression at 30 min post MI
A low power view of the cross sectional area of the heart showing expression of
GAL-3. The high expression is confined to the area supplied by LAD in the
anterior wall of left ventricle. B, Sham operated heart showing lower expression
of GAL-3 in the left ventricle and right ventricle (arrow heads).C&D,
Representative sections of the left ventricle from area supplied by LAD showing
high cytoplasmic expression of GAL-3 by cardiac myocytes (arrow head)
interspersed with cardiomyocytes with low expression. D, High power view
shows expression of GAL-3 in the cardiac myocytes cytoplasm (arrow heads),
nucleus (thick arrow) and endothelial cells (thin arrow), Streptavidin- biotin
immunoperoxidase method. E&F, immunofluorescent pattern of GAL-3 in the
area of LV supplied by LAD showing cardiomyocytes with higher cytoplasmic
expression of GAL-3 (E) (arrow heads). High power view (F) shows GAL-3
cytoplasmic expression in cardiomyocytes (arrow head), nuclear expression in
cardiomyocytes (thick arrow) and endothelial cell (thin arrow). Alexa Fluor 488
immunofluorescent technique.
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Figure 3.16: GAL-3 expression at 60 min post MI
A, Low power view of the heart showing a high expression of GAL-3 in the
anterior wall of left ventricle in the area supplied by LAD, interventricular
septum(arrow heads) and right ventricle (thin arrow). B, Sham operated heart
section showing low expression in the corresponding areas. C&D, Representative
sections of the left ventricle from area supplied by LAD showing high
cytoplasmic expression of GAL-3 by cardiac myocytes (arrow head) interspersed
with cardiomyocytes with low expression. D, High power view shows expression
of GAL-3 in the cardiac myocytes cytoplasm (arrow heads), nucleus (thick arrow)
and endothelial cells (thin arrow). Streptavidin- biotin immunoperoxidase method.
E&F, immunofluorescent pattern of GAL-3 in the area of LV supplied by LAD
showing cardiomyocytes with higher cytoplasmic expression of GAL-3 (E) (arrow
heads). High power view (F) shows GAL-3 cytoplasmic expression in
cardiomyocytes (arrow head), nuclear expression in cardiomyocytes (thick arrow),
prominent cross striations with z-band staining (thin arrows) and endothelial cell
(curved arrows). Alexa Fluor 488 immunofluorescent technique.
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Figure 3.17: GAL-3 expression at 4 hour post MI
A, Low power view of the heart showing a high expression of GAL-3 in the
anterior wall of left ventricle in the area supplied by LAD, interventricular
septum(arrow heads) and right ventricle (thin arrow). B, Sham operated heart
section showing low expression in the corresponding areas. C, Representative
sections of the left ventricle from area supplied by LAD showing high
cytoplasmic expression of GAL-3 by cardiac myocytes (arrow head) diffusely
surrounding the area of cardiomyocytes with low expression. D, High power view
shows expression of GAL-3 in the cardiac myocytes cytoplasm (arrow heads)
nucleus (thick arrow) and endothelial cells (thin arrow). Z-band staining is also
seen (curved arrow), Streptavidin- biotin immunoperoxidase method. E&F,
immunofluorescent pattern of GAL-3 in the area of LV supplied by LAD showing
cardiomyocytes with higher cytoplasmic expression of GAL-3(E) (arrow heads).
High power view (F) shows GAL-3 cytoplasmic expression in cardiomyocytes
(arrow head), nuclear expression in cardiomyocytes (thin arrow), prominent cross
striations with z-band staining (thick arrows) and endothelial cell (curved arrows).
Alexa Fluor 488 immunofluorescent technique.
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Figure 3.18: GAL-3 expression at 24 hour post MI
A, Low power view of the heart showing a high expression of GAL-3 in the anterior wall of left
ventricle in the area supplied by LAD, interventricular septum (arrow heads) and right ventricle
(thin arrow). Left ventricular area also shows a cluster of inflammatory cells showing intense
staining with GAL-3 (thick arrow). B, Sham operated heart section showing low expression in the
corresponding areas. C. Representative section of the left ventricle from area supplied by LAD
showing high cytoplasmic expression of GAL-3 by cardiac myocytes (arrow heads), surrounding
areas of no expression. Many neutrophil polymorphs (thick arrows) are also showing cytoplasmic
expression of GAL-3. D, High power view showing a well demarcated area of high cytoplasmic
expression of GAL-3 by cardiac myocytes (arrow heads) and endothelial cells (thin arrow).
Numerous neutrophil polymorphs expressing GAL-3 (thick arrows) are also seen in the section
scavenging the dead cardiomyocytes. Streptavidin- biotin immunoperoxidase method. E&F, Alexa
Fluor 488 immunofluorescent labeling of GAL-3 in the area of LV supplied by LAD showing
cardiomyocytes with higher cytoplasmic expression of GAL-3 which is sharply demarcated from
the surrounding dead cardiomyocytes infiltrated with GAL-3 expressing neutrophil polymorphs
(E) (arrow heads). High power view (F) shows GAL-3 cytoplasmic expression in cardiomyocytes
(arrow head), nuclear expression in cardiomyocytes (thin arrow) and neutrophil polymorphs (thick
arrow). Alexa Fluor 488 immunofluorescent technique.

88

Figure 3.19: GAL-3 mRNA expression in the ILV (Infarcted left ventricle) and
NILV (Non-infarcted left ventricle) expressed as fold changes relative to sham at
respective time points post MI (*shows p<0.05).

Figure 3.10: The graph represents ratio of plasma GAL-3 concentration in
myocardial infarction to plasma GAL-3 concentration in sham operated mice
C57BL6 mice. 24 hours post myocardial infarction show significant difference
from sham operated mice (*shows p < 0.05).
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Table 3.5: Fold changes in GAL-3 mRNA expression in the ILV (Infarcted left
ventricle) and NILV (Non-infarcted left ventricle) relative to sham at respective
time points post MI
Sham

Non-Infarcted
LV (NILV)

Infarcted LV
(ILV)

P value†

20 min Post MI

1.0155

1.2611

1.2409

0.212

30 min Post MI

0.9540

1.0726

1.4731

0.056

60 min Post MI

0.8091

0.7048

1.9180

0.032*

4 hr Post MI

1.0426

1.2885

2.9926

0.012*

24 hr Post MI

1.1183

4.0330

13.2393

0.00*

† shows p values comparing ILV and sham groups for respective time points (* shows p<0.05).

3.2.2.3 Plasma GAL-3 levels are significantly increased at 24 hour post MI
Plasma GAL-3 values in the naive control group were 44278.98 ± 3684.88
pg/ml.

GAL-3 plasma levels were significantly raised at 24 hour post MI

compared to sham operated mice (120220.94±20702.83 vs 96542.77±4935.79
p=0.01*). There was no significant difference between MI groups and sham
groups at earlier time points (Fig. 3.20).
3.2.3 Discussion
Myocardial Infarction is the leading cause of heart failure. The association of
GAL-3 with heart failure is already well established so it becomes important to
know when GAL-3 starts to appear after MI and whether ischemia regulates it at
transcriptional or translational levels in the myocardium. Permanent LAD ligation
in mice is a very appropriate in vivo model to study the very early changes that
occur in the heart following occlusion of blood flow to the myocardium.
Our results show that GAL-3 starts to increase in the left ventricle in the
area of infarction within one hour of ischemia/hypoxia. GAL-3 stays high till 4
90

hour post MI after which at 24 hour post MI it increases several fold compared to
the sham operated animals. GAL-3mRNA is also detected to be high at one hour
post MI time point in the infarcted tissue which stays high till 24 hours time point.
An interesting observation was that GAL-3mRNA increases in the infarcted tissue
at 60 min and 4 hours time points but as the time of ischemia/infarction increases
to 24 hours, the expression increases and spreads to the non-infarcted tissue of the
left ventricle surrounding the infarcted area.
We know that GAL-3 is important in the inflammatory response which plays
a role in cardiac remodeling (317). The several fold increase in the protein as well
as mRNA levels of GAL-3 at 24 hour post MI is understandable. At this time a
full fledge inflammatory response is underway in the infarcted myocardium, there
is coagulative necrosis and the area is flooded with neutrophils, which also
expresses GAL-3. The increase in myocardial GAL-3 levels in the first 4 hours of
MI gives us an insight into how the myocardium reacts immediately after the
ischemic insult. The neutrophil polymorphs have not yet reached the area of
infarction and the response seen at these earlier time points is purely due to the
resident cells, which are mainly the cardiomyocytes and the endothelial cells.
Our immunohistochemistry and immunofluorescent staining results show
that GAL-3 is expressed by cardiomyocytes and endothelial cells during the early
ischemic event and it co-localized with desmin in cardiomyocytes and factor 8relaed antigen in endothelial cells (Fig. 3.27). In a study on heart failure model on
Ren-2 rats, GAL-3 was shown to be expressed in fibroblasts and macrophages,
but not with cardiomyocytes (136). This difference may be due to the difference
in disease models used in the two studies. The appearance of GAL-3 at this early
time following MI is very significant in terms of its causal or consequential role in
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heart failure. We believe that GAL-3 increase at this early time post MI is an
immediate response of the myocardium to hypoxia or ischemia.
Plasma GAL-3 levels were high at 24 hour post MI time point compared to
sham operated animals which was expected due to the several fold high GAL-3
protein and mRNA levels seen in the LV tissue.
We have observed in our study that the levels of GAL-3 in sham operated
animals were higher than the non-operated naïve animals. The reason for this
increase is not clearly known, but may involve a generalized stress response to the
sham surgical procedure.

It has been reported in traumatic brain injury model

that animals exposed to sham surgery had higher GAL-3 levels when compared
to naïve animals (318). As there is some degree of mechanical/surgical stress
applied to the sham operated mice we suggest that GAL-3 levels seen in sham
groups may be the result of these factors. For these reasons we made sham
operated groups as our controls for all time points, and all our statistics were
calculated in comparison between MI groups and sham-operated groups to take
out the effect of mechanical/surgical stress from the real ischemic effect due to
ligation of LAD. In all early MI groups the values of GAL-3 are higher than
corresponding sham groups and show statistical significance at certain time
points. So the significant rise of GAL-3 levels at certain time points in MI groups
when compared to sham-operated groups is purely due to ischemia and not
surgical stress.
Although a contributory role for GAL-3 in the pathophysiology of heart
failure is already defined, we think that GAL-3 at early time point post MI works
to sustain the myocardium against the initial injury. Further studies need to be
carried out for proper assessment of GAL-3 in cardiovascular disease specially
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after Myocardial infarction to ascertain when GAL-3 becomes responsible for the
onset and progression of cardiac fibrosis and reduced ventricular function (144).
3.2.4 Conclusion
We have shown for the first time that GAL-3 is increased at both
transcriptional and translational level in the LV in early ischemic period. We
have also shown for the first time that GAL-3 is produced by cardiomyocytes and
endothelial cells in early post MI time which is significant because it can help in
understanding the mechanism of very early response of the myocardium after
acute infarction and help devise ways to save the viable tissue before permanent
damage sets in.
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Section 3: Hypoxia Inducible factor-1 alpha
in Early Myocardial Infarction
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3.3.1 Background
Hypoxia-inducible factor (HIF) is a set of transcription factors that regulate
the cellular response to hypoxia (147). HIF is a heterodimeric DNA-binding
complex composed of two basic helix-loop-helix proteins, the constitutive
expressed HIF-β or aryl hydrocarbon receptor nuclear translocator (ARNT) and
the oxygen sensitive hypoxia-inducible HIF-α (148). HIF-α heterodimerizes with
ARNT (HIF-1β), recognizes and binds to hypoxia response elements (HREs) in
the genes that have the consensus sequence G/ACGTG (150). The α-subunit is
degraded during normoxia mainly through a proteasome-dependent pathway (152,
153) after hydroxylation of two proline residues by prolyl-hydroxilases (PHDs)
(319, 320). During hypoxia, PHDs are inhibited and HIF-1 α subunit accumulates,
dimerizes with HIF-1β and drives expression of HIF target genes (155). Hypoxia
contributes significantly to the pathophysiology of major human disease,
including myocardial and cerebral ischemia, cancer and pulmonary hypertension
and so HIF-1α is a major player in the mechanism of injury in these diseases
(158).
HIF-1 alpha role in the heart is shrouded with many conflicting reports (321)
as discussed in detail in the review of literature of this dissertation, however there
is a general agreement that increase in the level of HIF-1α is one of the first
adaptations of the myocardium to ischemia (160). Here we look at the HIF-1 α
levels in the myocardium very early following MI in the mouse model of
permanent LAD ligation.
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3.3.2 Results
3.3.2.1 HIF-1 α in heart tissue
HIF-1 α concentration in LV tissue of the naïve group is 31.97±2.18 pg/mg
of total protein. HIF-1 α protein concentration shows a significant increase in the
LV at 20 minutes following MI group compared to sham operated control group
(95.5±12.4 vs 65.6±0.7 pg/mg, P = 0.047*) (Table 3.6) (Fig. 3.21). HIF-1 α
values in the MI groups are higher than corresponding sham operated groups at 30
minutes, 60 minutes and 4-hour groups but show no statistical significance
(36.34±2.62 vs 30.54±1.42 pg/mg, 40.85±4.6 vs 40.01±5.15 pg/mg, and
59.35±3.22 vs 54.98±4.26 pg/mg,). The 24-hour HIF-1 α level in sham-operated
group appears to be higher than the MI group but does not reach statistical
significance (46.65±2.42 vs 40.75±2.61 pg/mg). HIF-1 α value in LV in all MI
groups is higher than the baseline naïve control group. The pattern of HIF-1 α
protein expression in the LV after permanent ligation of LAD shows a transient
significant peak at 20 minutes following MI, which declines afterwards but still
remains high compared to the naïve control animal group (Table 3.6) (Fig. 3.21).
As we observed a peak of HIF-1 α at 20 minutes post MI time point, so we did a
separate experiment for 20 minutes time point to measure the HIF-1 α
concentration in the nuclear and cytoplasmic extracts of the LV. The results show
a significant rise of HIF-1 α concentration in the nuclear extract of the MI group
compared to the sham operated group (87.84±5.41 vs 70.75±3.72 pg/mg, p =
0.03*) (Table 3.7) (Fig. 3.22 ).
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Figure 3.21: HIF-1 α concentrations at 20 mins, 30 mins, 60 mins, 4 hours and 24
hours post myocardial infarction with corresponding sham operated groups in
C57BL6 mouse left ventricle. Control represents non-operated normal animal
heart (*shows p<0.05).

Figure 3.22: HIF-1 α levels in nuclear and cytoplasmic extracts of LV mouse
heart at 20 minutes following MI (*shows p<0.05).
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Table. 3.6 : HIF-1 α levels in pg/mg of total protein at different time points post
myocardial infarction.

Groups
Naive

Number
7

Mean(pg/mg)

Std. Dev.

Std. Error

31.97

5.78

2.18

20 min MI

8

95.49

35.09

12.41

20 min sham

7

65.58

1.86

0.70

30 min MI

8

36.34

7.39

2.62

30 min sham

6

30.54

3.47

1.42

60 min MI

8

40.85

12.98

4.59

60 min sham

7

40.01

13.61

5.15

4- hour MI

8

59.35

9.12

3.22

4- hour sham

7

54.98

11.28

4.26

24 hour MI
24-hour sham
* shows p<0.05

7
7

40.75
46.65

6.89
6.41

2.61
2.42

p value
0.047*

0.103
0.904
0.421
0.123

Table. 3.7: HIF-1 α levels in pg/mg total protein in nuclear and cytoplasmic
fractions of left ventricular heart tissue at 20 min post myocardial infarction
HIF-1α (LV)
Nuclear
fraction pg/mg

Cytoplasmic
fraction pg/mg

Groups

N

Mean

Std. Dev

Std. Error

P value

20 min MI

6

87.05

13.24

5.41

0.032*

20 min Sham

6

70.75

9.11

3.72

20 min MI

6

38.16

3.60

1.47

20 min Sham

6

34.11

4.70

1.92

* shows p<0.05
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0.125

There was a statistically significant difference between the different time
points within the MI groups as determined by one-way ANOVA (F (4,34) =
14.672, p = .000). Tukey post-hoc tests showed that the 20 min post MI HIF-1 α
level (M = 95.48, 95% CI [66.15, 24.82]) was significantly higher than 30 minute
(M = 36.34, 95% CI [30.15, 42.53], p = 0.00), 60 minute (M = 40.85, 95% CI
[30.00, 51.7], p = 0.00), 4 hour (M = 59.35, 95% CI [51.72, 66.98], p = 0.003),
and 24 hour post MI groups (M = 40.75, 95% CI [34.37, 47.13], p = 0.00).
The expression of HIF-1α is predominantly seen in the nuclei of endothelial
cells (Fig. 3.23 A) in the naïve heart. The expression of HIF-1 α in the nuclei of
cardiomyocytes is very low and in few cells in naïve heart. There is a higher
nuclear expression of HIF-1 α by cardiac myocytes and endothelial cells in the
area supplied by LAD artery at 20 (Fig. 3.23 E, G, H) and 30 minute (Fig. 3.23 I,
K, L), groups when compared with 60 minute (Fig. 3.23 M, O, P), 4 hour (Fig.
3.23 Q, S, T), and 24 hour (Fig. 3.9 K) following MI groups and all sham operated
groups. In 60 minutes (Fig. 3.23 M, O, P) and 4 hours (Fig. 3.23 Q, S, T), we
noticed a decrease in the number of cardiac myocytes that expresses HIF-1 α and
most of the cells that express HIF-1 α are endothelial cells. In the 24 hour post MI
group the expression of HIF-1α is in the nuclei of few cardiomyocytes and more
endothelial cells in areas surrounding the infarction while cardiomyocytes in the
center of infarction does not show any expression of HIF-1α (Fig. 3.9 K). On the
contrary, many infiltrating neutrophil polymorphs in the center of infarction show
nuclear expression of HIF-1 α (Fig. 3.9 K). As early as 60 minutes following MI
we can identify an area of infarcted cardiomyocytes that do not express HIF-1 α
(Fig. 3.23 M), this area is more obvious at 4 hours (Fig. 3.23 Q) and 24 hours
following MI (Fig. 3.9 K).
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Figure 3.23: HIF-1 α expression of the heart.
A. Representative section of naïve heart showing nuclear expression of HIF-1 by
a few endothelial cells (arrow head), streptavidin- biotin immunoperoxidase
method. B. Negative control section showing no HIF-1 a staining, streptavidinbiotin immunoperoxidase method. C. Positive control section of mouse placenta
showing nuclear staining of HIF-1 a by trophoblastic cells, Rhodamine,
immunofluorescent technique. D. Negative control section for HIF-1 a.
Rhodamine, immunofluorescent technique. E,I,M&Q shows representative
sections from the anterior wall of left ventricle in the area supplied by LAD 20
min, 30 min, 60 min and 4 hours following ligation of LAD, showing variable
nuclear staining of HIF-1 a by cardiac myocytes at different time points (arrow
head) and endothelial cells (thin arrow), streptavidin- biotin immunoperoxidase
method. F,J,N&R shows their corresponding Sham operated hearts showing low
nuclear expression of HIF-1 a by few endothelial cells (thin arrow), streptavidinbiotin immunoperoxidase method. Low and high power views of the left ventricle
20 min (G&H), 30 min (K&L), 60 min (O&P) and 4 hours (S&T) following
ligation of LAD showing high nuclear staining of HIF-1 a by cardiac myocytes
(arrow head), Rhodamine, immunofluorescent technique.
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3.3.2.2 HIF-1 alpha mRNA expression at 20 mins post MI:
As HIF-1 alpha protein level was significantly high at 20 mins post MI time
point. We checked the mRNA level at this point which showed no upregulation
of mRNA at 20 min post MI time point (Table 3.24).
3.3.2.3 Morphometric analysis
The frequency of cardiomyocytes expressing HIF-1 α in 20 minute post MI
group was significantly higher than 30 minute, 60 minute, 4-hour and 24-hour
post MI groups (Chi squared = 9.158 with 1 degree of freedom, P = 0.002*, Chi
squared = 34.1 with 1 degree of freedom, P = 0.0001*, Chi squared = 57.001 with
1 degree of freedom, P = 0.0001*, Chi squared = 84.5 with 1 degree of freedom, P
= 0.0001*, respectively). The frequency of endothelial cells expressing HIF-1 α
in 20 minute post MI group is significantly higher than 30 minute, 60 minute, 4hour and 24-hour post MI groups (Chi squared = 12.3 with 1 degree of freedom, P
= 0.0004*, Chi squared = 36.5 with 1 degree of freedom, P = 0.0001, Chi squared
= 49.1 with 1 degree of freedom, P = 0.0001, Chi squared = 54.3 with 1 degree of
freedom, P = 0.0001*, respectively). The frequency of endothelial cells expressing
HIF-1 α is significantly higher than cardiomyocytes at 4-hour and 24-hour post
MI groups (Chi squared = 6.84 with 1 degree of freedom, P = 0.008* and Chi
squared = 17.04 with 1 degree of freedom, P = 0.0001*, respectively).
The frequency of neutrophil polymorphs expressing HIF-1 α was
significantly higher than cardiomyocytes and endothelial cells at 24-hour post MI
groups (Chi squared = 81.9 with 1 degree of freedom, P= 0.0001* and Chi
squared = 27.9 with 1 degree of freedom, P= 0.0001*, respectively). A decrease
in the number of cardiomyocytes and endothelial cells that express HIF-1 α is
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*

Figure. 3.24: HIF-1α mRNA expression at 20 min Post MI time point in the
ILV (Infarcted left ventricle) and NILV (Non-infarcted left ventricle) expressed as
fold changes relative to sham at respective time points post MI.

Table 3.8: Morphometric analysis of expression of HIF-1α in cardiomyocytes,
endothelial cells and neutrophil polymorphs at different time points following
ligation of LAD.
HIF-1α Morphometric analysis
Post MI time
points

Cardiomyocytes
%

Endothelial cell
s%

Neutrophil
Polymorphs %

20 MINUTES
30 MINUTES
60 MINUTES
4 HOURS
24 HOURS

83
63
42
29
17

94
75
56
48
45

0
0
0
0
82
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associated with the increase in post MI time. Neutrophil polymorphs were counted
at 24-hour following MI as they are not seen before 4 hour post MI time (Table
3.8).
3.3.3 Discussion
HIF-1 α levels in the LV show a significant increase in 20 minute post MI
group compared to sham operated control group (Fig. 3.21, 3.22). In addition,
HIF-1 α value in the MI groups at 30 minutes, 1 hour and 4 hours are higher than
corresponding sham operated control groups but shows no statistical significance.
This is supported by one-way ANOVA and Tukey post-hoc test analysis of MI
groups which shows HIF-1 α value at 20 minute MI group is significantly higher
than other MI groups. Moreover, HIF-1 α values in all MI groups are higher than
the baseline non-operated naïve control groups. We show for the first time a
transient peak in LV HIF-1 α level at 20 minutes following MI, which declines
afterwards. The immunohistochemical and immunofluorescent staining results
are very characteristic and supportive of this pattern (Fig. 3.23).
We believe that in our experiments, the initial increase in HIF-1 α levels in
the LV is due to stabilization of HIF-1 α as a result of low intracellular level of
oxygen secondary to complete ligation of LAD artery.

This observation is

supported by our real time PCR results that show no upregulation of HIF-1 α
mRNA at this early time point. We also observed a decrease in LV level of HIF-1
α as the time of ischemia increased. We think that as the time of ischemia
increases the cardiomyocytes become necrotic and HIF-1 α level go down due to
protein degradation. As previously mentioned in the methods section (p. 42), we
took only the LV protein extraction, so the mass of heart tissue is similar between
samples. If the cells in the middle of the infarct are necrotic and HIF- 1 α is
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degraded as the time of ischemia increases then it is understandable that the levels
of HIF-1 α in the 1 hour, 4-hour and 24-hour post MI groups are not significantly
higher than corresponding sham operated groups.
HIF-1 α is being expressed by the nuclei of cardiomyocytes and endothelial
cells

follows

the

same

pattern

seen

in

immunohistochemical

and

immunofluorescent-stained sections and we are able to see that as the time of
ischemia increases the number of cells with high expression of HIF-1 α
decreases. This is supported by our morphometric analysis which shows a
significant decrease in the frequency of cardiomyocytes and endothelial cells that
express HIF-1 α with the increase of post MI time. Another observation pertinent
to HIF-1 α staining was that while the expression of HIF-1 α decreases in
cardiomyocytes as the time of ischemia increases, its expression in endothelial
cells essentially remains the same. A possible explanation for this can be related
to the fact that endothelial cells are proliferating cells that participate in healing
process of the infarcted zone and in the formation of collaterals while survived
cardiomyocytes do not proliferate. We think that when continuous ischemia
damages the cardiomyocytes its expression is lost but the surrounding endothelial
cells keep on proliferating and expressing HIF-1 α. HIF-1 α is a protective factor
that mediates the survival of injured cardiomyocytes in the setting of ischemic
injury by transcribing a variety of cardioprotective genes including erythropoietin,
vascular

endothelial

growth

factor,

inducible

nitric

oxide

synthase,

hemeoxygenase-1 and cardiotropin (321) . So we think that presence of HIF-1 α is
protective in the early post MI time point tested.
We have observed in our study that the level of HIF-1 α in sham operated
animals was higher than the non-operated naïve animals. This increase in sham
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operated animals can be due to factors related to surgical stress. One of the studies
(322) demonstrated that HIF-1 α protein in the myocardium could be induced by
mechanical stress to the heart. As there is some degree of mechanical/surgical
stress applied to the sham operated mice we suggest that HIF-1 α levels seen in
sham groups may be the result of these factors. For these reasons we make sham
operated group as our control for all time points, and all our statistics were done in
comparison between MI groups and sham-operated groups to take out the effect of
mechanical/surgical stress from the real ischemic effect due to ligation of LAD.
The significant rise of HIF-1 α levels at certain time points in MI groups when
compared to sham-operated groups is purely due to ischemia and not surgical
stress.
3.3.4 Conclusions
We report for the first time that HIF-1 α is significantly increased at 20 minutes
following myocardial infarction.
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Section 4: HIF-1 α correlates with GAL-1 and
GAL-3 in Early Myocardial Infarction
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3.4.1 Background
3.4.1.1 GAL-1 and HIF-1α
GAL-1 has been identified as a hypoxia-induced protein in a number of
studies (64-66). Recently, Zhao et al. (67) have demonstrated that HIF- 1 α
significantly increased GAL-1 expression in messenger RNA and protein levels in
four colorectal cancer cell lines and it has been proposed that GAL-1 gene is a
direct target of transcriptional factor HIF-1 α (66, 67). HIF-1 α itself is a
transcription factor mediating early (160) as well as late responses to myocardial
ischemia (323). We tried to establish whether there is any correlation between
GAL-1 and HIF-1 α in the ischemic myocardium at early post MI time points in
the murine model of permanent LAD ligation.
3.4.1.2 GAL-3 and HIF-1 α
GAL-3 has been linked to hypoxic/Ischemic injuries in a number of studies
in the kidneys, and brain (79, 145, 146). We have also shown in our work that
GAL-3 is expressed in relation to cardiac ischemia very early in the post MI
period. There is experimental evidence that GAL-3 expression is dependent on
HIF-1 α activity. It was shown on nucleus pulposus cells that upregulation of HIF1α caused an elevation in GAL-3 promoter activity and deletion of HIF-1 caused
loss of galectin-3 promoter activity. HIF-1 null cells also showed minimal
expression of GAL- 3. These results support the observation that GAL-3 is an
HIF-1 transcriptional target and that HIF-1 serves as a major regulator of GAL-3
expression (324).
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We sought to discover whether there was any correlation between GAL-3 and
HIF-1 α in the ischemic myocardium at early post MI time points in the murine
model of permanent LAD ligation.
3.4.2 Results
3.4.2.1 Co-localization of GAL-1 and HIF-1 α
Co-localization of GAL-1 and HIF-1 α cardiomyocytes and endothelial cells
is shown in Fig. 3.25. All cardiac myocytes that show nuclear expression of HIF-1
α also express GAL-1 in the cytoplasm and some nuclei. All endothelial cells that
show nuclear expression of HIF-1 α also express GAL-1 in the cytoplasm and
some nuclei. GAL-1 expression in cardiomyocytes is confirmed by co-localizing
it with Desmin (Fig. 3.26 C). GAL-1 and HIF-1 α expression in endothelial cells
is shown with co-localization with CD31 (Fig. 3.26 F&O, respectively). Few
tissue histiocytes, which express CD68, also show co-localization with GAL-1
and HIF-1 α (Fig. 3.26 I& L respectively). In general, few tissue histiocytes are
noticed during the first 24 hours following MI.
3.4.2.2 GAL-3 co-localize with HIF-1 α in early post MI
GAL-3 and HIF-1 α co-localize in cardiomyocytes and endothelial cells are
shown in Fig. 3.27 C. All cardiac myocytes that show nuclear expression of HIF-1
α also express GAL-3 in the cytoplasm and some nuclei and endothelial cells that
show nuclear expression of HIF-1 α also express GAL-3 in the cytoplasm and
some nuclei. GAL-3 expression in cardiomyocytes is shown by co-localizing it
with Desmin (Fig. 3.27 F). GAL-3 expression in endothelial cells is shown with
co-localization with factor-8 related antigen (Fig. 3.27 I). GAL-3 presence in the
neutrophil polymorphs is also confirmed by co-localization with lysozyme and
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Figure 3.25: Co-localization of Galectin-1 and HIF-1 α. A,D,G,J,M, Q show
representative sections of the left ventricle from areas supplied by LAD in 20
minutes (low power view), 20 minutes (high power view), 30 minutes, 60
minutes, 4 hours and 30 minutes (high power view) following MI respectively,
showing high cytoplasmic expression of galectin-1 by cardiac myocytes (thin
arrow), Alexa Fluor 488 immunofluorescent technique. B,E,H,K,N,W show
representative sections of the left ventricle from areas supplied by LAD in 20
minutes (Low power view), 20 minutes (high power view), 30 minutes, 60
minutes, 4 hours and 30 minutes (High power view) following MI respectively
showing high nuclear expression of HIF-1a by cardiac myocytes (thin arrow),
Rhodamine immunofluorescent technique. C,F,I,L,P,X shows Co-localization of
galectin-1 and HIF-1 a in the same sections at the respective time points. (arrow
head), Alexa Fluor-Rhodamine immunofluorescent technique.
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Figure 3.26: Co-localization of GAL-1, HIF-1 α, CD31, desmin and CD68. A,D,G,
Representative section of the left ventricle from areas supplied by LAD showing high
cytoplasmic expression of galectin-1 by cardiac myocytes, endothelial cells and
histiocytes respectively (thin arrows). J, showing high cytoplasmic expression of CD68 in
tissue histiocytes (thin arrows) and M showing high cytoplasmic expression of CD31 in
endothelial cells (thin arrows). Alexa Fluor 488 immunofluorescent technique. B.
showing high cytoplasmic expression of desmin by cardiac myocytes (thin arrow), E.
showing high cytoplasmic expression of CD31 by endothelial cells (thin arrow), H.
showing high cytoplasmic expression of CD68 by histiocytes (thin arrow), K. showing
high nuclear expression of HIF-1 a by histiocytes (thin arrow), N. showing high nuclear
expression of HIF 1 a by endothelial cells (thin arrow), Rhodamine, immunofluorescent
technique. C. Co-localization of galectin-1 and desmin in cardiac myocytes. F.
Colocalization of galectin-1 and CD31 in endothelial cells (arrow head), I. Colocalization of galectin-1 and CD68 in histiocytes (arrow head), L. Colocalization of
CD68 and HIF-1 a in tissue histiocytes (arrow head), O. Co-localization of CD31 and
HIF-1 a in endothelial cells (arrow head). Alexa Fluor 488-Rhodamine
immunofluorescent technique.
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Figure 3.27: Co-localization of GAL-3, HIF-1 α, desmin, factor 8 related antigen, lysozyme
and myeloperoxidase (MPO). A, shows representative section of the left ventricle from areas
supplied by LAD showing expression of GAL-3 by cardiac myocytes (thick arrows) and
endothelial cells (arrow heads), Alexa Fluor 488 immunofluorescent labeling. B shows HIF-1
alpha expression in the nuclei of the same section, Rhodamine immunofluorescent labeling and C
represents the co-localization of GAL-3 and HIF-1 α. D, shows GAL-3 expression by
cardiomyocytes (thick arrows) Alexa Fluor 488 –DAPI-immunofluorescent labeling, E shows the
same section with cytoplasmic expression of desmin, Rhodamine immunofluorescent labeling and
F shows the co-localization of GAL-3 with desmin in cardiomyocytes (nuclei stained by DAPI). G
shows GAL-3 expression in the endothelial cells (thin arrows) and cardiomyocytes (arrow head),
Alexa Fluor 488 immunofluorescent labeling, H shows endothelial cells expressing factor-8
related antigen (thin arrows) in the same section, Rhodamine immunofluorescent labeling and I,
shows the colocalization of GAL-3 and factor-8 related antigen in the endothelial cells. J, shows
lysozyme staining in the neutrophil polymorphs (arrow heads), Alexa Fluor 488 –DAPIimmunofluorescent labeling, K, shows neutrophil polymorphs expressing GAL-3 (arrow heads)in
the same section, Rhodamine-DAPI- immunofluorescent labeling, and L shows the double labeling
of GAL-3 and lysozyme in the neutrophil polymorphs. M , shows myeloperoxidase expression in
the neutrophil polymorphs (arrow heads), Alexa Fluor 488 –DAPI-immunofluorescent labeling, N,
shows neutrophil polymorphs expressing GAL-3 (arrow heads)in the same section, RhodamineDAPI- immunofluorescent labeling, and O shows the double labeling of GAL-3 and
myeloperoxidase in the neutrophil polymorphs.
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myeloperoxidase (MPO) in the neutrophils (Fig. 3.27, L and O).
3.4.2.3 Bioinformatic analysis results
The output from the clustalw2 program is shown in Fig. 3.32. We found at
least 4 potential HREs in the promoter region of Human GAL-1 gene (Fig.3.32,
A&B) and potential HREs in the promoter region of mouse GAL-1 gene (Fig.
3.32, C&D). Bioinformatic analysis shows that there are two potential HREs
(hypoxia response elements) in the promoter region of GAL-3 gene (324).
3.4.2.4 Proliferation and Apoptosis in Early Post Myocardial Infarction
Our staining with Ki-67 showed that there is a low proliferative activity in 20
minute, 30 minute, 60 minute and 4-hour post MI sections (Fig. 3.29). However,
in 24 hour post MI sections we are able to clearly see an increase in the expression
of Ki-67 in the endothelial cells in the area of infarction (Fig. 3.29 U&V) while
the relevant sham operated sections show very low expression of Ki-67 (Fig. 3.29
X).
We also found that there is very low expression of caspase-3 and cleaved
caspase-3 at 30 minutes, 60 min and 4 hours time points (Fig. 3.30 D, E, F). At 24
hour post MI group, however, we do find an increase in the expression of caspase3 and cleaved caspase-3 activity (Fig. 3.30 A, C), compared to the sham group
(Fig. 3.30 B). The expression of caspase-3 and cleaved caspase-3 was seen
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A.

B.

Figure 3.28: (A) Pattern of GAL-1 and HIF-1 α in the heart from 20 min post
MI till 24 hour post MI time points. (B) Pattern of GAL-3 and HIF-1 α in the heart
from 20 min post MI till 24 hour post MI time points.
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Figure 3.29: Ki-67 proliferative activity in the left ventricle.
A, B, C, D, Low Ki-67 proliferative activity in normal left ventricle showing
nuclear staining of Ki-67 in one interstitial cell (arrow head). E, F, G, 20 minutes
MI; I,J, K, 30 minutes MI; M,N,O 60 minutes MI; Q,R,S, 4-hour MI, Low Ki-67
proliferative activity: showing nuclear staining of Ki-67 in few endothelial cells
(arrow head) in left ventricle. U, V, W, 24-hour MI, high Ki-67 proliferative
activity showing nuclear staining of Ki-67 in a large number of endothelial cells
(arrow head) in the infarction area of left ventricle. H, L, P, T, X, showing faint
nuclear staining of Ki-67 in one endothelial cell in 20 minutes, 30 minutes, 60
minutes, 4-hours and 24 hour sham-operated left ventricle. A, E, I, M, Q, U are
stained by Streptavidin-Biotin immunoperoxidase method. The others are stained
by Alexa Fluor 488 immunofluorescent technique.
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Figure 3.30: Apoptotic activity in the left ventricle.
A. showing high expression of caspase- 3 in cardiac myocytes (arrow head)
surrounding the necrotic area, endothelial cells (thin arrow), and neutrophil
polymorphs (thick arrow) in 24-hour post MI, Alexa Fluor 488
immunofluorescent technique. B. showing no expression of caspase 3 in 24-hour
sham-operated left ventricle. C, showing high expression of cleaved caspase- 3 in
cardiac myocytes (thick arrows). Many apoptotic bodies (arrow head) are seen in
the infarcted area of left ventricle, streptavidin- biotin immunoperoxidase method.
D, showing very low apoptotic activity, only one cell stained with anti-cleaved
caspase 3 (arrow head) in the area of infraction in the left ventricle of 4-hour post
MI, streptavidin- biotin immunoperoxidase method. E, F, Showing no staining
with anti-cleaved caspase 3 in the left ventricle of 30 minutes and 60 minutes post
MI, streptavidin- biotin immunoperoxidase method
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Figure 3.31: Bcl2 activity in left ventricle.
A, B, C, D, showing high cytoplasmic expression of bcl2 by cardiac myocytes
(thick arrow), and endothelial cells (arrow head) at 30 minutes post MI in an area
supplied by LAD in the left ventricle, streptavidin- biotin immunoperoxidase
method. E, F, showing very low expression of bcl2 in few endothelial cells (arrow
head) in the left ventricle of naïve and 30-minutes sham operated heart.
Streptavidin- biotin immunoperoxidase method.
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in cardiac myocytes and endothelial cells in the area of infarction. Many apoptotic
bodies, expressing cleaved caspase-3, are seen in the area of infarction (Fig. 3.30
C) at 24-hour following MI.
Bcl-2 expression is increased in the 30 minutes post infarction time in the
LV in the area of infarction of the left ventricle (Fig. 3.31 A–D). Its expression is
seen in the cardiomyocytes and endothelial cells. However, the expression in the
endothelial cells is considerably greater than the cardiomyocytes. The Sham group
showed faint staining of bcl-2 and only in the endothelial cells.
3.4.3 Discussion
We have shown co-localization of GAL-1 and HIF-1 α in cardiac myocytes
and endothelial cells in LV sections from areas supplied by LAD at different time
points in the first 4 hours following MI. Cardiomyocytes and endothelial cells that
show nuclear expression of HIF-1 α also show cytoplasmic and nuclear
expression of GAL-1, while cells that do not express HIF-1 α also show no
expression of GAL-1, which might indicate a possible correlation in the
expression of both proteins.
In Fig. 3.9 K, L, M, we are able to show co-expression of GAL-1 and HIF-1
α in surviving cardiomyocytes and endothelial cells at the periphery of infarction
zone while dead cardiomyocytes in the centre of infarction do not show any
expression, which might also support a possible correlation between both proteins.
In the same figure, we are also able to show co-expression of GAL-1 and HIF-1 α
by neutrophil polymorphs that infiltrate the myocardium following MI to digest
dead cells and facilitate their removal at a later time by macrophages. Those
neutrophil polymorphs are moving in between dead cells in the ischemic zone, so
they are expected to be under hypoxic condition. Therefore, they are expressing
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HIF-1 α, as hypoxia can stabilize HIF-1 α and prevent its proteasomal
degradation. At the same time, we notice those invading neutrophil polymorphs
are also expressing GAL-1, which might also support a possible correlation.
In Fig. 3.28 we show the pattern of GAL-1 and HIF-1 α in the heart from
20 minutes till 24 hours post MI time points. It shows both proteins follow the
same pattern in the first 24 hours following MI and their co-localization seen by
immunofluorescent staining further supports our idea that GAL-1 is a possible
transcriptional target of HIF-1 α in the heart at least in the early period after MI.
We also found potential HREs in the promoter region of GAL- 1 through
bioinformatics analysis (Fig. 3.32). This is supported by a previous study (67),
which also showed that there are seven potential HREs within 2.2 kb region
upstream the transcriptional start site of GAL-1. We suggest that in our
experiment, GAL-1 gene transcription by HIF-1 α can lead to increased
expression of GAL-1 in cardiomyocytes, which might also prove to be
cardioprotective due to its anti-inflammatory properties (60, 61). As the time of
ischemia increases, cells in the centre of the infarct loose HIF-1 α and
consequently GAL-1 while the surrounding surviving cells express high levels of
HIF-1 α and subsequent GAL-1 to limit damage and prevent further injury
We have also shown co-localization of GAL-3 and HIF-1 alpha in
cardiomyocytes and endothelial cells in the area of infarction in the LV (Fig.
3.27). Cardiomyocytes and endothelial cells that show nuclear expression of HIF1 α also show cytoplasmic and nuclear expression of GAL-3, while cells that do
not express HIF-1 α they also show no expression of GAL-3. This indicates a
possible correlation also in the expression of both proteins.
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Recent studies have indicated that GAL-3 expression is dependent on HIF-1 α
activity. It was shown on nucleus pulposus cells that upregulation of HIF-1α
caused an elevation in galectin-3 promoter activity and deletion of HIF-1 α caused
loss of GAL-3 promoter activity (324). HIF-1 α null cells also showed minimal
expression of GAL-3. These results support the observation that GAL-3 is an
HIF-1 α transcriptional target and that HIF-1 α serves as a major regulator of
GAL-3 expression (324).

Bioinformatic analysis shows that there are two

potential HREs (hypoxia response elements) in the promoter region of GAL-3
gene (324). We therefore believe that GAL-3 is a transcriptional target of hypoxia
induced HIF-1 α in the early post MI heart and that its role in myocardial ischemia
needs to be elaborated.
To further look into the biological role underlying the early expression of
GAL-1, GAL-3 and HIF-1 α in cardiomyocytes, we looked at the pro-apoptotic
and anti-apoptotic proteins at these early time points. Pro-apoptotic caspase-3 and
cleaved caspase-3 were found to have a very low expression at early time points
post MI, while in the 24-hour post MI group the expression is increased in the
area of infarction compared to the sham operated group (Fig. 3.31). Moreover, the
anti-apoptotic Bcl-2 expression is high at early time points, especially in 30
minute post MI group, in the area of infarction (Fig. 3.32). Regarding GAL-1, and
HIF-1 α, we can see that in the early post MI time points there is predominantly
antiapoptotic activity in the left ventricle which correlates with the high tissue
GAL-1 and HIF-1 α levels at that time. While in 24-hour post MI time point we
have high apoptotic activity which correlates with low tissue levels of GAL-1 and
HIF-1 alpha at that time. This further supports our concept that GAL-1 and HIF-1
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alpha are part of the prosurvival mode of action of the cell after ischemic insult at
least in the early myocardial infarction time.
Gal-3 is shown to regulate survival in some tissues (98) but how Gal-3
regulates survival in cardiomyocytes still remains to be determined. One way of
mediating its pro-survival effects is through its role in apoptosis. The first
molecule in the cytosol identified as a GAL-3 ligand in vivo was Bcl-2, a
molecule involved in regulation of apoptosis (93). We have shown earlier (325)
that the anti-apoptotic Bcl-2 expression is high at early time points, especially in
30 minute post MI group, in the area of infarction which points towards an antiapoptotic role of GAL-3 in early MI. We have shown that in the early post MI
time points the total caspase-3 activity and Cleaved caspase-3 activity is low (325)
so we can conclude that there is predominantly antiapoptotic activity in the left
ventricle which correlates with the high tissue GAL-3 levels at that time.
Given the upregulation of GAL-3 in the myocardium very early after MI
and its correlation with HIF-1 α and anti-apoptotic proteins we believe that it may
be part of a pro-survival mechanism of the myocardium to deal with the
ischemic/hypoxic insult which can possibly be a part of the prosurvival gene
expression profile transcribed by HIF-1 α.
Although a contributory role for GAL-3 in the pathophysiology of heart
failure is already defined, we believe that GAL-3 at early time point post MI
works to sustain the myocardium against the initial injury. Further studies need to
be conducted for proper assessment of GAL-3 in cardiovascular disease especially
after myocardial infarction to see when GAL-3 becomes responsible for the onset
and progression of cardiac fibrosis and reduced ventricular function (144).
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Figure 3.32: Potential HREs in the promoter region of GAL-1 gene.
A, Human GAL-1 promoter with consensus sequence ACGTG (-1075). B, Human
GAL-1 promoter with consensus sequence CACGC (2519, 2533, 2935). C, Mouse
GAL-1 promoter with consensus sequence NCGTG (2978). D, Mouse GAL-1
promoter with consensus sequence TGCAC (2640).

We found that in the early post MI time there is low proliferative activity in
the LV (Fig. 3.29), so we are unable to comment on any proliferative role of
GAL-1, GAL-3 and HIF-1 α at these time points. While in 24-hour post MI group,
where we have a very high level of GAL-3, we noticed an increase in the
proliferative activity of endothelial cells around the area of infarction (Fig.3.29,
U&V) when compared with the sham-operated group, as part of the attempts to
increase vascularity in the ischemic area to overcome low perfusion as well as
participating in the healing process (326).
3.4.4 Conclusion
We show for the first time that GAL-1 and GAL-3 levels in the LV are
increased in early ischemic period which can possibly be a part of the prosurvival
gene expression profile transcribed by HIF-1 α.
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Section 5: Galectin-3 is an antiapoptotic and
proinflammatory mediator at 24 hours post
myocardial infarction
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3.5.1 Background
Galectin-3 (GAL-3) has been associated with heart failure (HF) in recent
years (144). Increased levels of GAL-3 were related to recurrent HF and increased
risk of death in a number of studies (139-142). GAL-3 was found to be upregulated in animal models of HF even before the development of HF (136) which
makes it very interesting to determine what happens in the heart when GAL-3
levels are high after myocardial infarction and before the development of HF
symptoms and signs.
Myocardial Ischemia/Infarction is a complex process involving different
mechanisms and pathways culminating in cardiac structural and

contractile

dysfunction (327). It is closely associated with an inflammatory reaction, which is
necessary for healing and scar formation (328). Experimental and clinical studies
have shown that the inflammatory response to myocardial infarction is associated
with the induction of cytokines such as tumor necrosis factor (TNF)-α, interleukin
(IL)-1β, and IL-6 (329-331).
Apoptosis in addition to necrosis is a mechanism which mediates cardiac
myocyte death during ischemic injury (253, 332-336). Hypoxia was shown to be
the proximate stimulus for myocyte apoptosis (337) and alone was able to induce
apoptosis in primary cultures of neonatal and adult cardiac myocytes (338).
Apoptosis is a highly regulated process in which several regulatory proteins
participate. It is the balance between these regulatory proteins that decides the
fate of the cell. Bax, bcl-2, Caspase-3, and cytochrome c are some of these
proteins related to apoptosis that have been studied in myocardial infarction (339).
Inflammation and apoptosis play a crucial role in MI and the question whether
these processes affect cardiomyocyte loss is extremely important.
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There are

potential ways to inhibit inflammation and apoptosis and such inhibition can
result in reduction in infarct size and improved myocardial function. To tackle
these interrelated issues, it is first necessary to identify key regulatory molecules
that mediate these two mechanisms.
GAL-3 is involved in many processes during the acute inflammatory
response. In addition to being highly expressed and secreted by macrophages
(123), it causes neutrophil activation and adhesion (124), chemoattraction of
monocytes or macrophages (77) and activation of mast cells (125). Intracellular
GAL-3 is also shown to promote the survival of inflammatory cells resulting in
persistence of inflammation (76).
Regarding the role of GAL-3 in apoptosis, there is evidence that GAL-3
contains the anti-death Asp-Trp-Gly-Arg (NWGR) motif (7, 13) which is critical
for its antiapoptotic function. The anti-apoptotic activity of GAL-3 was also
demonstrated in peritoneal macrophages when those from galectin-3-deficient
mice were more sensitive to apoptotic stimuli than those from control mice (75).
GAL-3 protects cells against apoptosis by working through different mechanisms
which suggest that GAL-3 regulates the common apoptosis commitment step.
As our previous results show substantial increase in the GAL-3 levels in the
cardiomyocytes, endothelial cells and neutrophil polymorphs in the heart as well
as plasma at 24 hours post MI time point, we tried to investigate if this high GAL3 at 24 hours post MI time has any role in inflammation and apoptosis in the
heart.

We used male C57BL6 mice and GAL-3 KO mice with the same

background strain to look for inflammatory and apoptotic markers in 24 hour post
myocardial infarction heart samples.
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3.5.2 Results
3.5.2.1 GAL-3 is a proinflammatory mediator at 24 hour post MI time
IL-6 levels were significantly higher in the LV of GAL-3 wild type mice at
24-hour post MI time point as compared to GAL-3 KO mice (98.91 ± 11.26 vs
67.39 ± 8.84 pg/mg, p=0.05) as measured by ELISA (Fig. 3.34 A) . This was also
reflected in the plasma where GAL-3 wild type plasma levels were higher than
GAL-3 KO plasma (Fig. 3.34 C) (Table. 3.9) IL-1β in the LV tissue also showed
higher values in the GAL-3 wild type compared to GAL-3 KO (53.38 ± 7.66 vs
40.85 ± 5.99 pg/mg, p=0.21) but did not reach statistical significance (Fig. 3.34
B). We also did immunohistochemical staining of 24 hour MI sections with
myeloperoxidase (MPO). MPO is an indicator of neutrophil polymorphs (PMN)
presence in tissues and is very important during inflammatory processes, so we
used MPO as an inflammatory marker (340). 24 hour MI heart sections are
visibly full of PMNs as part of the acute inflammatory response following MI.
Both GAL-3 wild type and GAL-3 KO LV sections showed neutrophils
expressing MPO. We observed no significant difference in the MPO expression or
the number of neutrophil polymorphs between the GAL-3 wild type and GAL-KO
heart sections (Fig. 3.35).
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A.

B.

Figure 3.33: (A) left ventricular GAL-3 concentrations at 24 hours post
myocardial infarction with corresponding sham operated groups in wild type
C57BL6 and GAL-3 KO mouse heart. (B) Plasma GAL-3 levels in the same
groups (*shows p<0.05).
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A.

B.

C.

Figure 3.34: (A) left ventricular IL-6 (B) IL1β concentrations at 24 hours post
myocardial infarction in wild type C57BL6 and GAL-3 KO mouse heart and (C)
Plasma IL-6 levels in the same groups (*shows p<0.05).
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Table 3.9. IL-6 and IL-1β levels in pg/mg of total protein in LV of wild type and
GAL-3 KO mice at 24-hour post MI.
Inflammatory markers
in the Heart

Mean Wild type±
S.E pg/mg

Mean GAL-3
KO± S.E pg/mg

p value

IL-6

98.91 ± 11.26

67.39 ± 8.84

0.05*

IL-1β

53.38 ± 7.66

40.85 ± 5.99

0.21

* Denotes p < 0.05, S.E = Standard error of mean

Figure 3.35: This figure shows myeloperoxidase (MPO) expression in the
neutrophil polymorphs at the site of infarction in the heart sections of GAL-3 wild
type (A,B,C) and GAL-3 KO (D,E,F) groups. Arrow heads show neutrophil
polymorphs expressing MPO. Streptavidin- biotin immunoperoxidase method (A,
B, D, E) and Alexa Fluor 488 immunofluorescent technique (C, F).
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3.5.2.2 GAL-3 has an anti-apoptotic role at 24 hour post MI time
Cleaved Capase-3 activity was measured by ELISA in the tissue homogenate
of LV of 24 hour post MI hearts in the wild type and GAL-3 KO mice. Our
results show that Cleaved Caspase-3 is significantly raised in the KO group as
compared to the wild type (2257.64 ± 75.99 vs 1600.49 ± 89.45 pg/mg, *p=0.00)
(Figure 3.36 B). Immunohistochemical staining of the heart tissue sections
showed a granular cytoplasmic and nuclear expression of cleaved caspase-3 in
apoptotic cells in the area of infarction in both the GAL-3 wild type and GAL-3
KO groups. The number of apoptotic cells that express Cleaved Caspase-3 in the
GAL-3KO group was significantly higher than the wild type group (Fig. 3.37).
Immunohistochemical staining of other players of apoptosis was also
carried out. The expression of cytochrome c was cytoplasmic mainly seen in the
cardiomyocytes but endothelial cells and neutrophil polymorphs also stained
positive. We found increased intensity of expression of cytochrome c at 24 hour
KO MI group as compared to sham. The number of cardiomyocytes expressing
cytochrome c was also higher in the GAL-3 KO group than GAL-3 wild type
group (Fig. 3.37).
Bcl-2 was expressed by cardiac myocytes and endothelial cells in the area
of infarction in GAL-3 wild type mice. While in GAL-3 KO group there was no
expression of Bcl2 in the area of infarction (Fig. 3.37).
24 hour post MI time is associated with high proliferative activity in the
myocardium so we stained our sections with cyclin D1 to see if raised GAL-3
levels have any relation to the proliferative activity in the heart. Cyclin D1
showed characteristic nuclear expression mainly in the endothelial cells
concentrated in the area of infarction. Some Neutrophils also stained positive for
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A.

B.

.
C.

.
Figure 3.36: (A) Plasma concentrations of Troponin I at 24 hours post myocardial
infarction with corresponding sham operated groups in wild type C57BL6 and
GAL-3 KO mouse heart. (B) left ventricular Cleaved Caspse-3 and (C) Total
Akt-1 concentrations at 24 hours post myocardial infarction in wild type C57BL6
and GAL-3 KO mouse heart (*shows p<0.05).
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Figure 3.37: Apoptotic markers in myocardial infarction
A&B represents low power view of heart sections showing higher expression of
cytochrome c in GAL-3 KO MI (B) than GAL-3 wild type MI (A). C&D show
high power view of GAL-3 wild type (C) and GAL-3 KO MI heart section (D)
expressing cytochrome c in the cytoplasm of cardiomyocytes. The intensity and
extent of staining in KO group is higher than the wild type, Streptavidin-biotin
immunoperoxidase method.
E&F represents low power view of heart sections expressing bcl2 in GAL-3 wild
type MI (E) and GAL-3 KO MI (F) groups. G&H are the high power views of
these sections showing increase in bcl2 immunostaining in the wild type group
(G) compared to GAL-3 KO (H) group, Streptavidin-biotin immunoperoxidase
method.
I&J represent heart sections from the GAL-3 -wild type MI group showing
cleaved caspase-3 expression in apoptotic cells (arrow head)in the area of
infarction. K&L represent heart sections from GAL-3 KO MI group showing
increase in the number of apoptotic cells expressing cleaved caspase-3 (arrow
head).
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cyclin D1. We found no significant difference in the number of cells stained or
the intensity of expression between GAL-3 wild type and GAL-3 KO post MI
groups (Fig. 3.38). Total Akt-1 was measured in LV tissue homogenates by
ELISA and heart sections stained for phospho-Akt showed no significant
differences between the GAL-3 wild type and GAL-3 KO groups (Fig. 3.36 C).
3.5.2.3 GAL-3 and Oxidative stress
Superoxide dismutase (SOD) and Total Glutathione were measured in the
LV homogenate and found to be not significantly different between Wild type MI
and GAL-3 KO groups (Fig. 3.39).
3.5.2.4 GAL-3 and Troponin I
There was no significant difference between the plasma troponin I values
between the 24-hour post MI GAL-3 wild type and GAL-3 KO groups. Both of
the groups show clear rise of Troponin I as compared to corresponding shams but
fail to show any differences between the GAL-3 KO and GAL-3 wild type (Fig.
3.36 A).
3.5.3 Discussion
The functions of GAL-3 are diverse depending upon its localization within
the tissue. It may be extracellular, cytoplasmic or nuclear (107, 108, 110, 111).
To understand the precise function of GAL-3 in regulating different biological
functions requires that specific in vivo model systems be used (341). Our model
is a murine model of MI where the LV has undergone infarction and the LV as a
whole is used to look for changes that may have occurred in wild type and GAL-3
KO hearts.
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Figure 3.38: A represents cyclin D1 expression in the heart section for GAL-3
wild type MI group showing a characteristic nuclear expression (arrow heads) in
the cardiomyocytes. B show the heart sections from the GAL-3 wild type sham
operated group clearly showing a decrease in number of cardiomyocytes
expressing cyclin D1. C&D represent the GAL-3 KO MI and GAL-3 KO sham
heart sections respectively showing increased number of cardiomyocytes
expressing cyclin D1 in MI as compared to the sham group. No difference was
observed in the GAL-3 wild type MI and GAL-3 KO MI heart sections.
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A.

B.

Figure 3.39: (A) SOD % inhibition activity and (B) total Glutathione levels in the
LV at 24 hours post myocardial infarction with corresponding sham operated
groups in wild type C57BL6 and GAL-3 KO mouse heart.
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Previously we have shown that after 24 hours of permanent ligation of LAD,
the LV tissue of wild type mice showed a significant increase in GAL-3 level in
MI group when compared with corresponding sham group and that it was being
produced by cardiomyocytes, endothelial cells and neutrophils. This significant
increase prompted us to investigate the role of GAL-3 in relation to inflammation
and apoptosis in the heart.
Our results here show that IL-6 levels were significantly higher in the GAL-3
wild type mice as compared to GAL-3 KO after 24 hours of permanent ligation of
LAD. Plasma IL-6 also showed the same pattern of increase as the LV tissue.
This means that GAL-3 plays a role in the regulation of IL-6 production in the LV
of the heart 24 hours post MI. This was previously seen in breast cancer cells
where upregulation of IL-6 involved activation of the Ras/MEK/ERK pathway
which was activated by GAL-3 (96). IL-6 role in ischemia and hypoxia is well
established.

Studies have shown that IL-6 is produced by cultured neonatal

cardiac myocytes in response to hypoxic stress (342) and by cardiac myocytes in
vitro and in vivo in response to ischemia (343). IL-6 plasma levels have also been
shown to be elevated in acute MI after short periods of coronary occlusion (343).
Here we report that in the Heart LV the high GAL-3 levels regulate IL-6
production and so point towards its proinflammatory role in MI. Our results did
not show any difference in the LV IL-1β levels between GAL-3 wild type and
GAL-3 KO mice suggesting that GAL-3 has no regulatory effect on IL-1β at 24
hours post MI time point. Our immunohistochemical staining of neutrophils with
MPO in the 24 hour post MI heart sections also showed no significant differences
between the number of neutrophil polymorphs between GAL-3 wild type and
GAL-3KO. Also the expression of MPO was not different between the two
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groups. A previous study has shown that GAL-3 can directly activate both mouse
and human neutrophils (127). GAL-3 KO mice were also shown to produce a
reduced inflammatory response after the induction of peritonitis (76) implying
that intracellular GAL-3 promoted the survival of inflammatory cells resulting in
the prolongation of inflammation (76). Our model did not demonstrate any
difference in the neutrophils number or activity between GAL-3 wild type and KO
groups which may be due to the difference in the mechanism of disease studied.
Here we are studying the infarcted myocardium which may behave in a
completely different way than peritonitis, for example. In the immune system,
GAL-3 displays both pro- and anti-inflammatory roles depending on the target
cell type, whether GAL-3 is acting exogenously or endogenously, its expression
level and other inflammatory factors (76). We report here that at 24- hour post MI
time GAL-3 has a predominant proinflammatory role in the myocardium.
Regarding the role of apoptosis in MI, we know that there are two major
apoptotic pathways namely intrinsic and extrinsic pathway. Intrinsic apoptotic
signaling causes cytochrome c release from the mitochondria. Cytochrome c in
the cytosol initiates the formation of “apoptosome,” which consists of cytochrome
c, caspase adaptor proteins such as Apaf-1, and caspases (344-346) and results in
caspase activation, a commitment step for apoptosis induction. Extrinsic apoptotic
signals are mediated by cell-surface death receptors, including tumor necrosis
factor, Fas and TRAIL receptor families. The death domains of the death receptor
form the “death-inducing signaling complex,” where caspases are activated.
GAL-3 has been found to be critically involved in apoptosis depending on its
subcellular localization. Intracellular GAL-3 can inhibit apoptosis (93) whereas
extracellular GAL-3 induces apoptosis (90). Our results show that proapoptotic
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protein like Cleaved caspase-3 and Cytochrome c are significantly high in GAL-3
KO group as compared to GAL-3 wild type. We checked anti apoptotic Bcl-2 and
found that its expression is considerably reduced in GAL-3 KO compared to
GAL-3 wild type. Our results suggest that at 24 hour post MI time, GAL-3 is
controlling the apoptotic pathway by negatively regulating the proapoptotic
proteins and increasing the anti-apoptotic bcl-2. Studies have shown that in
ischemia induced apoptosis in rats there was a decrease in bcl-2 protein values and
an increase in the expression of Bax (336). It has already been shown by us that
the level of proapoptotic proteins was significantly higher in MI group compared
to sham. We also know that GAL-3 translocates to the perinuclear membrane
following apoptotic stimuli (133) (134). It is enriched in the mitochondria and
prevents mitochondrial damage and cytochrome c release. Caspase-3 is a critical
downstream protease in the apoptotic cascade (347, 348). In this study we show
that at 24 hour post MI time GAL-3 is acting as an antiapoptotic molecule which
is evident by higher expression of bcl2 in GAL-3 wild type mice when compared
with GAL-3 KO mice as well as a lower expression of Cytochrome c in GAL-3
wild type mice than GAL-3 KO mice. This leads to a lower number of apoptotic
cells in GAL-3 wild type mice than GAL-3 KO mice. Knocking out GAL-3 gene
leads to increase in cleaved caspase -3 activity and apoptotic cells in the area of
infarction.
To investigate if anti apoptotic activity of GAL-3 is associated with its ability
to activate Akt signaling, we checked total Akt-1 levels in LV tissue
homogenates. Akt is an anti-apoptotic protein, activated by phospholipid products
of phosphatidylinositol 3-kinase (PI3K) and is a downstream target of PI3K in cell
survival signaling (349). We found higher levels of Total Akt-1 in the GAL-3
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wild type group compared to the GAL-3KO group but the trend did not reach
statistical significance. Thus it is not clear if the anti apoptotic role of GAL-3 at
24 hours post MI time is due to Akt activation. PI3K/AKT pathway can be
activated by multiple factors and there are many players that are working at the
same time in the infarcted myocardium of the heart, GAL-3 being one of them.
We also stained our heart sections for cyclin D1 to see if GAL-3 has any
effect on the proliferative activity of 24-hour post MI myocardium. GAL-3 has
been shown to activate cyclin D1 which is important for cardiac fibroblast
proliferation leading to myocardial fibrosis and heart failure (92). Nuclear GAL-3
expression may cause these effects through enhanced cyclin D1 promoter activity
(24). Although cyclin D1 activity was seen to be significantly increased in MI
groups as compared to sham operated animals we found no differences between
GAL-3 wild type and GAL-3 KO groups suggesting that at this time point post MI
GAL-3 does not affect the proliferation of cardiac fibroblast.
Our study demonstrates here that at 24 hours after the infarction the high
GAL-3 levels in the myocardium are mediating a proinflammatory and anti
apoptotic environment that may shape the future course of the disease.
Inflammation will cause healing and scarring which if excessive can lead to
adverse cardiac remodeling progressing to heart failure (350). Anti apoptotic
mechanism in cardiomyocytes on the one hand may be beneficial as it may protect
the cardiomyocytes against death and prevent myocyte loss though on the other
hand may prove to be deleterious. The rescued cardiomyocytes may not remain
functional or may undergo necrosis later or maybe apoptosis is a mechanism by
which the heart limits the extent of a more destructive process of necrosis with its
accompanying inflammation (337). In addition, inhibition of apoptosis in the
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neutrophil polymorphs can prolong its stay in the infarcted myocardium
potentiating the effect of inflammation and destruction (127).

Apoptosis can

therefore be considered a double edged sword which can work in either way.
Considering the Troponin I levels in the plasma of GAL-3 wild type and GAL-3
KO mice we found that the levels were not significantly different in the two
groups. Troponin I can be taken as a marker of cardiomyocyte necrosis (351,
352) and can be indirectly linked to the infarct size necrosis (351, 352). We can
suggest from this result that GAL-3 may have no effect on infarct size. The level
of oxidative stress was also not significantly different between the two groups.
Lieberthal et al. showed that the severity and duration of ATP depletion
determines the mechanism of death (353). ATP concentration below a certain
threshold become necrotic, whereas an ATP value above that threshold induces
apoptosis (353)
At 24-hour post infarction time the predominant form of cell injury is
necrosis. Ischemia/ infarction in cardiomyocytes results in metabolic inhibition
with ATP depletion and favors necrotic cell death, whereas metabolic inhibition
under ATP replenishing conditions, which happens with ischemia/reperfusion,
increases the proportion of apoptotic cells (353, 354). The predominant mode of
cell death here in our model is cardiac myocytes coagulative necrosis and so it is
very likely that GAL-3 role in apoptosis is not very prominent at 24 hour
permanent ligation model.
Our previous experimental results have shown that GAL-3 expressed very
early after MI may be part of the survival mechanism of the cardiomyocytes after
ischemia or infarction. Along the same continuum, other studies have linked
GAL-3 to fibrosis and heart failure (138). We, therefore, propose that GAL-3
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should be viewed as regulatory molecule acting in the myocardium at various
stages of myocardial infarction.
3.5.4 Conclusion
In conclusion we showed in our study that after 24-hour of permanent
ligation of LAD GAL-3 levels are high which regulate proinflammatory and
antiapoptotic mechanisms in the myocardium that will shape the future course of
the disease.
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Section 6: Galectin-3 reduces myocardial
damage in Ischemia/Reperfusion injury
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3.6.1 Background
Early and successful myocardial reperfusion after an acute myocardial
infarction is the most effective strategy for salvaging the myocardium and
improving the clinical outcome. This process of restoring blood flow to the
ischemic myocardium can, however, induce myocardial reperfusion injury and
can paradoxically reduce the beneficial effects of myocardial reperfusion. The
injury results in the death of cardiac myocytes that were viable immediately
before myocardial reperfusion (8).

This is the reason that despite optimal

myocardial reperfusion, the rate of death after an acute myocardial infarction
approaches 10% (355), and the incidence of cardiac failure after an acute
myocardial infarction is almost 25%.
Reperfusion injury can cause four types of cardiac dysfunctions. The first
type is myocardial stunning, when despite restoration of coronary flow, the
myocardium shows mechanical dysfunction (356). The second type is the noreflow phenomenon, when there is a failure to reperfuse an ischemic area (258,
259). The third type is the reperfusion arrhythmia (357) and the last type is lethal
reperfusion injury. The concept of this unique type of injury was first introduced
when researchers noticed (358) that a large fraction of cellular enzymes were
released not during hypoxia, but on sudden reoxygenation (358) emphasizing the
point that

reoxygenation of ischemic myocardium generates a degree of

myocardial injury that greatly exceeds the injury induced by ischemia alone (358).
Experimental studies have shown that the reperfusion of ischemic
myocardium generates oxidative stress (359). The generations of reactive oxygen
species (ROS) act as the central mediators of ischemia-reperfusion injury. These
species can initiate spontaneous, and self-propagating radical reactions with

142

biomolecules that can impair myocardial function by activating intracellular
proteolytic enzymes and induce cell death by initiating mitochondrial permeability
transition (264). O2•− is the parent radical involved in reperfusion (360, 361).
This was earlier shown as part of ROS generation in an intact dog model (362).
Most cells including cardiomyocytes contain enzymatic antioxidant defense
mechanisms that quickly convert ROS to water. These antioxidant systems
include superoxide dismutase, catalase, and the glutathione redox system (363).
Superoxide dismutase (SOD) is one of the most important antioxidant
enzymes, which can be either reduced or oxidized to convert O2 •− to O2 and
H2O2(285) (21). H2O2 is then converted to water by catalase (286) or by the
glutathione peroxidase system (287). Experiments using isolated heart models in
the presence or absence of superoxide dismutase also showed ROS as likely
mediators of reperfusion injury (289, 290). The effectiveness of GSH as an
antioxidant is a result of its ability to remove hydrogen peroxide, a reaction
catalyzed by GSH peroxidase. The oxidized glutathione (GSSG) is reduced back
to GSH by GSH reductase. Glutathione is an important antioxidant (291) and
plays an important role in protecting the ischemic myocardium against reperfusion
injury (292). Catalase also provides significant antioxidant protection to the
myocardium against ischemia reperfusion (297, 298).
So far we know that GAL-3 is closely associated with myocardial infarction
in the early post MI time point and later with myocardial fibrosis and heart failure.
We want to further investigate its role in ischemia-reperfusion injuries as this
phenomenon is extremely relevant to the early intervention after acute MI and will
open a door to look at this molecule from a new perspective. We have used a
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murine model of Ischemia-reperfusion in the heart where a period of 30 min
ischemia was followed by 24 hours of reperfusion.
3.6.2 Results
3.6.2.1 GAL-3 is increased after Ischemia-reperfusion injury in the heart
GAL-3 levels were significantly higher in the LV of GAL-3 wild type mice
at 30 min ischemia and 24 hour post reperfusion time point as compared to sham
operated mice (7861.99± 768.82 vs 4784.59 ± 273.49 pg/mg, p=0.00) as
measured by ELISA (Fig. 3.40 A). Our immunohistochemistry results also show
significantly increased expression of GAL-3 in the heart section of IR group as
compared to sham operated animals (Fig. 3.41).
3.6.2.2 GAL-3 decreases myocardial injury in IR model
To assess the extent of myocardial injury we checked plasma Troponin I
levels in GAL-3 Wild type IR group and GAL-3 KO IR group. The results show
that Troponin I levels were significantly increased in the plasma of GAL-3 KO IR
group as compared to the GAL-3 Wild type IR group (8.97 ± 1.38 vs 3.73 ± 1.17
ng/ml, p=0.012) (Fig. 3.40 B).
3.6.2.3 GAL-3 and oxidative stress in IR
To assess the effect of GAL-3 on the oxidative stress we measured the status
of the anti oxidant enzymes SOD and Total Glutathione in the LV tissue protein
extract in the GAL-3 wild type IR group and GAL-3 KO IR group.

Total

glutathione levels were significantly raised in the GAL-3 wild type IR group (Fig.
3.42 A) compared to the GAL-3 KO IR group (5.77 ± 0.51 vs 3.13 ± 0.32 nmoles/
mg protein, p=0.001).
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A.

B.

Figure 3.40: (A) left ventricular GAL-3 concentrations in the wild type C57BL6
IR group and GAL-3 KO IR group with their corresponding shams. (B) Plasma
troponin I levels in the same groups (*shows p<0.05).
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Figure 3.41: A&B represents low power view of heart sections showing GAL-3
expression in IR group (A) as compared to Sham operated control group (B).
Expression is seen as more intense staining in the LV area supplied by LAD
(arrow heads) as well as right ventricular wall (thin arrow) (A). C&D show high
power view of IR (C) and sham heart section (D) expressing GAL-3 in the
cytoplasm of cardiomyocytes (arrow head) and nuclei (thin arrow) (C). The
intensity and number of positive staining in IR group is higher than the Sham.
Streptavidin- biotin immunoperoxidase method.
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A.

B.

Figure 3.42: (A) left ventricular Total GSH concentrations in the wild type
C57BL6 IR group and GAL-3 KO IR group. (B) left ventricular SOD inhibition
activity in the same groups (*shows p<0.05).
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Figure 3.43 : A&B represent a low power view of heart sections showing a significantly
increased expression of catalase (thin arrows) in the area supplied by the LAD in GAL-3 wild type
IR group (A) as compared to the GAL-3 KO IR (B) group, Alexa Fluor 488 immunofluorescent
labeling. C&D represent high power view of heart section showing cardiomyocytes (thin arrows)
and inflammatory cells (arrow heads) expressing catalase in GAL-3 wild type IR group (C). GAL3KO IR group shows comparatively fewer cardiomyocytes expressing catalase and mainly
expressed by inflammatory cells (arrow heads), Alexa Fluor 488 immunofluorescent labeling.
E, shows a high power view of GAL-3 wild type IR group showing catalase expression by
cardiomyocytes (arrow heads), inflammatory cells (thin arrows). Some neutrophil polymorphs are
surrounding a dead cardiomyocyte (thick arrow). F, represents a corresponding high power view
of heart section from the GAL-3 KO IR group with visibly lower catalase expression in
cardiomyocytes (thick arrow) and mainly expressed by inflammatory cells (arrow heads). Alexa
Fluor 488 immunofluorescent labeling. G&I show the low and high power view of the heart
section of the GAL-3 wild type IR group expressing catalase as a diffuse cytoplasmic staining in
cardiomyocytes (arrow heads) and endothelial cells (thick arrow). Streptavidin- biotin
immunoperoxidase method. H&J represent low and high power views of the GAL-3 KO IR group
showing a lower expression of catalase by cardiomyocytes (arrow heads), endothelial cells (thick
arrow) and inflammatory cells (thin arrows). Streptavidin- biotin immunoperoxidase method.
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SOD levels were also significantly raised in the GAL-3 wild type IR group as
compared to GAL-3 KO IR group (13.5267 ± 1.47122 vs 9.5785 ± 0.75898,
p=0.041) (Fig. 3.42 B). Immunohistochemical and immunofluorescent stained
sections of the LV show increased expression of catalase in GAL-3 wild IR group
than in GAL-3 KO group (Fig. 3.43).
3.6.2.4 GAL-3 role is proinflammatory and anti-apoptotic in IR
Cleaved Capase-3 activity was measured by ELISA in the tissue homogenate
of LV of 24 hour post MI hearts in the GAL-3 wild type IR and GAL-3 KO IR
mice. Our results show that Cleaved Caspase-3 is significantly raised in the GAL3 KO group as compared to the GAL-3 wild type (2367.14 ± 124.99 vs 2001.12 ±
103.80 pg/mg, *p=0.045) (Fig. 3.44 A). Immunohistochemical staining of heart
tissue sections showed a granular cytoplasmic and nuclear expression of cleaved
caspase-3 in apoptotic cells in the LV, in the area supplied by LAD, in both the
GAL-3 wild type IR and GAL-3 KO IR groups. The number of apoptotic cells in
the GAL-3KO IR group was higher than the GAL-3 wild type IR group (Fig.
3.45). The expression of cytochrome c was cytoplasmic mainly seen in the
cardiomyocytes but endothelial cells and neutrophil polymorphs also stained
positive. We found increased intensity of expression of cytochrome c in the LV,
in the area supplied by LAD, in GAL-3 wild type IR group and GAL-3 KO IR
group as compared to sham. The cardiomyocytes expressing cytochrome c was
also comparatively higher by intensity and number of cells in GAL-3 KO IR
group than GAL-3 wild type IR group (Fig. 3.45).
Immunohistochemical staining of Bcl-2 expression in LV sections have
shown Bcl-2 was expressed by cardiac myocytes and endothelial cells in the LV,
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A.

B.

C.

Figure 3.44: (A) left ventricular cleaved caspase-3 in the wild type C57BL6 IR
group and GAL-3 KO IR group. (B) left ventricular IL-6 and (C) IL-1β in the
same groups (*shows p<0.05).
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Figure 3.45: A&B represents low power view of heart sections showing
cytochrome c expression in GAL-3 wild type IR (A) and GAL-3 KO IR (B)
groups. C&D show high power view of GAL-3 wild type (C) and GAL-3 KO IR
heart section expressing cytochrome c in the cytoplasm of cardiomyocytes. The
intensity and number of positive staining in KO group is higher than the wild
type. Streptavidin- biotin immunoperoxidase method.E&F represents low power
view of heart sections expressing bcl2 in GAL-3 wild type IR (E) and GAL-3 KO
IR (F) groups. G&H are the high power views of these sections showing increase
in bcl2 immunostaining in cardiac myocytes (arrow heads) and endothelial cells
(thin arrows) in the GAL-3 wild type group (G) compared to GAL-3 KO (H)
group. Streptavidin- biotin immunoperoxidase method. I&J represent high power
views of heart sections from the GAL-3 wild type MI group showing cleaved
caspase-3 expression in apoptotic cells (arrow heads) in the area of infarction.
K&L represent high power views of heart section from the GAL-3 KO MI group
showing increase in the number of apoptotic cells expressing cleaved caspase-3,
(arrow heads). Streptavidin- biotin immunoperoxidase method.
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in the area supplied by LAD, in GAL-3 wild type IR mice and GAL-3 KO IR
mice. The expression of Bcl2 was comparatively higher by intensity and number
of cells in GAL-3 wild type mice than in Gal-3 KO mice (Fig. 3.45).
IL-6 levels were significantly higher in the LV of GAL-3 wild type IR as
compared to GAL-3 KO IR mice (61.22 ± 7.14 vs 44.45 ± 2.03 pg/mg, p=0.041)
as measured by ELISA (Fig. 3.44 B).

IL-1β in the LV did not show any

difference between the wild type IR compared to GAL-3 KO IR (37.3355 ±
3.68054 vs 38.0934 ± 1.32297 pg/mg) (Fig. 3.44 C)

We also conducted

immunohistochemical staining of IR sections with myeloperoxidase (MPO). MPO
is an indicator of neutrophil polymorphs (PMN) presence in tissues and is very
important during inflammatory processes, so we used MPO as an inflammatory
marker (340). IR heart sections are visibly full of PMNs as part of the acute
inflammatory response.

Both GAL-3 wild type IR and GAL-3 KO IR LV

sections showed neutrophils expressing MPO.

We observed no significant

difference in the number of MPO expressing neutrophils in the GAL-3 wild type
IR as compared to the GAL-KO IR heart sections (Fig. 3.46).
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Figure 3.46: This figure shows myeloperoxidase (MPO) expression in the
neutrophil polymorphs at the site of infarction in the heart sections of GAL-3 wild
type IR (A,C) and GAL-3 KO IR (B,D) groups. Arrows show expression of MPO
by neutrophil polymorphs stained by Streptavidin- biotin immunoperoxidase
method (A, B) and Alexa Fluor 488 immunofluorescent technique (C, D).
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3.6.3 Discussion
Blumgart et al. (364) reported pathologic observations

that extensive

infarction occurred when coronary occlusion was maintained for 40 minutes or
longer, while occlusions of 5–20 minutes did not result in infarction. With
occlusions of intermediate duration, the extent of necrosis depended on the time to
reperfusion (365). After 30 minutes of Ischemia followed by 24 hours reperfusion
we create an environment where ischemic damage is limited to a time when
irreversible damage starts to occur and 24 hour reperfusion time gives adequate
time for reperfusion related changes to take place. Our results here show that there
is significant increase in GAL-3 levels in the heart LV of IR mice as compared to
sham which signifies that GAL-3 plays a role in the ischemia/reperfusion injury in
the heart.
Most interestingly, we found a significant difference in the plasma levels of
troponin I between GAL-3 wild type IR and the GAL-3 KO IR mice groups. We
found that the troponin I levels were significantly higher in GAL-3 KO group than
the GAL-3 wild type group depicting that GAL-3 is regulating troponin I levels in
the IR model. This observation made us explore the cause of this change. In MI
where the predominant injury was myocardial necrosis we failed to find a
significant difference between troponin I values between GAL-3 wild type and
GAL-3 KO groups suggesting that GAL-3 has no obvious role in regulating
cardiomyocytes necrosis in 24 hour permanent ligation model. In IR, however,
GAL-3 is decreasing the myocardial injury as shown by lower troponin I levels in
GAL-3 IR mice. In support of our observation we noticed more anti-apoptotic and
less pro-apoptotic protein expression in GAL-3 wild IR group than in GAL-3 KO
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IR group, leading to more apoptotic cells in GAL-3 KO IR group supporting the
anti apoptotic role of GAL-3 in IR.
Oxidative stress plays a major role in causing IR injuries in the heart. To see
if GAL-3 in IR causes any change in the level of anti oxidant enzymes to counter
the oxidative stress we tested the SOD levels and Total Glutathione levels in the
heart LV and stained the heart sections for catalase.
Our results show that both the SOD and Glutathione levels were significantly
increased in the GAL-3 wild type IR as compared to the GAL-3 KO IR. This
signifies that GAL-3 is associated with an increase in the anti oxidant activity in
the IR injured myocardium.

The immunohistochemical and immunofluorescent

staining results also show higher expression of catalase in GAL-3 wild type IR
mice than in GAL-3 KO IR mice which also supports an anti-oxidant role of
GAL-3.
SOD, Glutathione and catalase are the most important cellular defense mechanism
against oxidative injury and are the major intracellular redox buffer in ubiquitous
cell types (366) (367). Accumulating evidence suggests that the intracellular redox
status regulates various aspects of cellular function (367).
GAL-3 actions with regards to oxidative stress are variable. Some studies
point to its role as an inducer of ROS, but other studies explain its role as a
molecule that is protective against ROS mediated injuries.

In an ischemia

reperfusion model in the kidney it was shown that ROS production was more
prominent in GAL-3 wild type control mice as compared to GAL-3 knockout
mice (368). Early data have also demonstrated that GAL-3 could stimulate
superoxide production by neutrophils (126) and by monocytes (123). Thus the
presence of GAL-3 produces more ROS and more damage. However, here we
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found increased anti-oxidant activity in the LV myocardium after IR in
conjunction with less myocardial damage. There can be many explanations for
this phenomenon. The function of antioxidant systems is to modify the highly
reactive oxygen species to form intermediate which no longer pose a threat to the
cell. A balance is essential between oxidation and antioxidant’s level in the
system for healthy biological integrity to be maintained. In previous studies,
ischemia and reperfusion impaired superoxide dismutase activity and decreased
cellular glutathione-to-glutathione disulfide ratio suggested that the extent of
superoxide anion radical

produced at reperfusion exceeded the capacity of

endogenous cellular antioxidant systems (288). However, the same oxidative
stress can lead to increase in the antioxidant capacity and so the increase we
witness in the antioxidant enzymes may be due to the increase in the oxidative
stress. This phenomenon was observed in a study by Bandeira et al. when the
total SOD activity and the lipid peroxidation were higher in diabetics compared to
non-diabetics (369). Another study by Savu et al also showed increase in antioxidant capacity despite high levels of oxidative stress (370).
GAL-3 has been reported to interfere with ROS generation (94).

It is

suggested that GAL-3 might interfere with very early stages of cell death that are
associated with perturbation of mitochondrial homeostasis and subsequent
formation of ROS.

Some studies have indicated GAL-3 to be protective in

ischemia reperfusion injuries.

It was found to be involved in the kidney

regeneration following ischemia reperfusion injury (371). Also, it was shown to
play a protective role against liver ischemia reperfusion injury (372). Thus the
increase in the anti-oxidant activity linked to GAL-3, observed in the present
study, may suggest two possibilities. Either it is the result of a possible adaptive
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response, probably due to the increased production of the oxidative radicals or due
to the inherent role of GAL-3 in decreasing oxidative stress.

The second

possibility holds more weight as this anti-oxidant activity is in conjunction with a
lower cleaved caspase-3 and lower Troponin I level in GAL-3 wild IR group
when compared with GAL-3 KO group. Our results also point towards a
proinflammatory and antiapoptotic activity of GAL-3 in the heart after IR injury.
This is in accordance with our results from MI groups.
3.6.4 Conclusion
GAL-3 can interfere with redox pathways controlling cell survival and
death and plays a protective a role in the pathogenesis of ischemia reperfusion
injury in the heart.
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Section 7: Myocardial Infarction and
Myocardial Ischemia-Reperfusion: A
Comparison from GAL-3 perspective
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3.7.1 Background
Coronary Heart Disease affects the heart due to the detrimental effects of
acute myocardial infarction (MI) and Ischemia-reperfusion injury (IR).
Understanding the mechanism underlying these two processes is important as
these two types of injuries are interrelated as well as different. Prolonging the
period of acute myocardial ischemia for more than 20 minutes causes a “wave
front” of cardiomyocyte death that begins in the subendocardium and extends
transmurally toward the epicardium (242). This is the reason for why when a
patient is presented with an acute myocardial infarction, the most effective
therapeutic intervention is timely myocardial reperfusion using thrombolytic
therapy or primary percutaneous coronary intervention to salvage the ischemic
myocardium. The process of reperfusion, the very event critical for survival, can
itself cause injury to the cardiomyocytes, a phenomenon known as the
‘reperfusion injury’ (8, 243, 263).
During acute myocardial ischemia, the lack of oxygen switches the cell
metabolism to anaerobic respiration, with lactate accumulation, ATP depletion,
Na+ and Ca2+ overload and inhibition of myocardial contractile function (246,
255).

Reperfusion results in reactivation of electron transport chain which

generates ROS. ROS induces opening of MPTP, contributing to intracellular Ca2+
overload, lipid peroxidation of cell membrane, and oxidative damage to DNA. In
addition there is neutrophil accumulation in response to ROS, cytokines and
complement. All these processes can independently induce cardiomyocyte death
of the acutely ischemic myocardium (8, 243, 263).
Oxidative stress, apoptosis and inflammation are the most important
mechanisms that are initiated during ischemia and continue over several hours
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into reperfusion (255). Understanding the contribution of these processes to MI
and IR is essential to look for therapeutic measures that can help reduce the
myocardial infarct size. In order to investigate these processes, we compared the
pathology and the oxidative, apoptotic and inflammatory changes in these two
models of MI and IR. Our MI model has permanent LAD ligation for 24 hours
and our IR model has LAD ligation for 30 minutes followed by reperfusion for 24
hours.
3.7.2 Results
3.7.2.1 Histological changes in MI and IR models
The main histologic change in acute MI at 24-hour time point is coagulative
necrosis of cardiomyocytes with heavy neutrophil polymorphs infiltration (Fig.
3.47). The ischemic cardiomyocytes appear eosinophilic with loss the cross
striation and disappearance of the nuclei. LV sections studied 24 hours after IR
injury show necrosis of cardiomyocytes with interstitial edema and accumulation
of RBCs in the interstitial space with many neutrophil polymorphs infiltration the
injured myocardium (Figure 3.48). These features are seen both in wild type mice
and in GAL-3 KO mice (Fig. 3.47, 3.48).
3.7.2.2 Inflammatory mediators are raised in the MI model
IL-6 levels in the LV of the MI group were significantly raised as compared
to the IR group (98.91 ± 11.26 vs 61.22 ± 7.14 pg/mg, *p=0.013). Plasma IL-6
was also significantly increased in the MI group as compared to the IR group
(465.98 ±167.47 vs 59.68±9.61 pg/ml, *p=0.046) (Fig. 3.49 A&B).
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Figure 3.47: A&B represent high power views of wild type MI heart sections
showing characteristic ischemic cardiomyocytes appearing eosinophilic with loss
of cross striations (thin arrow) and neutrophil polymorphs (arrow heads) flooding
the infarcted area. C&D show the corresponding heart sections from GAL-3 KO
MI group showing the same changes as stated above. H&E staining method.
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Figure 3.48: A&B represent high power views of wild type IR heart sections
showing injured cardiomyocytes with interstitial edema (thick arrow), RBCs in
the interstitial spaces (thin arrow) and neutrophil polymorphs infiltration (arrow
heads). C&D show the same histological features in the GAL-3 KO IR heart
sections.
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A.

B.

C.

Figure 3.49: (A) left ventricular IL-6 concentrations (B) Plasma IL-6 levels and
(C) left ventricular IL-1β concentrations in 24 hour MI and IR groups (*shows
p<0.05).
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Heart LV IL-1β concentrations were not significantly different between the
groups (Fig. 3.49 C). Immunohistochemical staining of the heart section with
Myeloperoxidase (MPO) showed significant differences between the MI and IR
groups.

The number of neutrophils as well as the intensity of staining was

increased in the MI group as compared to the IR group.
3.7.2.3 Apoptotic markers are raised in the IR model
Heart LV cleaved caspase-3 levels were significantly increased in the IR
group as compared to the MI group (2001.12 ±103.80 vs 1600.49 ± 89.44 pg/mg
protein. *p=0.01) (Fig.

3.50 A) Immunohistochemical staining of the heart

sections with cleaved caspase-3 also showed more apoptotic cells in the IR group
as compared to the MI group (Figure 3.51). Cytochrome c was also seen to be
increased in the heart sections from the IR group as compared to the MI group by
immunohistochemistry. The expression is cytoplasmic seen predominantly in
cardiomyocytes, but endothelial cells and neutrophil polymorphs also stained
positive for it (Fig. 3.51).
The anti apoptotic protein Bcl-2 was seen to be expressed by
cardiomyocytes and endothelial cells.

The expression was higher in the IR

compared to the MI groups (Fig. 3.51).
3.7.2.4 Antioxidant enzyme levels in MI and IR models
The levels of antioxidant enzymes are not significantly different between the
MI group and the IR group. Heart LV Total Glutathione levels was 46.71 ± 9.41
pg/mg in the MI group as compared to the IR group, which showed 37.34 ± 3.68
pg/mg.
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A.

B.

Figure 3.50: (A) left ventricular cleaved caspase-3 concentrations and (B)
Plasma troponin I levels in 24 hour MI and IR groups (*shows p<0.05).

165

Figure 3.51: A&B represents low power view of heart sections showing
cytochrome c expression in MI (A) and IR (B) groups. C&D show high power
view of MI (C) and IR heart section expressing cytochrome c in the cytoplasm of
cardiomyocytes. The intensity and number of positive staining in IR group is
higher than the MI. Streptavidin- biotin immunoperoxidase method.
E&F represents low power view of heart sections expressing bcl2 in MI (E) and
IR (F) groups. G&H are the high power views of these sections showing increase
in bcl2 immunostaining in cardiac myocytes (arrow heads) and endothelial cells
(thin arrows) in the IR group (G) compared to MI (H) group. Streptavidin- biotin
immunoperoxidase method.
K&L represent high power views of heart sections from the MI group showing
cleaved caspase-3 expression in apoptotic cells (arrow heads) in the area of
infarction. I&J represent high power views of heart section from the IR group
showing increase in the number of apoptotic cells expressing cleaved caspase-3,
(arrow heads). Streptavidin- biotin immunoperoxidase method.
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A.

B.

Figure 3.52: (A) left ventricular Total glutathione concentration and (B) left
ventricular SOD % inhibition activity in 24 hour MI and IR groups (*shows
p<0.05).
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Heart LV SOD inhibition activity was also not different among the MI and IR
group (11.26 ±2.12 % vs 13.53 ±1.47 %) (Fig. 3.52).
3.7.2.5 Troponin I is raised in the MI model
Troponin I, a marker of cardiomyocytes necrosis is significantly increased in
the MI group as compared to the IR group (12.58 ± 0.82 vs 3.73 ±1.17 ng/ml,
*p=0.00) (Fig. 3.50 B).
3.7.3 Discussion
For many years, it was thought that myocardial reperfusion is only beneficial
and that there was no cell death related to it (243, 251, 252).

Later when

cardiomyocytes death was seen in the reperfused myocardium, it was postulated
that they are the already irreversibly damaged cardiomyocytes that were fated to
die during ischemia (253). The concept of reperfusion injury was presented when
it was shown that reperfusion induced death in cardiomyocytes that were viable
during ischemia (358). Comparisons between these two types of injuries are still
continuing till today because of two main reasons. First, it is almost impossible to
estimate the effects of reperfusion (254) and second, despite advances in
antithrombotic, anti-platelet and PCI technologies, there is still no effective way to
prevent the myocardial reperfusion injury (255).
Our study attempts to show substantial differences in the local
microenvironment of the myocardium between these two modes of injury and
analyze these changes keeping in focus our protein of interest GAL-3.
The MI model shows an inflammatory response associated with induction of
IL-6 in the heart LV as well as plasma. This model was also associated with an
increase in the neutrophil polymorphs number in the infarction related
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myocardium as compared to the reperfused myocardium. Raised troponin I also in
the MI group shows increased necrosis in this model which is an indirect estimate
of the infarct size. The results comparing the MI and IR model show that in MI
there is increased myocardial damage via ischemic necrosis and inflammatory
mechanisms. IR model also shows inflammation but it is unclear whether the
inflammatory response that accompanies an acute MI contributes to the
pathogenesis of myocardial reperfusion injury or whether it is a reaction to the
acute myocardial injury (373).
Our IR model showed enhanced proapoptotic mediators in the myocardium
as compared to the MI model. This means that the main mode of cardiomyocyte
death in IR is apoptosis. It was shown by Lieberthal et al. that the severity and
duration of ATP depletion determines the mechanism of death: cells with an
intracellular ATP concentration below a certain threshold become necrotic,
whereas an ATP value above that threshold induces apoptosis (353) (354). As MI
model is related to more ATP depletion as compared to IR model where
reperfusion may replenish the ATP stores, the main mechanism of cell death is
caspase activated apoptosis in IR model.
Perhaps the most interesting observation made in our study is the level of
antioxidant enzymes measured in the MI and IR models.

We did not find

significant differences between the groups signifying that the level of antioxidant
enzymes is approx the same whether the myocardium is subjected to 24 hours of
permanent ischemia or whether it is subjected to 30 mins of ischemia followed by
24 hours of reperfusion. We submit that this observation should be looked at
from a fresh angle. There is ample evidence that the level of oxidative stress
generated in reperfusion injuries is considerably more than mere ischemic injury.
169

In the first few minutes of myocardial reperfusion, a burst of oxidative stress (358,
374) is produced by a variety of sources. Organelles may begin to produce
reactive oxygen species.

Myocytes produce both hydrogen peroxide and

superoxide radicals (375). The electron transport chain of mitochondria is also a
potential source of free radicals in both the endothelial cell and myocyte (376).
This detrimental oxidative stress mediates myocardial injury and cardiomyocyte
death. The same oxidative stress can lead to increase in the antioxidant capacity
and so the level of antioxidant enzymes capacity may reflect the oxidative stress
(369). The level of oxidative stress and subsequent anti oxidant protection in IR is
dependent on the time of ischemia before reperfusion is initiated and the
reperfusion time (263, 377, 378). However, controversies do exist in this respect
(379). Our MI and IR model showing the same level of anti-oxidant capacity may
be related to the particular ischemia and reperfusion time in our models.
We have analyzed our protein of interest GAL-3 in MI model and IR model
separately in previous chapters and observed that in MI model GAL-3 acts as a
proinflammatory and anti apoptotic mediator with no effect on the cardiomyocyte
necrosis. In the IR model, GAL-3 (in addition to being proinflammatory and
antiapoptotic mediator) also acts as a regulator of antioxidant activity in the
myocardium and leads to a decrease in cardiomyocyte necrosis and indirectly
decreased infarct size. The difference of GAL-3 activity in these two models as
seen in our experiments shows that these two processes of cardiomyocyte injury
are indeed very distinct and the local microenvironment of the myocardium
determines the particular roles of molecules and enzymes that are part of their
pathogenesis.

170

A number of investigators have shown that radical scavengers including
superoxide dismutase and catalase are capable of eliminating the oxidative stress
radicals thus protecting the reperfused myocardium (366, 380) and limit infarct
size in experimental models of myocardial infarction.

We believe that in

ischemia followed by reperfusion there is increased oxidative stress and GAL-3
through its action in positively regulating the antioxidant players, leads to a
decrease in cardiomyocytes necrotic death and infarct size. We also believe that
as the main mode of death in ischemia reperfusion is apoptosis, GAL-3’s anti
apoptotic activity may also have contributed to the decrease in cardiomyocyte
injury.
3.7.4 Conclusion
Our results are significant in terms of IR injuries as the main goal in
treatment of acute infarction is early revascularization with reperfusion.
Reperfusion affects a larger portion of the left ventricle than infarction alone (302)
so reperfusion injury may act as an independent determinate of cardiac
remodeling in addition to infarct size. GAL-3 is now recognized as a definite
player in cardiac remodeling and progression to heart failure so understanding the
local microenvironment in which GAL-3 works after ischemia/infarction or
ischemia-reperfusion can open a new window in understanding the exact role of
GAL-3 in the heart.
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Chapter 4: General Conclusions and Future
Directions
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4.1 General conclusions
Cardiovascular disease is a major cause of disability and premature death
throughout the world. Individual cardiovascular procedures are also among the
most expensive (381) compared to other diseases. Various studies and surveys
have shown that even developed nations are finding it nearly impossible to meet
the costs of curative care (382), so prevention and early diagnosis of
cardiovascular diseases is the keystone of management in this millennium. There
is extensive research going on all over the world to fully understand the
mechanisms and pathways that may contribute to coronary artery disease.
Myocardial infarction causes injury of the cardiomyocytes resulting in necrosis,
and subsequent fibrosis and scar formation leading to adverse cardiac remodeling,
which is the precursor of heart failure.

Early and successful myocardial

reperfusion is the most effective strategy for salvaging the myocardium and
improving the clinical outcome. Reperfusion itself can paradoxically cause injury
to the myocardium and reduce the beneficial effects of myocardial reperfusion.
Despite optimal myocardial reperfusion, the rate of death after an acute
myocardial infarction approaches 10% (355), and the incidence of cardiac failure
after an acute myocardial infarction is almost 25%.
In this thesis, we have investigated the mechanism of injury of myocardial
infarction and ischemia reperfusion in association with GAL-1, GAL-3 and HIF-1
α. We have demonstrated that GAL-1, GAL-3 and HIF-1α are expressed in the
myocardium within the first hour of the ischemic episode. This expression along
with the anti-apoptotic environment in the myocardium in the early post MI
period suggests that Gal-1, Gal-3 and HIF-1 α may be part of the prosurvival
mechanism of action of cardiomyocytes immediately after exposure to hypoxia.
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We have also demonstrated that GAL-3 acts as a pro-inflammatory and antiapoptotic mediator within a day of myocardial infarction and plays a modulatory
role in oxidative stress related ischemia reperfusion injury.
The main findings in this thesis related to the points described above are as
follows:



There is a transient rise in the GAL-1 level in the LV within the first hour
of permanent ligation of LAD. The increased expression of GAL-1 in the
left ventricle is very well demarcated in the MI group in all tested time
points. As the time of ischemia increases the dying cells stop expressing
of GAL-1 in the area supplied by LAD, while surviving cells, which are
seen at the periphery of infarction zone, show high expression of GAL-1.
GAL-1mRNA in the infarcted tissue is detected to be significantly higher
at 30 min and is significantly increased at 4 hours and 24 hours post MI
time points. This result indicates that the increase in GAL-1 at the protein
level in early post MI time is due to transcriptional pressure from
transcription factors that have come into play due to Ischemic/hypoxic
injury to the myocardium. Another significant finding of our study is that
GAL-1 plasma level is significantly high around 4 hours and 24 hours post
MI time compared to sham operated control mice. We believe that heart
GAL-1 levels in the first hour post infarction signify an increase in
transcription of the protein whereas, at 4 hours and 24 hours post MI, the
high GAL-1 plasma levels are due to leakage of this protein from injured
cardiomyocytes as well as increased transcription of this protein.
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GAL-3 increases in the left ventricle in the area of infarction within the
first hour of ischemia/hypoxia. GAL-3 stays high till 4 hours post MI after
which at 24 hours post MI it increases several fold compared to the sham
operated animals. GAL-3mRNA is also detected to be high at one hour
post MI time point in the infarcted tissue, which stays high till 24 hours
time point.

Thus, GAL-3 is increased at both transcriptional and

translational level in the LV in early ischemic period.

GAL-3 is

expressed by cardiomyocytes and endothelial cells during the early
ischemic event as it co-localized with desmin in cardiomyocytes and factor
8-relaed antigen in endothelial cells.


We show for the first time a transient peak in the level of HIF-1 α in LV at
20 minutes following MI.

We suggest that this increase is due to

stabilization of HIF-1 α as a result of low intracellular level of oxygen
secondary to complete ligation of LAD artery.

This observation is

supported by our real time PCR results that show no upregulation of HIF-1
α mRNA at this early time point. We also observed a decrease in LV level
of HIF-1 α protein as the time of ischemia increased. We think that as the
time of ischemia increases the cardiomyocytes become necrotic and HIF-1
α level go down due to protein degradation. HIF-1 α was also seen to be
expressed by the nuclei of cardiomyocytes and endothelial cells. Another
observation pertinent to HIF-1 α staining was that while the expression of
HIF-1 α decreases in cardiomyocytes as the time of ischemia increases, its
expression in endothelial cells essentially remains the same. This is due to
the fact that endothelial cells are proliferating cells that participate in
healing process of the infarcted zone and in the formation of collaterals
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while survived cardiomyocytes do not proliferate, when continuous
ischemia damages the cardiomyocytes its expression is lost but the
surrounding endothelial cells keep on proliferating and expressing HIF-1α.
It has already been reported that HIF-1 α is a protective factor that
mediates the survival of injured cardiomyocytes in the setting of ischemic
injury by transcribing a variety of cardioprotective genes including
erythropoietin, vascular endothelial growth factor, inducible nitric oxide
synthase, hemeoxygenase-1 and cardiotropin (321). We propose that the
presence of HIF-1 α in the myocardium is protective in the early post MI
time point tested.


We have demonstrated that the high GAL-1 and GAL-3 levels in the LV in
early ischemic period are part of the prosurvival gene expression profile
transcribed by HIF-1 α. GAL-1 has been identified as a hypoxia-induced
protein in a number of studies (64-66). GAL-3 also has been linked to
hypoxic/Ischemic injuries in the kidney, and brain (79, 145, 146). We have
shown co-localization of GAL-1 and GAL-3 with HIF-1 α in cardiac
myocytes and endothelial cells in LV sections from areas supplied by
LAD at different time points following MI. Cardiomyocytes and
endothelial cells that show nuclear expression of HIF-1 α also show
cytoplasmic and nuclear expression of GAL-1 and GAL-3 while cells that
do not express HIF-1 α also show no expression of GAL-1 and GAL-3.
This indicates a possible correlation in the expression of both proteins.
This colocalization is prominent in the surviving cardiomyocytes and
endothelial cells at the periphery of infarction zone while dead
cardiomyocytes in the centre of infarction do not show any expression. At
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24-hour post MI time point the infarcted area is flooded with neutrophil
polymorphs, which also show nuclear expression of HIF-1 α.

These

neutrophil polymorphs are moving in between dead cells in the ischemic
zone, and so are under hypoxic condition. Hypoxia stabilizes HIF-1 α and
prevents its proteasomal degradation resulting in expression of HIF-1 α by
these neutrophils, which at the same time show co-expression of GAL-1
and GAL-3. Bioinformatic analysis shows seven potential HREs (hypoxia
response elements) within 2.2 kb region upstream the transcriptional start
site of GAL-1 (67), and two potential HRE’s in the promoter region of
GAL-3 gene (324). We therefore propose that GAL-1 and GAL-3 are
transcriptional targets of HIF-1 α in early post MI.


We have shown that early expression of GAL-1, GAL-3 and HIF-1 α in
cardiomyocytes correlates with a predominant antiapoptotic activity in the
left ventricle. Pro-apoptotic caspase-3 and cleaved caspase-3 were found
to have a very low expression, while anti-apoptotic Bcl-2 expression was
high at early time points post MI. A decrease in apoptosis is an indicator
of promoting the survival of cells. This supports our concept that GAL-1,
GAL-3 and HIF-1 alpha are part of the prosurvival mode of action of the
cell after ischemic insult at least in the early myocardial infarction time



We have shown that GAL-3 levels are high, after 24 hours of permanent
ligation of LAD, which regulate proinflammatory and antiapoptotic
mechanisms in the myocardium. GAL-3 plays a proinflammatory role in
the LV by regulating IL-6 production and is controlling the apoptotic
pathway by negatively regulating the proapoptotic proteins, Cleaved
caspase-3 and Cytochrome c, and increasing the anti-apoptotic bcl-2. Our
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previous experimental results have shown that GAL-3 expressed very
early after MI may be part of the survival mechanism of the
cardiomyocytes after ischemia or infarction. Along the same continuum,
other studies have linked GAL-3 to fibrosis and heart failure (138). We,
therefore, propose that GAL-3 should be viewed as regulatory molecule
acting in the myocardium at various stages of myocardial infarction.


Our results here show that there is significant increase in GAL-3 levels in
the heart LV of IR mice as compared to sham which signifies that GAL-3
is playing a role in the ischemia/reperfusion injury in the heart. Oxidative
stress is a major component of the IR injury. Our results show that both
the SOD, Glutathione and catalase levels were significantly increased in
the GAL-3 wild type IR as compared to the GAL-3 KO IR. This signifies
that GAL-3 is associated with an increase in the anti oxidant activity in the
IR injured myocardium.

SOD, Glutathione and catalase are the most

important cellular defense mechanism against oxidative injury and are the
major intracellular redox buffer in many cell types (366) (367). GAL-3,
through its action in positively regulating the antioxidant players, leads to
a decrease in cardiomyocytes necrotic death and infarct size as evidenced
by a significantly lower troponin I level in the plasma of GAL-3 wild mice
as compared to GAL-3 KO mice subjected to IR injury. We therefore
suggest that GAL-3 can interfere with redox pathways controlling cell
survival and death and thus plays a protective a role in the pathogenesis of
ischemia reperfusion injury in the heart.


Finally, we have compared our MI and IR models and discussed the
different mechanism of injuries with respect to GAL-3. In our MI model
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GAL-3 was found to be a proinflammatory and anti-apoptotic mediator
with no effect on the cardiomyocytes necrosis. In IR model GAL-3 in
addition to being proinflammatory and antiapoptotic mediator also acts as
a regulator of antioxidant activity in the myocardium and leads to decrease
in cardiomyocytes necrosis and indirectly decreased infarct size. The
difference of GAL-3 activity in these two models as seen in our
experiments show that these two processes of cardiomyocytes injury are
indeed very distinct and the local microenvironment of the myocardium
determines the particular roles of molecules and enzymes that are part of
their pathogenesis. Our results are significant in terms of IR injuries
because the main goal in treatment of acute infarction is early
revascularization with reperfusion. Reperfusion affects a larger portion of
the left ventricle than infarction alone (302) so reperfusion injury may act
as an independent determinate of cardiac remodeling in addition to infarct
size. GAL-3 is now recognized as a definite player in cardiac remodeling
and

progression

to

heart

failure

so

understanding

the

local

microenvironment in which GAL-3 works after ischemia/infarction or
ischemia-reperfusion can open a new window in understanding the exact
role of GAL-3 in the heart.
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4.2 Future directions
Research on Galectins in the heart has gained momentum in the past few
years.

GAL-1 has not been studied extensively in relation to myocardial

ischemia. However, GAL-3 is actively being studied in laboratories as well as in
clinical trials on a global scale to elucidate its role in heart failure. Our work
showed that GAL-3 acts according to the microenvironment of the myocardium.
This has opened a new door and a chance to look at GAL-3 from a fresh
perspective. More work needs to be done to investigate GAL-3 in ischemia
reperfusion injury in particular to find out other players that work in association
with GAL-3 and may help attenuate IR injury.
There is a pressing need to study GAL-1 and GAL-3 in the heart in
association with other co-morbidities like diabetes or atherosclerosis. Heart
diseases are seldom found alone in patients in clinical practice, so in future it is
important to include these co-morbidities in the animal model.
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